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Figure 3.1. Chemical structures of the compounds employed in this study. DMPD (N1,N1-
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incubation for 30 min (for L2-b2) and 10 min (for DPA1 and DPA2). 1H NMR spectra of 
(d) L2-b1 (black), (e) PMA1 (black), and (f) PMA2 (black) with ZnCl2 (1 equiv, red) in 
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Abstract 
 
Alzheimer’s disease (AD) is one of the fatal and leading causes of death. Amyloid-
 (A) and transition metal ions have been suggested to be involved in AD pathogenesis. 
These two pathological factors can bind each other and may influence peptide 
aggregation, producing toxic oligomeric A species, as well as generation of reactive 
oxygen species (ROS) leading to oxidative stress. In addition, there may be interactions 
of metal-free and -associated A (metal–A) with other proteins [i.e., human serum 
albumin (HSA), S100 proteins]. Unfortunately, a clear relationship between A, metal 
ions, and other proteins in AD etiology has not been identified.  
In order to understand the role of metal–A species in AD, several chemical tools 
have been studied and presented their abilities to modulate metal-free A and/or metal–
Aaggregation, control metal–A-mediated ROS formation, scavenge free radicals, as 
well as alleviate metal-free A-/metal–A-associated cytotoxicity. The structural moieties 
responsible for such reactivities, however, are not completely elucidated. Therefore, in 
this thesis, to gain a better understanding of structure-interaction-reactivity relationships 
between small molecules and metal-free A or metal–A, naturally occurring flavonoids 
(morin, quercetin, galangin, and luteolin) with structural variations (i.e., the number and 
position of hydroxyl functionality on a flavonoid backbone) and two series of rationally 
designed chemical reagents were investigated. Four flavonoids in this study could 
significantly modulate aggregation pathways of metal–A over metal-free A and mediate 
metal-free A-/metal–A-linked cytotoxicity to different extents. Our studies demonstrate 
that the variations of hydroxyl groups within a flavonoid backbone can modify their 
reactivity toward metal-free A and metal–A species. In addition, the motif of N1,N1-
dimethylbenzene-1,4-diamine could be considered to be essential for targeting and 
modulating A aggregation pathways and scavenging free radicals. Our findings and 
understandings about structure-interaction-reactivity relationships between small 
molecules and metal-free A or metal–A can help optimize activities of small molecules 
as chemical tools toward amyloidogenic peptides. Moreover, we have examined the 
interactions of A with other proteins (i.e., HSA, S100 proteins) with and without metal 
xxviii 
 
ions and their influence on the peptide aggregation. HSA and S100 proteins could alter 
the A aggregation pathways by directly binding to metal-free A and metal–A followed 
by formation of complexes which possibly are less toxic than protein-free A aggregates.  
Taken together, the studies described in this thesis demonstrate the pivotal 
functionalities of chemical tools for their reactivity toward metal-free and metal-bound A, 
as well as present the initial information on a link of protein–protein–small molecule 
(metal) networks to AD etiology. Our overall results and observations will be able to 
provide insight into new discovery of chemical tools and therapeutics toward AD. 
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Chapter 1: Proteins and Metal Ions Involved in  
Pathogenesis of Alzheimer’s Disease 
 
 
 
A portion of this chapter was previously published in a publication [Lee, H. J.;‡ Korshavn, 
K.;‡ Kochi, A.; Derrick, J. S.; Lim, M. H. Chem. Soc. Rev. 2014, 43, 6672. (‡ Equal 
contribution)]. 
 
 
1.1. Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is the most common neurodegenerative disease and 
currently afflicts more than 28.5 million people worldwide.1-5 Patients suffering from AD 
experience a gradual impairment of both short-term and long-term memory due to 
neuronal loss.2,6 Multiple features, including metal ion dyshomeostasis and disruption of 
membrane structures by oligomeric formation of aggregated proteins [i.e., amyloid- (A), 
hyperphophorylated tau (ptau) aggregates], have been implicated in the onset and 
progression of AD.4,6-14 Recent researches have suggested that some of these 
characteristics could be intertwined with other facets (i.e., metal–protein interactions, 
protein–protein interactions, ROS) of the disease.3,4  
AD is commonly associated with shrinkage of both the neocortex and 
hippocampus, as well as deposits of senile plaques (mainly composed of aggregated A) 
and neurofibrillary tangles (NFTs; containing ptau aggregates).6,15,16 Along with the 
protein aggregation, metal ion dyshomeostasis is observed within the AD-affected brain.2 
In the samples obtained from the brains of AD patients, plaques are shown to contain 
highly concentrated Cu, Zn, and Fe as high as ca. 0.4, 1.0 and 0.9 mM, respectively. In 
contrast, the age-matched, healthy brain tissues contain concentrations of ca. 0.07, 0.3, 
and 0.3 mM for Cu, Zn and Fe, respectively.2,6 As a complicated condition in the brain, 
there may be interactions between pathological factors, such as metal–protein or protein–
protein interactions [e.g., interaction between A and biomolecules with or without metal 
 2 
 
ions], could affect the pathogenesis of AD.6 Particularly, tau and acetylcholinesterase 
(AChE) have been reported to be interacting with A and metal ions directly and indirectly 
leading to AD.17-24 Herein, we discuss the current knowledge of interrelationships among 
A, tau, AChE, and/or metal ions toward AD etiology. 
 
1.2. Proteins in AD pathology 
 
1.2.1. Amyloid- (A) 
 A is an aggregation-prone peptide and its aggregates are the major component 
of the senile plaques, one of the AD hallmarks, which are located in various regions of 
the brain.2,3,6,15,16,25-28 Thus, the amyloid cascade hypothesis, suggested to be linked to 
the onset and progression of AD which may be caused by the imbalance of generation, 
aggregation, and clearance of A.29 The A peptide is produced via the proteolytic 
cleavage reaction of the amyloid precursor protein (APP) by - and -secretases 
producing 38-43 amino acids in length (Figure 1.1a).2,3,6,15,16,25-27 The cleaved and 
released A peptides are unfolded as mostly random coils with some -helical and -
sheet structures.2,3,6,15 Two most common isoforms of A are A40 and A42. A42 has 
been observed to be predominant in senile plaques as well as considered more toxic than 
A40.2,3,6,15,16,25-27 Two more hydrophobic amino acids in the C-terminus region of A42 
may lead the peptide more aggregation-prone than A40.2,3,6,15 The sequential addition of 
A peptides to aggregate from monomers to oligomers, protofibrils, or fibrils, occurs via 
hydrophobic interaction and/or hydrogen bonding through both the central self-
recognition region (residues from L17 to A21; Figure 1.1b) and C-terminus hydrophobic 
region.2,26 Moreover, A has been shown to coordinate with metal ions, including Cu(I/II), 
Zn(II), Fe(II/III), and these metal ions can facilitate the peptide aggregation and stabilize 
toxic conformations of Avide infra).2,3,6,15,16,25-27 Upon the aggregation process (Figure 
1.1c), soluble oligomeric A aggregates have been observed to be toxic by disrupting the 
membranes (resulting in ion channels and subsequently disturbing cation and anion 
homeostasis)7,8 as well as binding to synaptic protein receptors with decreasing neuronal 
plasticity,9 which could lead to memory impairment and consequently neurodegeneration. 
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Figure 1.1. A schematic presentation of the amyloid cascade hypothesis. (a) The cleavage reaction of APP 
by -, -, and -secretases to generate A peptides. (b) The amino acid sequences of A40 and A42: black, 
hydrophilic residues; blue, hydrophobic residues; red, suggested Cu(II) binding residues; purple, central 
self-recognition regions. (c) Aggregation of A (from monomers to higher order species, such as oligomers, 
protofibrils, and fibrils) with or without metal ions (red circles). 
 
1.2.2. Tau 
 The other hallmark of AD is the NFT that is mainly composed of aggregates of 
ptau.6,15,16 It has been proposed that the toxicity and physiological changes induced by 
ptau can be a critical cause of neurotoxicity and subsequently lead to neurodegeneration 
and AD.5,6,10,12,25,30 In addition, tau and ptau also can interact with A directly and 
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indirectly (vide infra).19,31-33  
Tau protein has 352-441 amino acid residues in length and been classified as a 
microtubule-associated protein (MAP) for structural integrity and stability to microtubules 
which help maintaining the shape of neurons for signal transduction.6,10,12,13,25,30,34 
Moreover, tau has been suggested to be involved in transport nutrients, neurotransmitters 
and organe l les. 1 0 , 1 2 , 2 5 , 3 0  S ix iso forms of  tau exis t  and the se isoforms  
 
Figure 1.2. One of the full-length tau protein isoforms, 4R2N. Each isoform can have 0-2 acid repeats (0N-
2N; orange), three or four microtubule binding domains (3Rs or 4Rs; green) and proline-rich domain 
between those acid repeats and microtubule binding domains (blue). 4R2N isoform has four R domains 
(R1, R2, R3 and R4) and two N domains (N1 and N2). 
have different numbers of microtubule-binding repeat domains (R; R1, R2, R3, and R4); 
three or four R domains (3R or 4R) of 31-32 amino acids in the C-terminal region; 0, 1, or 
2 inserted acid repeats (N; N1 or N2) in the N-terminal region.6,10,12,13,30,34-37 Furthermore, 
tau is water-soluble because of its numerous charged residues and its net isoelectric point 
(pI) for the protein is from 6.5 to 9.5 depending on isoforms.30,34,38 The N-terminal region 
(pI = 3.8) is negatively charged; microtubule-binding domains in C-terminus (pI = 10.8) 
and proline-rich domains (pI = 11.4) in the middle of the protein are positively charged at 
a physiologically relevant pH (pH 7.4).30,34,38 To interact with microtubules, positively 
charged microtubule-binding and proline-rich domains of tau are binding to negatively 
charged residues of microtubules and -tubulin on the inner microtubule surface, 
respectively.12,34 These bindings are controlled by kinases and phosphatases. Once tau 
is phosphorylated, it disassembles from microtubules and makes them to be 
depolymerized, resulting in the disruption of axonal transport of vesicles by kinesin and 
dendrite structures. Tau can obtain its function back upon dephosphorylated, 
however.6,10,12,13,30,34,35 Although normal healthy tau is less aggregation-prone,37 the 
misregulated activity of kinases and phosphatase can lead the formation of ptau to 
aggregate and form paired helical filaments (PHF) and NFT.10,12,30,34,38 Moreover, 
oligomeric forms of ptau may bind and disrupt membranes similar to A oligomers (vide 
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supra).10,11 
 
1.2.3. Acetylcholinesterase (AChE) 
The synaptic dysfunction of cholinergic systems has been suggested to be 
involved in neurodegeneration and possibly cause AD.39-41 Since the loss of cholinergic 
neurons, which have a function of releasing acetylcholine (ACh, a neurotransmitter 
released by nerve cells to send signals to other neurons) in basal forebrain is observed 
in the AD environment, this cholinergic hypothesis for AD pathogenesis is proposed.2,25,39-
41 Misregulation between ACh release and choline uptake for recycle and synthesis of 
ACh has been also observed in the AD-afflicted brain.42,43 Since ACh plays important 
roles in neurological signaling pathways, the misregulated level of ACh is critical.44,45 To 
maintain the appropriate amount of AChs in nerve systems, current therapeutics have 
been focused on inhibiting the activity of AChE, involved in the cleavage reaction of 
neurotransmitters, including ACh.46-48 AChE is a serine hydrolase which hydrolyzes the 
neurotransmitter, ACh, to terminate the stimulation in neurosynaptic clefts (Figure 1.3).49-
52 The catalytic triad S200, H440, and E327; Torpedo californica; electric eel AChE) in 
the esteric site is located at the bottom of ca. 20 Å  deep cavity with aromatic amino 
acids.50-52 Moreover, the anionic site is responsible for proper orientation of substrates 
toward the catalytic triad.49,53 
 
Figure 1.3. A schematic description of the active site and enzymatic reaction of AChE. Aromatic amino 
acids in anionic sites interact with ACh via electrostatic interaction, which leads ACh to the esteric site with 
a proper orientation for the enzymatic reaction. AChE cleaves ACh to produce choline and acetic acid to 
terminate the stimulation. Choline will be reused for generating ACh. 
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1.3. Metal ions in AD 
 
1.3.1. Metal ions in the brain  
Metal ion [i.e., Cu(I/II), Zn(II), Fe(II/III)] dyshomeostasis and oxidative stress by 
misregulated, redox-active metal ions [i.e., Cu(I/II), Fe(II/III)] in the brain could be causes 
of the onset and progression of AD.2,3,5,6,15,54-56 To uncover the effects of metal ions on 
AD pathology, gaining a better understanding about the functions of metal ions in the 
brain is important. Metal ions serve many vital roles, including secondary messengers in 
cellular signaling as well as stabilizing the proteins’ structures to function properly.2,3,54  
Copper is the third most abundant transition metal in the body; this metal in the 
brain accounts for ca. 9% of total Cu in the body.3,54 The major oxidation states of Cu are 
+1 and +2. Cu(I) is typically found in the intracellular environment while Cu(II) is more 
common in the extracellular environment.54 Cu in the brain is categorized into two main 
groups, either bound to proteins, including cytochrome c oxidase (CcO) for adenosine 
triphosphate (ATP) production, Cu/Zn superoxide dismutase (SOD1) for ROS regulation, 
or unbound in labile, synaptic pools.2,3,54 
In addition, zinc is the second most abundant metal in the body; it is most 
concentrated in the brain.54 Like Cu, Zn exists either protein-bound or labile forms.54 The 
majority of Zn in biology is protein-bound, where it is regulated [i.e., metallothioneins 
(MTs)] and transported [i.e., Zn transporters (ZnTs)] to play a role in other biological 
processes or aid in the conformational stability of proteins (i.e., SOD1).2,54 Moreover, the 
labile Zn pool is also necessary for neurotransmission; Zn(II) is released into the synaptic 
cleft, along with glutamate, following the excitation of glutamatergic neurons.2,3,54 
Although the role of Zn(II) in neurotransmission is not fully understood, it is suggested to 
be involved in the modulation of neurotransmission through interactions with other 
biomolecules, such as N-methyl-D-aspartate (NMDA) and -aminobutyric acid (GABA) 
receptors, to regulate their activity.2,3,54  
Iron is the most abundant transition metal in the brain, likely related to the high 
demand of dioxygen (O2).54 Fe is required for many biological processes, including 
neurotransmitter production and O2 transport/storage.2,54 Fe is physiologically found 
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mainly in two oxidation states (+2 and +3); approximately 25% of Fe in the body is bound 
to transferrin and ferritin in the Fe(III) state.2,54 Ferritin, a globular protein consisting of 24 
subunits, binds up to 4,500 atoms of Fe in order to protect cells from Fe-mediated 
oxidative damage and allow for the release of Fe(III) when needed.54,57 Additionally, Fe 
is indispensable for critical functions in the body and a product generated upon the 
breakdown of heme, an Fe containing cofactor, has physiological roles as antioxidants 
and anti-inflammatory agents.58 Heme is degraded by hemeoxygenase (HO) enzymes.58 
Among HO isoforms, HO1 is used in a defense mechanism against cellular oxidative 
stress in concert with SOD1.58 HO2 is implicated in the maintenance of heme 
homeostasis and the prevention of nitric oxide (NO)-mediated damage, such as 
inflammation and glutamate excitotoxicity.59,60 
 
1.3.2. Reactive oxygen species (ROS) induced by metal ions in AD 
The AD environment (i.e., miscompartmentalization of metal ions, oxidative stress) 
may lead to the disruption of proteins’ activities,2,54 which may promote the conditions 
observed in the diseased state.2,54,61 Dysregulated metals could cause oxidative stress, 
which is believed to be correlated to AD development. Labile redox-active metal ions 
could generate ROS via Fenton-like reactions (eqs 1 and 2).2,3,6,62 
 
Cu(II)/Fe(III)  +  H2O2    Cu(I)/Fe(II)    +  HO2  +   H+  (eq 1) 
Cu(I)/Fe(II)    +  H2O2    Cu(II)/Fe(III)  +  HO  +   OH– (eq 2) 
 
Organisms have natural antioxidant defense mechanisms that regulate the amount 
of ROS present in the body; however, in the diseased state, the system in place for ROS 
elimination and production (e.g., SOD1) may be malfunctional, leading to ROS 
accumulation and oxidative stress.2,54 High levels of ROS can oxidize lipids on the 
membranes and proteins, rendering them unstable and/or nonfunctional which can cause 
neurodegeneration and subsequently AD.2  
Along with the overproduction of ROS by various metal ions, the loss of ROS 
detoxification machinery could overwhelm endogenous antioxidant systems.2,54 Current 
research has found one of the key antioxidant enzymes, SOD1, a homodimeric Cu- and 
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Zn-containing enzyme to be a major target of oxidation.54,63 Through a two-step redox 
reaction on the Cu center at the catalytic site, SOD1 converts harmful superoxide radical 
anion (O2•−) that escapes from the mitochondria into O2 and hydrogen peroxide (H2O2).2,63 
The loss of Cu results in complete inactivation of the enzyme.63 SOD1 binds Zn to stabilize 
the active structure, facilitating Cu-catalyzed antioxidant activities.64 The malfunction of 
SOD1 due to loss of Cu and Zn can be a factor for ROS accumulation, ultimately leading 
to oxidative stress and neurodegeneration.54,65   
 
1.4. Metal–protein interactions in AD 
 
1.4.1. Interaction of metals with A 
In vitro studies have demonstrated that Cu(I/II), Zn(II) and Fe(II/III) can coordinate 
with A generating metal–A complexes. Cu(I/II)–A or Zn(II)–A are shown to alter the 
aggregation of the peptide; Cu(I/II)–A or Fe(II/III)–A can overproduce ROS causing 
oxidative stress (eqs 3-8).2,3,6,66  
The coordination of Cu–A is very dynamic and pH dependent with Kd ranging 
from 10-11 to 10-7 M for 1:1 complexes of Cu(II)–A and Cu(I)–A40/Cu(I)–A42 (10-14 and 
10-7 M, respectively).2,3,62,67-70 In addition, Zn(II) binding of A has Kd values (ca. 10-9–10-
6 M)2,3,62,67-69 and the Kd value is shown to be ca. 10-4 M for Fe(II) binding to A16,71,72 
which suggests weaker binding of these metal ions to A than Cu(I/II). The predominant 
coordination at a physiologically relevant pH (e.g., 7.4) for Cu(II) or Cu(I) is suggested to 
occur via 3N1O (three nitrogen donor atoms and one oxygen donor atom; proposed to be 
H6, H13/H14, N-terminal amine, and D1 carboxylate) or 2N (two nitrogen donor atoms; 
suggested to be H13 and H14), respectively.2,3,66 Furthermore, all three histidine residues 
and additional candidates (D1, R5, Y10, E11 or water molecules) are involved in the 
coordination of Zn(II)–A.16,67-69 These binding of Cu(I/II) and Zn(II) to A could facilitate 
the peptide aggregation and increase neurotoxicity.67,68 Depending on the conditions, 
Cu(II) could promote the formation of A fibrillar or amorphous aggregates facilitating the 
rate of the nucleated aggregate formation compare to metal-free conditions.68,73 At a 
physiological pH, a supra-stoichiometric amount of Zn(II) could cause the generation of 
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amorphous A aggregates while fibrils were formed under sub-stoichiometric 
conditions.73,74 
Redox-active transition metal ions bound to A, Cu(I/II)–A and Fe(II/III)–A 
species, could lead to oxidative stress and eventually the disease due to their potential 
involvement in ROS overproduction (Fenton-like reactions are described in eqs 3-8). Cu–
A species have a redox potential, 0.30 V, versus normal hydrogen electrode (NHE).2,3,66  
 
Cu(II)–A   +   reductant             Cu(I)–A   +   reductant+  (eq 3) 
Cu(I)–A   +   O2                Cu(II)–A–O2•–   (eq 4) 
Cu(II)–A–O2•–   +   e–   +   H+      Cu(II)–A–HO2•–   (eq 5) 
Cu(II)–A–HO2•–   +   H+             Cu(II)–A   +   H2O2  (eq 6) 
Cu(II)–A   +   H2O2             Cu(I)–A    +   HO2   +   H+ (eq 7) 
Cu(I)–A    +   H2O2              Cu(II)–A   +   HO   +   OH–  (eq 8) 
 
Few structural studies have been reported for Fe coordination to A due to the 
propensity of Fe(II) to be oxidized to Fe(III) and precipitated as Fe(OH)3 (s) and other 
complexes.66 Preliminary results proposed D1, E3, and three H6/H13/H14 may be 
involved in Fe(II) coordination to A.66 The redox potential of Fe(II)/Fe(III) in the Fe–A-
nitriloacetic acid complex was determined to be 0.23 V versus NHE.75 
 
1.4.2. Relations of metal ions and tau 
Unlike A with metal ions, tau with metal ions has been studied relatively 
limited.17,18 Although the full length of tau has not been applied to metal binding studies, 
metal binding of smaller fragments with different R domains was investigated by 
biochemical and biophysical analyses.17,18,76-79 From the Cu(II) binding studies with R1, 
R2, and R3 domains, the fragment could bind more than one equiv of Cu(II) with two 
histidine residues and modulate the secondary structure of the protein once Cu(II) was 
added.76-78 In addition, the longer fragment which has 198 amino acids (called as K32; 
containing all four R domains with two flanking regions to mimic the full length tau) was 
applied to Cu(II) binding studies and demonstrated 1:1 binding.17 Two cysteine and two 
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histidine residues (C291 and C322; two of H299, H329, or H330) were suggested to be 
involved in Cu(II) binding.17 Zn(II) binding also affects the neurotoxicity and aggregation 
of tau.18,79 Tau244-372 fragment has been applied for Zn(II) binding studies and a 
tetrahedral geometry was observed through C291, C322 and two histidine residues.79 
The fibrillization of the peptide was accelerated upon addition of sub-stoichiometric 
amounts of Zn(II) while less fibrils were formed in the excess of Zn(II) which was similar 
to Zn(II)–A aggregation.79 Additionally, Zn(II) could induce the phosphorylation of tau by 
activating kinases and inhibiting phosphatases,18,80,81 which may enhance the 
neurotoxicity.18 Trivalent cations [i.e., Fe(III), Al(III)] could induce ptau aggregation as 
well.6,82,83 Tau is observed to interact with the metal ions; however, it is required to perform 
metal binding studies with full-length tau, instead of its fragments, for a better 
understanding of the relationship between metal ions and tau.   
 
1.4.3. Metal ions and AChE 
The metal interactions of AChE has been rarely studied.49 When AChE was 
surrounded by metal ions [i.e., Hg(II), As(III), Cu(II), Zn(II)], its activity was observed to 
be decreased while alkali metal ions [i.e., Na(I), K(I)] may not affect its activity.49,84 The 
amino acids with aromatic substituents [W84, Y121, W279, F330, and Y334], located at 
the anionic site near the esteric site (Figure 1.3), may interact with Cu(II) and Al(III); 
however, it has not been clearly studied.51,53 Interestingly, Li(I) may have the 
neuroprotective activity toward A–AChE complexes.22,23 Li(I) has been reported that it 
can robustly protect individual brain mitochondria loaded with Rhodamine 123 
(mitochondrial potential dye) against Ca(II)-induced depolarization indicating this metal 
ion could prevent the cytoplasmic Ca(II) influx induced by the protein complex.22,85 
 
1.5. Protein–protein interactions found in AD 
 
1.5.1. A–tau interactions 
Since either the amyloid cascade hypothesis or tau hypothesis cannot explain 
completely the AD etiology, there has been suggested the main proteins in these 
hypotheses are related to each other directly or indirectly.6,17,19-21,25,86,87 A42 and ptau 
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were colocalized in dystrophic neurites near A plaques; monomeric and oligomeric A 
species were also detected with hyperphosphorylated tau in the neurons from the 
postmortem brain sections of AD patients and the AD transgenic 3xTg mouse model.21,88 
The direct interaction between A and tau can modulate their actions (i.e., aggregation, 
toxicity, phosphorylation).19,20,89-94 The toxicity of A in hippocampal neurons has also 
been observed to be increased with tau. Tau phosphorylation has been shown in both the 
hippocampal and cholinergic neurons with A.89,91,94 Once A25-35 presents excess to 
tau273-284, amyloid fibrils were formed, while granular aggregates were generated under 
tau273-284-abundant conditions to A25-35.20 Although the binding of two proteins has been 
studied, it has not been clearly revealed the binding sites and modes in the full length 
proteins.20,21 The previous studies demonstrate that the hydrophobic region of A may 
bind to the R2 domain of tau to form stable complexes; furthermore, experimental results 
with A25-35 and tau273-284 also suggest their hydrophobic and hydrogen bonding 
interactions.20,21,95 Moreover, A could indirectly  modulate tau phosphorylation and ptau 
degradation by upregulating kinases and pro-inflammatory cytokines.32 These findings 
indicate that A and tau are interacting each other directly and indirectly, which can 
damage neuronal structures and functions, resulting in facilitation of AD 
progression.20,21,94 Unfortunately, there are limited studies about the A–tau interactions 
under metal-present conditions. 
 
1.5.2. A–AChE interactions 
In the AD-afflicted brain, AChE has been found to colocalize with A deposits in 
senile plaques.22,23 AChE can interact with A directly via hydrophobic interaction, 
through its peripheral anionic binding site (PAS).22-24 The A fibrillization process was 
facilitated by forming A–AChE complexes.22-24 In addition, the aggregates of A–AChE 
complexes may be more toxic than A aggregates without AChE.22-24,96 Similar to A-
associated cytotoxicity, the disruption of intracellular Ca(II) levels by A–AChE complexes 
could lead to the loss of mitochondrial membrane potential and malfunction, subsequently 
linked to neurotoxicity.22  
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1.6. Usage of chemical tools to understand the relationships between A, tau, 
and AChE with or without metal ions in AD 
 
1.6.1. A-related chemical reagents  
In order to design small molecules to investigate and alter the interactions between 
A and metal ions, we must consider multiple properties (i.e., A interaction, metal 
chelation, ROS scavenging capability). Several compoundss such as natural products 
(i.e., EGCG and myricetin) or synthetic chemicals [i.e., N1,N1-dimethyl-N4-(pyridin-2-
ylmethyl)benzene-1,4-diamine (L2-b), N1,N1-dimethylbenzene-1,4-diamine (DMPD), 4-
(dimethylamino)-2-(((2-(hydroxymethyl)quinolin-8-yl)amino)methyl)phenol (ML)], have 
been screened or designed, respectively, to present the following properties (Figure 
1.4).97-103 First, to target and redirect the actions of metal-free A and metal–A (i.e., 
aggregation, ROS generation), small molecules should have A interacting properties 
through specific structural moieties (e.g., a dimethylamino group, the DMPD motif) and 
metal interacting sites.37,38,97-103 For targeting metal–A, the geometry and coordination 
number at the metal center of potential metal-ligand complexes should be considered.104 
Since metal binding affinity and reactivity toward metal–A species are related, the 
reactivity of small molecules can be affected by the metal binding affinity.6,55,56,97,103 If the 
Kd values for metal ions of small molecules are similar or lower compared to those of A, 
these compounds may not be able to chelate out the metal ions from metal–A complexes 
and could generate ternary complexes with metal–A, showing modulation of metal–A 
aggregation.55,105 Secondly, to control the generation of ROS, redox cycle of redox-active 
metals should be inhibited through consideration of the preferred geometry at the metal 
center depending on the oxidation states of metal ions.103 Thirdly, the compounds also 
need to have ability to remove the existing ROS regulating oxidative stress.101,103 Lastly, 
as therapeutics, compounds should (i) not be toxic with or without metal ions and to 
perform the desired reactivity in vivo; (ii) pass into the blood-brain barrier (BBB) for their 
efficacy in the brain.55,97,101,103,105-109 
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1.6.2. Tau-related chemical tools 
In order to modulate the peptide aggregation pathways and alleviate the toxicity 
induced by tau and ptau with metal ions, microtubule stabilizers (Paclitaxel and 
Epothilone D) and Clioquinol (CQ; an effective chemical reagents for redirecting A  
 
Figure 1.4. Small molecules targeting A, tau, and/or AChE. Chemical structures of natural products and 
synthetic small molecules: (left) AChE inhibitors (green): Silibinin, 3,5,7-trihydroxy-2-(3-(4-hydroxy-3-
methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)chroman-4-one; IDN 5706, 
(1S,5S,6R,7S,9S)-4,9-dihydroxy-5-((S)-1-hydroxy-2-methylpropyl)-6-methyl-1,3,7-tris(3-methylbut-2-en-1-
yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-en-2-one; (middle) A-related features (blue): Myricetin, 
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; EGCG, (−)-epigallocatechin-3-gallate; 
DMPD, N1,N1-dimethylbenzene-1,4-diamine; L2-b, N1,N1-dimethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-
diamine; ML, 4-(dimethylamino)-2-(((2-(hydroxymethyl)quinolin-8-yl)amino)methyl)phenol; (right) naturally 
occurring microtubule stabilizers with tau-related features (orange): Paclitaxel, 
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-
12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-
7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate; Epohilone D, 
(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-
yl)oxacyclohexadec-13-ene-2,6-dione. Hybrid 5 (N1-{[6-((10-((6-chloro-1,2,3,4-tetrahydroacridin-9-
yl)amino)decyl)amino)pyridin-2-yl]methyl}-N4,N4-dimethylbenzene-1,4-diamine) can target and modulate 
both AChE and metal-free A and metal–A aggregation pathways. Clioquinol (CQ; 5-chloro-7-
iodoquinolin-8-ol) can target and affect the actions of both A and tau. Currently used AD therapeutics 
(bottom, gray): AChE inhibitors: denepezil, 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-
1H-inden-1-one; rivastigmine, (S)-3-(1-(dimethylamino)ethyl)phenylethyl(methyl)carbamate; 
galantamine, (4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-
benzo[2,3]benzofuro[4,3-cd]azepin-6-ol; tacrine, 1,2,3,4-tetrahydroacridin-9-amine. NMDA receptor 
antagonist: memantine, 3,5-dimethyladamantan-1-amine. 
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aggregation) were applied (Figure 1.4, right).18,56,110,111 Paclitaxel is a natural product 
extracted from Western yew and has a function as a microtubule stabilizer.110,111 
Depending on its concentration, Paclitaxel shows its neuroprotective effects. The lower 
concentration of Paclitaxel could attenuate the toxicity, while excess of the compound 
causes several side effects (e.g., neutropenia, peripheral neuropathy).110,111 Another 
compound, Epothilone D, displays its BBB permeability and restores the axonal transport 
in vivo.111 Furthermore, CQ was examined its ability to mediate the toxicity induced by tau 
and ptau proteins in fly models.18 CQ could cause conformational changes of ptau to 
normal tau under Zn(II)-present conditions diminishing tau-relatd toxicity.18 Overall, some 
chemical tools have been applied to study the interaction between tau and ptau with or 
without metal ions, modulate their aggregation pathways and reduce the associated 
toxicity. Unfortunately, multiple research groups have not been conducting to accumulate 
the knowledge of metal–tau interactions. Once sufficient information and knowledge are 
obtained about the structure-interaction-reactivity of multi-targeting chemical tools toward 
both A and tau with and without metal ions, small molecules will be developed as future 
multi-targeting therapeutics for AD with being nontoxic and BBB permeable. 
1.6.3. Current and potential AD therapeutics related to AChE 
Several AD therapeutics targeting AChE (i.e., donepezil, rivastigmine, 
galantamine, tarcrine; Figure 1.4, bottom) toward inhibition of AChE’s activity are 
currently available; however, they are not the fundamental cure for the 
disease.2,23,42,50,51,87 These drugs are interacting with different binding sites of AChE. For 
example, donepezil forms a complex with AChE through PAS; rivastigmine targets sthe 
esteric site (Figure 1.3); galantamine and tacrine bind to the anonic site (Figure 1.3).42,50  
Recently, chemical reagents which target A, metals, and AChE have been 
screened or designed and developed.112-116 A natural product (a flavonoid), Silibinin, has 
been reported to inhibit the A aggregation and AChE’s activity in vitro and in vivo, as 
well as improve the spatial learning ability of APP/PS1 Tg mice.113 Another small 
molecule, tetrahydrohyperforin (IDN 5706), has been suggested to be a next potential 
therapeutic for AD.23,114-116 This compound has high stability and oral bioavailability and 
presents less memory impairments.114,115 Furthermore, it can diminish the size of 
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thioflavin-S (ThS)-positive plaques which may be caused from its ability to release AChE 
from A–AChE complexes or inhibit the interaction between A and AChE in vitro and in 
vivo.114,116 Moreover, IDN 5706 could improve the memory of APP/PS1 mice.115 In 
addition, a synthetic chemical reagent, Hybrid 5, which is designed to target both A and 
AChE presented its ability to redirect the peptide aggregation pathways and inhibition of 
AChE ‘sactivity.112 
 
1.7. Methods to study the relations among A, other proteins, and/or metal ions 
by small molecules 
In order to understand and analyze the interaction between A, other proteins [i.e., 
human serum albumin (HSA), S100 protein], and/or metal ions, chemical tools can be 
utilized to many biochemical and biophysical methods. The techniques in this thesis to 
evaluate the interaction and influence of small molecules and proteins with metal-free A 
and metal–A to modulate peptide aggregation and alleviate peptide associated 
cytotoxicity, as well as the free radical scavenging capability, metal binding, and BBB 
permeability of compounds listed with brief explanation.   
 
1.7.1. The examination of the protein aggregation 
The thioflavin-T (ThT) assay has been applied to determine the progression of 
amyloidogenic proteins aggregation, especially the formation of fibrils (Figure 1.5).117-120 
Since ThT assay may be significantly interfered if the absorbance of small molecules and 
their metal complexes overlap with the assay (ex = ca. 440 nm, em = ca. 490 nm for 
ThT), this assay can be only employed to evaluate the influence of proteins (i.e., HSA, 
S100 proteins) on A aggregation.117-120 Moreover, many metal ions, including Cu ions, 
are known to quench the fluorescence of ThT,121 mostly employed for measuring the 
metal-free or Zn(II)-induced A aggregations.  
  To determine the effect of proteins and small molecules on A aggregation 
pathways with or without metal ions [i.e., Cu(II), Zn(II)] by other than ThT assay, gel 
electrophoresis can be applied to separate and detect the A aggregates based on size, 
charge, and molecular weight.97-100,103,122 The protein bands can be visualized by Western 
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blotting (gel/Western blotting) with proper anti-bodies or coomassie blue staining; 
however, it only presents the A species which can enter into the gel matrix and cannot 
provide the morphologies of resulting A aggregates (e.g., amorphous, fibrils).122,123 
 
Figure 1.5. ThT assay mechanism. The single bond in ThT (red arrow) can rotate freely once it is bound to 
non-fibrillar A species. In contrast, less rotation of the bond is allowed with presenting fluorescence (ex = 
ca. 440 nm and em = ca. 490 nm) when ThT is bound to amyloid fibrils. 
Thus, the additional method for investigating the morphologies of A aggregates 
in resulting solution is required and transmission electron microscopy (TEM) can be 
used.97-100,103,124 Using this technique, structures of resulting A aggregates can be 
classified as fibrils, protofibrils, or amorphous aggregates.125 By comparison the 
morphological differences from the small molecules-treated or other proteins-treated and 
-untreated A, their influences and interactions toward A aggregation pathways and 
interactions can be understood better.   
 
1.7.2. Strategies for studying the interactions among A, proteins, metal ions and 
small molecules 
 The interaction between the factors, A, other proteins with or without metal ions 
and/or small molecules can be studied by mass spectrometry (MS). With nano 
electrospray ionization (nESI; can use small sample volumes, 1-3 L of nM-M of 
samples, is less sensitive to salts in the buffer, and ionizes the samples very softly to 
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allow observe relative weak and biologically relevant non-covalent interactions126), MS 
can be applied to detect and observe various A species from monomeric to soluble 
oligomeric forms of complexes with metal ions, other proteins, and/or small 
molecules.100,103,126-128 Additionally, the exact species and stoichiometry of the factors in 
the complexes can be investigated by ion mobility-MS (IM-MS) technique.100,103,126,128 IM-
MS, when used in tandem MS/MS, can measure the arrival time of each species based 
on its m/z values passing through the inert gas that depends on the 3D structural volume 
of each species,126,128,129 thus, the structural changes by the interaction with other bio-
/small molecules can be detected as well.100,128 
  NMR can also be employed to study the interactions between factors at the 
molecular level.103,130 2D 1H15N band-selective optimized flip-angle short transient 
heteronuclear multiple quantum coherence (SOFAST-HMQC) NMR can be used to 
observe changes in the spectra of a 15N-backbone-labeled A upon titration of a metal 
ion, protein or small molecule.100,103,130 The titration induced spectral changes with 
specific residues indicating the binding site of the protein. Moreover, reappearance, 
partial reappearance, or change in signal corresponding to residues involved in metal 
binding can also give information on the compound’s interaction with the metal ion 
component of the metalprotein complex.100,131  
  In addition, the interaction of small molecules with proteins in the absence and 
presence of metal ions can be studied by another NMR method, saturation transfer 
difference (STD).103,132 This technique can produce an atomic-level map of the small 
molecules’ atoms are in contact or interact with the protein species indicating the 
important moieties for the interaction by exploiting the dynamic of ligand binding.100,103,132-
134 Since the non-covalent binding of a compound with a protein and metalprotein 
species is labile, the protein is magnetically saturated. Upon the ligand binds to protein, 
the saturation is transferred from the protein to the compound. If the saturated molecule 
disassociates before relaxing, signal is produced proportional to the previous proximity of 
the ligand atoms to the protein or metalprotein complex.132-134 Furthermore, unlike 
SOFAST-HMQC NMR, STD method can be used to study the interaction of compounds 
with aggregated forms (e.g., fibrils).103 
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1.7.3. Approaches for investigating chemical and biological properties of small 
molecules 
 The characterization of each small molecule needs to be carried out, especially, 
metal bindings, anti-oxidant capacity, and BBB permeability of the compounds are 
important for our studies. The metal binding properties of small molecules can be 
determined by monitoring the changes in the UV–Visible (UV–Vis) spectroscopic or 1H 
NMR spectra of the compound upon the addition of metal ions.99,106,108 Additionally, pKa 
and pM values can be obtained through observing UV–Vis spectra with pH titrations and 
employed special software for the calculation.99,102,135  
  In addition, in order to evaluate the ability of compounds to modulate oxidative 
stress, their anti-oxidant property, Trolox equivalent antioxidant capacity (TEAC) assay 
has been performed. This assay measures the organic free radical scavenging capability 
of compounds by comparing that of Trolox, a water soluble vitamin E analogue.103,136,137 
Through the assay, the small molecules undergo electron transfer mechanisms to 
scavenge free radicals and it can be monitored at a wavelength which does not have any 
interference with the compounds at ca. 734 nm.136,137 Moreover, this assay can be carried 
out in more biological relevant condition, in cell lysate.103,138 
  Furthermore, the BBB permeability of each small molecule is an important feature 
to be considered once designing and developing them. The parallel artificial membrane 
permeability assay adapted for the blood-brain barrier (PAMPA-BBB; common assay for 
estimating the ability to passively diffuse across the BBB) can be applied to calculate 
logBB values and by following Lipinski’s rules, the BBB permeability of compounds can 
be evaluated.139-141 In this assay, the porcine brain lipid-soaked membrane is used for 
simulating the blood-brain barrier. The diffusion of each compound across this membrane 
from the donor well to acceptor well (Figure 1.6) is measured and logPe values are 
calculated by ‘two-way flux’ equation: CA(t) = M/(VD + VA) + (CA(0) – M/(VD + VA))e–PeA(1/VD 
+ 1/ VA)t [CA(t), the concentration of the compound in the acceptor well at time t; M, the total 
amount of the compound in the system; VD, the volume of donor well; VA, the volume of 
the acceptor well; CA(0), the concentration of the compound in the acceptor well at the 
beginning of the experiment; Pe, the effective artificial-membrane permeability; A, the 
area of the membrane].139-141 Additionally, since neutral form of molecules typically 
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passively diffuse across the BBB more readily, the charge of the compounds need to be 
estimated at a physiological relevant pH (pH 7.4),142 by obtaining pKa values of 
compounds (vide supra). 
 
Figure 1.6. The PAMPA-BBB assay. Small molecules in the donor wells diffuse across the lipid membrane 
which is simulated as BBB into the acceptor wells. After 4 h incubation in this study, the concentration of 
the compounds in the both donor and acceptor wells is measured and calculated the permeability value, 
logPe. 
1.7.4. Determination of the ability of small molecules to regulate the toxicity 
induced by metal–protein and protein–protein complexes in cells 
The toxicity of metal–protein or protein–protein complexes in cells and the recovery 
of this cytotoxicity by small molecules can be estimated by measuring cell viability. The 
studies in this thesis used human neuroblastoma cell lines for cell viability assays, MTT 
assay. This MTT assay monitors the produced purple-colored formazan from the 
reduction of a yellow MTT. This reduction reaction only can occur in living cells by 
NADPH-dependent cellular reductase.143-145 The absorbance values at ca. 600 nm are 
compared to control cells that were not treated by any complexes and compounds to 
determine the cell viability.143 
 
1.8. Conclusion 
 The correlations of multiple factors (i.e., A, tau, AChE, metal ions, ROS) cause 
the complication of AD pathogenesis and lack of the accurate information about the 
etiology of the disease limiting the development of effective drugs for fundamental cure. 
In order to reveal the mechanisms of the onset and progression of the disease, the 
interactions between the factors have to be understood and studies have been focused 
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on interpreting the relationships between the proteins (e.g., A, tau, AChE) and metal 
ions by employing small molecules. These investigations can be the first-stepping stone 
to establish protein–protein–small molecules networks in the disease pathology and 
discover treatments for AD, and to achieve this successfully, continuous studies for 
understanding the relationships between these multiple pathological factors are 
necessary. 
 
 
Figure 1.7. MTT reduction reaction by NADPH-dependent cellular reductase in living cells. Once yellow 
colored MTT reduces by cellular reductase in living cells, purple colored MTT formazan is produced. MTT, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; MTT Formazan, 1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan. 
 
1.9. Scope of this thesis 
 Either screened natural products or designed chemical tools presented their ability 
to target and redirect metal-free A and/or metal–A aggregation. Although small 
molecules have been examined for their reactivity (i.e., modulation of metal-free A 
and/or metal–A aggregation pathways, regulation of A-/metal–A-associated 
cytotoxicity), along with antioxidant capacity and BBB permeability, the structural moieties 
responsible for such reactivity have not been clearly understood. In addition, the protein–
protein interactions between A and A-interacting proteins in the absence and presence 
of metal ions, which may be related to AD pathology, have not been fully revealed. 
Therefore, the studies presented in this thesis demonstrate the critical structural motifs of 
small molecules for their reactivity toward metal-free A and metal–A aggregation, ROS 
levels, cytotoxicity, as well as A–protein interactions. In Chapter 2, four naturally 
occurred flavonoids, morin, quercetin, galangin, and luteolin, which have slightly different 
structures from myricetin (that presents its anti-amyloidogenic and anti-oxidant properties, 
and mediation of cytotoxicity), have been examined for their inhibitory abilities toward 
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metal-free A and metal–A aggregation and toxicity, as well as their free radical 
scavenging capacity in vitro by biochemical and biophysical methods. Chapter 3 
describes the chemical library of L2-b and DMPD derivatives for identifying the structural 
moieties essential for regulating activities of metal-free A, metal–A, and free radicals. 
From Chapters 2 and 3, an understanding about the structure-interaction-reactivity 
relationship of small molecules toward metal-free A and metal–A could be obtained 
and applied this knowledge for future screening of natural products and designing 
synthetic chemicals. Chapter 4 and Appendix A outline the information of the interaction 
between A and A-interacting proteins (i.e., HSA, S100 proteins) with and without metal 
ions. HSA and S100 proteins could influence on AD etiology by themselves and 
interacting with other pathological features. Taken together, the investigations from these 
studies have revealed a part of relations between multiple AD pathological facets, and 
can be a milestone to understand the complicated AD etiology. 
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Chapter 2: Effects of Hydroxyl Group Variations on a Flavonoid Backbone 
toward Modulation of Metal-free and Metal-induced Amyloid- Aggregation  
 
 
This chapter is based on work that will be submitted for publication. We thank Professor 
Ayyalusamy Ramamoorthy and Kyle J. Korshavn for NMR experiments; Professor 
Brandon T. Ruotolo and Dr. Richard A. Kerr for IM-MS analysis; Jeeyeon Lee for studies 
of metal binding and cell experiments with Juhye Kang. I was involved in metal binding 
studies, gel and TEM analyses for A aggregation, cell viability measurements as well as 
manuscript writing. 
 
 
2.1. Introduction 
Alzheimer’s disease (AD) has been grown as one of the most severe incurable 
neurodegenerative diseases.1-8 AD patients have symptoms of memory loss and being 
unable to conduct daily activities and eventually, the disease can lead patients to death.2-
8 This fatal disease can be characterized by shrinkage of the brain size and the presence 
of abnormally folded protein aggregates, such as amyloid- (A) peptides aggregates and 
neurofibrillary tangles composed with hyperphosphorylated tau proteins in the brain.2-10 
In addition to that, it has been suggested that dyshomeostasis of metals (i.e., Cu and Zn) 
is linked to the onset and progression of AD pathology as well.2-14 Cu(II) and Zn(II) are 
observed to bind to A facilitating peptide aggregation, and generating oligomeric 
species, suggested to be toxic; Cu(II)-bound A could generate reactive oxygen species 
(ROS) causing oxidative stress.2-14 Although toxic A conformations and oxidative stress 
induced by metal-associated A (metal–A) species have been proposed to be involved 
in AD pathogenesis,2-14 the interrelationship between metal ions and A peptides in AD 
development has not been fully elucidated. 
To gain a better understanding of the relationship between metal–A and AD 
pathogenesis, chemical tools capable of interacting directly with both metal ions and A 
species and subsequently modulating A aggregation pathways have been developed 
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and examined their reactivity (i.e., redirection of metal–A aggregation pathways, 
regulation of metal-free A and metal–A triggered cytotoxicity).15-27 Recently, these 
chemical tools have been found through a rational structure-based design strategy and 
screening of natural products, including flavonoids and curcumin.15-27 
Among natural products, flavonoids have been of interest due to their anti-oxidant 
and anti-inflammation properties and potential usage for cancer, cardiovascular diseases, 
and dementia cares.18,20,28-32 Flavonoids are polyphenolic compounds which are 
abundant in vegetables, fruits, or berries.18,20,28-32 Recently, myricetin (Figure 2.1) and ()-
epigallocatechin-3-gallate (EGCG) have been presented to interact with both metal ions 
and A peptides, confirmed by biochemical and biophysical techniques, as well as have 
their abilities to modulate metal–A aggregation in vitro and alleviate toxicity triggered by 
metal–A in living cells.18,20 Although some flavonoids present their anti-amyloidogenic 
 
Figure 2.1. Structures of flavonoids. Myricetin: 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-
one; morin: 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; quercetin: 2-(3,4-
dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; galangin: 3,5,7-trihydroxy-2-phenyl-4H-chromen-4-
one; luteolin: 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one. Groups highlighted in blue and 
red indicate the structural variations from the B and C rings of myricetin. Potential donor atoms for metal 
interaction are in bold. 
property, the structural moieties of flavonoids, responsible for such reactivity, are not 
identified. Multiple previous studies have probed potential metal chelation sites of 
numerous flavonoids and their influence on metal-free A aggregation.18,20,30-40 Detailed 
investigations of the interaction between A and flavonoids, and their effects on metal–
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A aggregation have been rarely reported, however.18,20 In particular, a structure-
interaction-reactivity relationship between flavonoids and metal–A has not been clearly 
described and presented.  
Herein, we present the interaction and reactivity with metal-free A and metal–A 
of four rationally selected flavonoids (i.e., morin, quercetin, galangin, luteolin; Figure 2.1) 
along with their metal chelation property. These flavonoids contain structural variations 
(i.e., number and position of hydroxyl groups) on the structure of myricetin (Figure 2.1) 
which is indicated to control metal–A40 aggregation pathways and mitigate cytotoxicity 
induced by metal–A.20 Morin, quercetin, and galangin (Figure 2.1) have different 
numbers of hydroxyl groups on the B ring while A and C rings have same structure as 
myricetin. Luteolin has the same catechol group on the B ring as quercetin, while it does 
not have a hydroxyl group on the C ring (C3 position; 3-OH). Through our studies, the 
selected flavonoids are observed to display the influence on both aggregation and toxicity 
of metal-free A and metal–A with different degrees. Hydroxyl groups on the B ring might 
have a significant effect on modulation of metal–A aggregation pathways; the 3-OH 
group might also play a role to interact with metal ions and A peptides. Moreover, our 
biophysical analyses employing 2D nuclear magnetic resonance (NMR) and ion mobility-
mass spectrometry (IM-MS) also demonstrate interactions of our selected flavonoids, 
composed of different numbers and positions of hydroxyl substituents, with metal-free A 
and/or metal-bound A to distinct extents. Taken together, our studies provide insights 
into a structure-interaction-reactivity relationship between flavonoids and metal–A (over 
metal-free A), which could advance our knowledge on the development of chemical tools 
for elucidating the role of metal–A in AD. 
 
2.2. Results and discussion 
 
2.2.1. Rational selection of flavonoids toward metal-free A and metal-induced A 
aggregation 
Some naturally occurring flavonoids (i.e., myricetin) are shown to target metal–
A40 species and modulate their aggregation pathways in vitro;20 however, the structural 
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moieties responsible for interacting with metal–A40 species and affecting their 
aggregation are not fully identified. To obtain a better understanding of a structure-
interaction-reactivity relationship between flavonoids and metal-free A or metal–A, four 
different flavonoids (morin, quercetin, galangin, and luteolin; Figure 2.1) were selected 
with the structural variations of hydroxyl groups on a flavonoid backbone of myricetin. 
Investigations of flavonoids, composed of the different number or position of hydroxyl 
groups on the B and C rings (Figure 2.1), toward metal-free A and metal–A [two major 
isoforms of A (A40 and A42) found in the AD-affected brain]2,6 could be valuable to 
determine which structural portions are important for their influences on A aggregation 
pathways. Thus, morin, quercetin, and galangin were chosen for our studies, which have 
the different number of the hydroxyl groups on the B ring while they have the same 
structure of the A and C rings (Figure 2.1). A hydroxyl group on the C ring at the 3C 
position (3-OH group) with the most acidic proton is shown to be involved in metal 
binding;39,41 hence, for our studies, we also included luteolin, which has a catechol group 
on the B ring as quercetin but does not contain the 3-OH moiety. 
 
2.2.2. Effects of flavonoids, morin, quercetin, galangin, and luteolin on metal-free 
A and metal-induced A aggregation in vitro 
To identify how the structural variations of flavonoids affect metal-free A and 
metal–A aggregation, two different experiments, inhibition and disaggregation 
experiments (Figures 2.2. and 2.3) were conducted. For inhibition experiments (Figures 
2.2. and 2.3, left), freshly dissolved A (25 M) with or without CuCl2 or ZnCl2 (25 M) 
was treated with flavonoids (50 M) for 24 h. In the case of disaggregation experiments 
(Figures. 2.2 and 2.3, right), fresh A (25 M) was dissolved and incubated for 24 h with 
or without CuCl2 or ZnCl2 (25 M), then flavonoids (50 M) were added to the resulting 
solution and incubated for additional 24 h. Size distributions and morphological changes 
of resulting A species from both experiments were observed by gel electrophoresis 
followed by Western blotting (gel/Western blot) with an anti-A antibody (6E10) and TEM, 
respectively.  
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From both inhibition and disaggregation experiments, flavonoids might not 
be able to significantly modulate metal-free A40/A42 aggregation (Figures 2.2 and 
2.3). Relatively similar molecular weight (MW) distribution of resulting metal-free 
A species from both inhibition and disaggregation experiments with or without 
flavonoids were detected by gel/Western blot (Figures 2.2 and 2.3). Myricetin is not 
observed to noticeably present its regulatory property toward metal-free A40 
aggregation,20 and simple variations on its structural backbone (i.e., number and 
position of hydroxyl groups) could not help the molecules have ability to redirect 
metal-free A40/A42 aggregation. On the other hand, in both inhibition and 
disaggregation experiments, various MW distributions was shown upon treatment 
of flavonoids to metal–A with different degrees (Figures 2.2 and 2.3). From 
inhibition studies, influence of flavonoids on the formation of diverse MW 
distributed metal–A40 aggregates was indicative and visualized by the 
gel/Western blot (Figure 2.2a). Noticeably, as depicted in Figure 2.2a, the samples 
containing Cu(II)–A40 and flavonoids showed more various-sized peptide species, 
compared to Zn(II)–A40 with flavonoids. In the case of Zn(II)–A40, higher sized 
A40 species (above 100 kDa MW) and smaller sized A40 species (lower than 50 
kDa) were detected by gel/Western blot (Figure 2.2a). Besides, upon treatment 
with flavonoids, smaller and more amorphous Cu(II)–A40 species and less 
structured Zn(II)–A40 species were observed by TEM, relative to flavonoid-
untreated A samples (Figure 2.2b).  
These results are similar to experimental data of previous studies using 
myricetin that presents its noticeable modulation ability toward metal–A40 
aggregation over metal-free A40 aggregation.20 Although morin and quercetin 
have less hydroxyl groups on the B ring than myricetin, they still exhibited their 
ability to redirect metal–A40 aggregation to different extents. A catechol moiety on 
the B ring (shown in quercetin) may have other influence on modulation of metal–
A aggregation pathways than hydroxyl groups on the B ring located apart from 
each other (shown in morin). Moreover, luteolin, which lacks an additional hydroxyl 
group on the C ring from quercetin, may have a slight effect on metal–A40 
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Figure 2.2. Influence of flavonoids on metal-free and metal-induced A40 aggregation. Top: Scheme of 
inhibition (left) and disaggregation (right) experiments. For the inhibition experiment (a and b), A40 was 
first treated with or without CuCl2 or ZnCl2 followed by addition of flavonoids. The resulting samples were 
incubated at 37 °C for 24 h with constant agitation. For the disaggregation experiment (c and d), A40 in the 
absence and presence of CuCl2 or ZnCl2 was initially incubated for 24 h with steady agitation. Flavonoids 
were then added into the resulting solution which was followed by an additional incubation for 24 h at 37 
°C with constant agitation. Resultant A40 species were visualized by gel/Western blot with an anti-A 
antibody (6E10) and TEM. Conditions: [A40] = 25 M; [CuCl2 or ZnCl2] = 25 M; [flavonoid] = 50 M; pH 
6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 37 C; 24 h; constant agitation. 
(more noticeable for Cu(II)–A40 than Zn(II)–A40). The only structural variation 
between quercetin and luteolin is the presence and absence of 3-OH, respectively, 
and this small substituent change can cause different oxidized forms which could 
alter the interaction between flavonoids and metal–A40, and modulation of metal–
A40 aggregation to different extents.42-44 Besides, as 3-OH along with 4-oxo is 
suggested to be involved in metal chelation by quercetin,33,34,39,45,46 the presence 
of 3-OH may help quercetin interact with metal–A species. In addition, galangin 
does not have a hydroxyl group on the B ring, but it has 3-OH and 4-oxo; thus, it 
might maintain its reactivity toward metal–A40. Overall, metal–A40 aggregation 
could be altered by treatments of the flavonoids with different degrees when the 
structure variations on the backbone occur. 
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Furthermore, from inhibition experiments with metal–A42, morin and 
quercetin presented greater influence on the peptide aggregation than luteolin, 
while galangin might not have an effect on metal–A42 aggregation (Figure 2.3a). 
Various-sized Cu(II)–A42 species treated with morin or quercetin were indicated 
showing the smearing throughout the lanes from gel/Western blot results (Figure 
2.3a). Luteolin may redirect Cu(II)–A42 aggregation slightly, while galangin may 
not be able to modulate Cu(II)–A42 aggregation pathways. When Zn(II)–A42 was 
treated with morin and quercetin, different MW distribution patterns of resulting 
A42 species from the samples without flavonoids were observed (Figure 2.3a). 
Luteolin also displayed a very slight difference MW distribution of Zn(II)–A42 over 
the flavonoid-untreated Zn(II)–A42 sample. The morphologies of metal–A42  
 
Figure 2.3. Effect of flavonoids on metal-free and metal-induced A42 aggregation. Top: Schemes of 
inhibition (left) and disaggregation (right) experiments. For the inhibition experiment (a and b), A42 was 
first treated with CuCl2 or ZnCl2 and followed by addition of flavonoids. The resulting samples were 
incubated at 37 °C for 24 h with constant agitation. For the disaggregation experiment (c and d), A42 in the 
presence of CuCl2 or ZnCl2 were initially incubated for 24 h with steady agitation. Flavonoids were then 
introduced into the resulting solution, followed by an additional incubation for 24 h at 37 °C with constant 
agitation. The resultant A42 species were visualized by gel/Western blot with an anti-A antibody (6E10) 
and TEM. Conditions: [A42] = 25 M; [CuCl2 or ZnCl2] = 25 M; [flavonoid] = 50 M; pH 6.6 (for Cu(II) 
experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 37 C; 24 h; constant agitation. 
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incubated with morin, quercetin, and luteolin showed smaller and more amorphous 
than samples without flavonoids (Figure 2.3b), observed by TEM. The results of 
inhibition experiments with A42, flavonoids with hydroxyl groups on the B ring 
(morin, quercetin, and luteolin) may be important to target and modulate metal–
A42 aggregation pathways. 
From the disaggregation experiments (Figures. 2.2c,d and 2.3c,d), morin, 
quercetin, galangin and luteolin could disassemble both Cu(II)– and Zn(II)–A40 
aggregates or alter their further aggregation to different extents. The resultant 
Cu(II)–A40 species treated with flavonoids, except luteolin, presented various 
distributed MW by gel/Western blot (Figure 2.2c). Relative to other flavonoids, 
luteolin displayed very slight modulation of Cu(II)–A40 aggregation. Upon addition 
of flavonoids to Zn(II)–A40, higher-sized (above 100 kDa MW) and smaller sized 
(lower than 50 kDa MW) A40 species were detected (Figure 2.2c) as similar to the 
results of inhibition experiments. By TEM, the morphologies of metal–A40 
incubated with flavonoids were observed smaller and more amorphous metal–A40 
than compound-free metal–A40 samples (Figure 2.2d).  
Moreover, Cu(II)– or Zn(II)–A42 aggregates incubated with morin and 
quercetin displayed various distributions of MW, while luteolin- or galangin-treated 
samples presented slight different MW distribution and did not show difference 
compared to the samples without flavonoids, respectively (Figure 2.3c). 
Furthermore, the morphologies of resultant metal–A42 aggregates incubated with 
flavonoids were detected as thinner fibrils or smaller and amorphous metal–A42 
species than metal–A42 samples without compounds. As mentioned from the 
inhibition studies, the results from disaggregation experiments, the presence of 
hydroxyl groups on the B ring of flavonoids may have their influence on the 
interaction with metal–A42 and subsequent ability to control the aggregation 
pathways. 
Taken together, the overall gel/Western blot and TEM results, the flavonoids 
(morin, quercetin, galangin, and luteolin; Figure 2.1) suggest that they could alter metal-
induced A aggregation over metal-free A aggregation. The structural difference, such 
 35 
 
as the number and position of hydroxyl groups on the B and C rings of flavonoid 
backbone, could affect their ability to alter metal–A aggregation pathway to different 
extents. Morin and quercetin containing hydroxyl groups on both B and C rings are 
observed to redirect metal–A40 and A42 aggregation pathways significantly; galangin, 
which does not have a hydroxyl group on the B ring, may prefer to modulate metal–A40 
aggregation over metal–A42 aggregation; luteolin, which has a catechol moiety on the B 
ring and does not have 3-OH, could slightly influence on metal–A40/A42 aggregation 
pathways, compare to morin and quercetin. 
 
2.2.3. Cu(II) binding of morin, quercetin, galangin, and luteolin 
Since the selected flavonoids have shown more noticeable ability to modulate 
Cu(II)–A40 aggregation over both metal-free A40 and Zn(II)–A40 aggregation, Cu(II) 
binding of flavonoids in both the absence and presence of A40 were investigated by UV–
Visible spectroscopy (UV–Vis; Figure 2.4). As expected from the previously reported 
studies (O donor atoms for metal binding),33-35,45,46 optical spectra changes were 
observed upon the addition of CuCl2 into the solution containing flavonoids [20 mM 
HEPES, pH 7.4, 150 mM NaCl]. 
 
Figure 2.4. Interaction of flavonoids with Cu(II) in both the absence and presence of A40, monitored by 
UV–Vis. (a) The spectra of flavonoids in the absence (black) and presence (gray and blue) of Cu(II) without 
A40. (b) The spectra of the samples containing A40, one equiv of CuCl2, and/or selected flavonoids. A 
solution containing A (dark gray) was treated with CuCl2 for 2 min (light gray) followed by flavonoids (blue). 
The spectra of flavonoids are presented in black. Conditions: [A40] = 25 M; [CuCl2] = 12.5-25 M; 
[flavonoid] = 25 M; 20 mM HEPES, pH 7.4, 150 mM NaCl; room temperature; 10 min. 
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Variations in UV–Vis spectra, such as new optical bands and changes in 
absorbance intensity, were indicated. New optical bands were detected after the addition 
of CuCl2 at ca. 325 and 405 nm (for morin), 448 nm (for quercetin), 417 nm (for galangin), 
and 413 nm (for luteolin) (Figure 2.4a). These spectral changes were similar to previous 
metal binding studies, indicating the potential involvement of hydroxyl groups on the B 
and C rings in Cu(II) binding.33,34,39,45,46 Based on the previous studies, the groups of 3-
OH/4-oxo, 5-OH/4-oxo, or a catechol (Figure 2.1) have been proposed as metal chelation 
sites.39,45,46  
In addition, Cu(II) binding of these flavonoids in the presence of A40, which could 
help understand their reactivity toward Cu(II)–A aggregation, was studied by UV–Vis. 
To determine if flavonoids could interact with Cu(II) surrounded by A40, flavonoids were 
introduced to the solution containing Cu(II) pre-treated with A40. After morin, quercetin, 
galangin, and luteolin were added to Cu(II)–A40 solution [Cu(II):A:flavonoids, 1:1:1], 
optical spectra indicative of Cu(II) binding were obtained (Figure 2.4b), which were slightly 
different from those of Cu(II)–ligand complexes [Cu(II):flavonoids, 1:1] without A40 in the 
solution (Figure 2.4a), suggesting that Cu(II) binding to these flavonoids could be 
interfered by A peptides. Overall, from our UV–Vis experiments, morin, quercetin, 
galangin, and luteolin in this study can interact with Cu(II) even in the presence of A40. 
 
2.2.4. Interaction of flavonoids with soluble A species 
The interaction of morin, quercetin, galangin, and luteolin with A40 was 
investigated with 2D band-Selective Optimized Flip-Angle Short Transient Heteronuclear 
Multiple Quantum Correlation (SOFAST-HMQC) NMR.47 Previously, this has been 
applied to identify which chemical alterations to a framework can direct the binding of 
ligand to A40 and can elucidate the structural basis for distinct reactivity.18,19,21,22,27 The 
chemical shift perturbation (CSP) induced by the addition of compound to the peptide was 
monitored to determine potentially preferred binding modes (Figure 2.5).  
All four flavonoids caused modest (0.02-0.04 ppm) chemical shifts in different 
regions of the A40 sequence. Among them, morin induced the most chemical shifts of 
amino acid residues in A and may primarily target the self-recognition site (residues from 
L17 to A21)5-8,14 and C-terminus hydrophobic region (Figure 2.5). Quercetin relatively 
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noticeably interacts with F20, in the central hydrophobic region of the peptide,5-8,14 and 
V12 and Q15 which are forming a groove between -helix and N-terminus tail (Figure 
2.5f).48 Galangin may be able to interact with V18 and F20 from the self-recognition 
region5-8,14 and V12 (Figure 2.5g). Luteolin, which lacks 3-OH, preferentially perturbs E11 
and L17 above all other residues (Figure 2.5h). Furthermore, morin, quercetin, and 
galangin which have 3-OH could cause higher CSP on F20 than other A40 amino acid 
residues, the presence of 3-OH may lead the interaction of the flavonoid framework with 
F20 in the self-recognition region of the peptide. Although these three flavonoids could 
target F20, they have interacted with different regions of A40 peptides; thus, the position 
of the hydroxyl groups on the B ring also may have an effect on the interaction between 
A40 and flavonoids. This suggests that the flavonoids showing small different substitution 
patterns around the B ring interact with soluble A40 in a slight different manner. Taken 
together, the variations of hydroxyl groups on both B and C rings could alter the interaction 
of flavonoids toward A40 peptides. 
 
Figure 2.5. The interaction of flavonoids with 15N-labeled A40, monitored by 2D-SOFAST-HMQC NMR. 
Spectra were recorded as (a) morin, (b) quercetin, (c) galangin, and (d) luteolin was titrated into a solution 
of 15N-labeled A40 from 0 (red spectra) and 10 (blue spectra) equiv of flavonoids. The chemical shift 
perturbation (CSP) was calculated for each residue upon the titration of (e) morin, (f) quercetin, (g) galangin, 
and (h) luteolin in order to investigate their potential interaction with A. The average chemical shift (dashed 
line) plus standard deviation (dotted line) were plotted for reference. CSP values which exceed the sum of 
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the average CSP and the standard deviation are indicative of noticeable interactions. Conditions: [A40] = 
80 M; [flavonoid] = 0-800 M; 20 mM PO4, pH 7.4, 50 mM NaCl; 7% D2O (v/v); 10 °C. 
 
2.2.5. Direct binding properties of flavonoids to A species and conformational 
changes 
 The interactions between monomeric and dimeric A40 species and the flavonoids 
studied herein were further monitored in the absence and presence of Cu(II) by nano-
electrospray ionization MS (nESI-MS) combined with ion mobility-mass spectrometry (IM-
MS), optimized for the detection of non-covalent protein complexes49-51. Data presented 
in Figures 2.6 and 2.7 supports that both quercetin and luteolin are capable of binding 
A40 in the absence of any metal ions. Contrary to expectations, monomeric A40 binding 
to quercetin and luteolin was only observed for the 3+ charge state, highlighting the weak 
binding of these molecules to the peptide. Expanding our analyses to incorporate A40 
dimers (Figure 2.8), the results reveal that morin is shown to interact with metal-free A40, 
pointing to a likely binding site comprised of a surface only presented in oligomeric A. 
The analyses of dissociation constants (Kd; Table 2.1) on all metal-free data sets indicate 
that this oligomeric binding surface results in the complex generation of A with morin, 
quercetin, and luteolin; however, their binding with metal-free A monomer and dimer is 
relatively weak (Kd ≥ 400 M). The absence of any observable A–galangin complexes 
in our data suggests no noticeable and possible interactions of this flavonoid with metal-
free A or larger and higher-order oligomers, too transient for IM-MS detection. 
In order to investigate the redirecting activity of these small molecules toward 
metal-induced A aggregation in more detail, we performed MS experiments on 
Acomplexes in samples incubated in the presence of Cu(II) (Figure 2.6). Interestingly, 
our data supports that each sequential copy of morin bound to A40 requires an 
stoichiometric equivalents of Cu(II). These observations, when compared to our metal-
free analyses, highlight the metal dependence of A–morin binding. Quercetin, in 
contrast, is not shown to have such stoichiometric dependencies. Consistent with other 
data presented here, our results support the greater ability of morin and quercetin to target 
metal-bound A40 than luteolin and galangin. Note that, while the analysis of flavonoid  
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Figure 2.6. Mass spectrometric analysis of flavonoid-bound A40 monomers in both the absence and 
presence of Cu(II). Mass analysis of monomeric A40 (20 M) independently incubated with 120 M of 
either (a) morin, (b) quercetin, (c) galangin, or (d) luteolin in the (i) absence and (ii) presence of a source of 
Cu(II) (Copper(II) acetate). Charge states are those that best represent the dominant ligand bound species 
observed. Dashed lines represent the expected binding locations of the noted species based on theoretical 
average m/z values. (e) Ion mobility arrival times extracted from the full width half maximum (FWHM) of the 
observed 4+ morin- and quercetin-bound A40 species. Calculated collision cross section values for these 
data are summarized in Table 2.2. 
 
binding to Cu(II)-bound A40 dimers was attempted, data proved to be inconclusive due 
to poor signal to noise levels associated with increased metal adduct formation and 
propensity for A aggregation. 
 To gain further insight into the mode of action at molecular level for the flavonoids 
studied herein, in the context of A40, we applied IM-MS in order to capture the size 
distributions of the metal–A–flavonoid complexes discussed above. Data for all 
observed 4+ ligated A40 monomer species are presented in Figure 2.6, with collision 
cross section data (Table 2.2). Our overall IM-MS results indicate, in all instances, that 
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Figure 2.7. Mass spectrometric analysis of luteolin- and quercetin-bound A40 monomers in both the 
absence and presence of Cu(II). Whilst small molecules are expected to be observed in complex with both 
the 3+ and 4+ peptide species,17,18 luteolin and quercetin are shown to bind to only the 3+ peptide in the 
absence of Cu(II).17,18 4+ species binding is indicated in the samples containing a source of Cu(II). Such 
differences may be explained by poor binding levels of these small molecules to A peptides in the absence 
of Cu(II). The dashed lines represent the expected binding location of the noted species based on 
theoretical average m/z values. 
 
flavonoid binding leads to the formation of conformationally distinct species compared to 
the metal-free/-bound states. As such, these results are consistent with other IM-MS 
results for small molecules, previously reported to alter A aggregation pathways.17,18 
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Table 2.1. Kd analysis of flavonoid-bound A40 in the absence of Cu(II). 
 
Values were calculated using previously published methods.52,53 Conditions: [A] = 20 M; [Cu(II)] = 20 M; 
[compound] = 120 M. Errors shown represent single standard deviations. 
 
Figure 2.8. Mass spectrometric analysis of flavonoid-bound A40 dimers. Mass analysis of the dimeric metal 
free A40 (5+) in the presence of each the natural products support that whilst quercetin and luteolin are 
capable of binding the monomeric species, morin binds to the peptide via a site comprised of a surface only 
present in oligomeric A. The dashed lines represent the expected binding location of the noted species 
based on theoretical average m/z values. 
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Table 2.2. Collision cross section data of all extracted ion mobility arrival times for the observed 4+ monomer 
species. 
 
Collision Cross Section values calculated for 4+ morin- and quercetin-bound A40 species arrival times 
extracted from the full width half maximum (FWHM). Errors represent least square analysis encapsulating 
inherent calibrant error from drift tube measurements (3%),54 calibration curve error, and two times the 
replicate standard deviation error. The dominant conformational species for each extracted data set is 
denoted with the suffix *. 
 
2.2.6. Regulation of toxicity induced by metal-free A and metal–A by morin, 
quercetin, galangin, and luteolin in living cells 
 The ability of morin, quercetin, galangin, and luteolin to recover toxicity induced by 
metal-free A and metal–A was investigated in human neuroblastoma SH-SY5Y (5Y) 
cells. The cytotoxicity was determined by the MTT assay following previously published 
methods (Figure 2.9).18,20-22,27 5Y cells were incubated with metal ions (10 M) and 
flavonoids (10 M) with or without A40 or A42 (10 M) for 24 h. 
In the absence of A, flavonoids may not significantly affect cell viability with and without 
metal ions. On the other hand, when A40 or A42 was introduced to 5Y cells, it presented 
cell survival by 85(±3)% and 86(±1)%, respectively (Figure 2.9). Moreover, cells which 
were treated with A40 or A42 and Cu(II) lowered viability [73(±1)% and 68(±2)%], 
respectively, while cells added with A40 or A42 and Zn(II) showed similar survival to 
metal-free A-treated cells [87(±2)% and 83(±2)%, respectively] (Figure 2.9). Both morin 
and quercetin could reduce the toxicity induced by metal–A more than 10% while 
galangin and luteolin could recover very slightly cell viability by ca. 3-5% from toxicity 
triggered by metal–A (Figure 2.9). These results may be related to their ability to redirect 
metal–A aggregation pathways to less toxic pathways, along with their known anti-
oxidant activity.55-57 Morin and quercetin, which have hydroxyl functionality on both B and 
C rings [possibly important for modulation of A aggregation (vide supra) and anti-oxidant 
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property56] may be able to alleviate the toxicity triggered by A and metal–A in living 
cells more significantly than galangin or luteolin. 
 
 
Figure 2.9. Viability of flavonoids with or without metal ions in both the absence and presence of A. 
Cytotoxicity was measured by the MTT assay after 24 h incubation of SH-SY5Y cells with and without A, 
a metal chloride salt (CuCl2 or ZnCl2), or selected flavonoids. The cell viability (%) was calculated compared 
to cells treated with equivalent amounts of DMSO only (0-1%, v/v). Lanes: (1) A ± [CuCl2 or ZnCl2]; (2) A 
± [CuCl2 or ZnCl2] + morin; (3) A ± [CuCl2 or ZnCl2] + quercetin; (4) A ± [CuCl2 or ZnCl2] + galangin; (5) 
A ± [CuCl2 or ZnCl2] + luteolin. Conditions: [A] = 10 M; [CuCl2 or ZnCl2] = 10 M; [flavonoid] = 10 M. 
Values represent the mean of four independent experiments (± standard error). 
 
2.3. Conclusion 
Morin, quercetin, galangin, and luteolin are shown to have their ability to redirect 
metal–A40/A42 aggregation pathways more noticeably than metal-free A40/A42 
aggregation. Each flavonoid shows different degrees on metal binding, A interaction, 
and modulation of metal–A aggregation. Such different properties are observed to be 
dependent on structural variations. The flavonoids with hydroxyl groups on both B and C 
rings (morin and quercetin) are indicated to significantly present their reactivity toward 
metal–A aggregation and metal binding properties. Furthermore, these flavonoids could 
distinguishably attenuate toxicity induced by metal–A in living cells. On the other hands, 
the flavonoids with lack of hydroxyl groups on the B or C ring (galangin and luteolin) are 
observed to have less reactivity toward metal–A species. Such reactivity differences 
between the flavonoids with different number and location of hydroxyl groups are also 
demonstrated through biophysical investigations on direct interactions with metal-free A 
and/or metal-bound A using 2D NMR and IM-MS. The data indicate weak interactions 
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of these flavonoids with metal-free A monomer and dimer to distinct extents. Given the 
low affinity for metal-free A binding, it is unsurprising that significant effect on metal-free 
A aggregation is not observed in our inhibition and disaggregation studies using the 
relatively low concentration of the flavonoids when compared to the 2D NMR and IM-MS 
results. Toward targeting and interacting metal-bound A40, morin and quercetin are 
shown to have the greater ability than luteolin and galangin. Moreover, upon binding with 
morin and quercetin, the formation of conformationally distinct peptide species occurs 
compared to the metal-free/-bound states. Taken together, our studies demonstrate that 
such slight structure modifications of flavonoids (i.e., the variation of hydroxyl groups on 
their B and C rings) could tune their interactions with metal ions, A species, and metal–
A, which could subsequently alter their abilities to metal–A aggregation pathways and 
recover A/metal–A related cytotoxicity. 
 
2.4. Experimental section 
 
2.4.1. Materials and methods 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. Morin and quercetin were purchased from Abcam (Cambridge, 
MA, USA); galangin and luteolin were acquired from Santa Cruz Biotechnology (Dallas, 
TX, USA) and Alfa Aesar (Ward Hill, MA, USA), respectively. The flavonoids were used 
without further purification. Trace metal contamination was removed from buffers and 
solutions used for A experiments by treating with Chelex (Sigma-Aldrich, St Louis, MO, 
USA). A40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and A42 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were obtained from 
Anaspec (Fremont, CA, USA) and Anygen (Nam-myun, Jangseong-gun, Korea). Double 
distilled H2O (ddH2O) was obtained from a Milli-Q Direct 16 system (Merck KGaA, 
Darmstadt, Germany). Optical spectra for metal binding studies were recorded on an 
Agilent 8453 UV−Visible (UV−Vis) spectrophotometer. Transmission electron microscopy 
(TEM) images were collected on a JEOL JEM-2100 transmission electron microscope 
(UNIST Central Research Facilities, Ulsan, Korea). A SpectraMax M5 microplate reader 
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(Molecular Devices, Sunnyvale, CA, USA) was used to measure the absorbance for the 
MTT assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. 
 
2.4.2. Amyloid- (A) peptide experiments 
A experiments were conducted as previously published methods.16-27 A peptides 
were dissolved with ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized, 
and stored at −80 °C. A stock solution (ca. 200 M) was prepared by re-dissolving A 
with NH4OH (1% w/v, aq, 10 L) followed by dilution with ddH2O. The concentration of 
the solution was determined by measuring the absorbance of the solution at 280 nm ( = 
1450 M-1cm-1 for A40;  = 1490 M-1cm-1 for A42). Buffered solutions [20 mM HEPES (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 6.6 or 7.4, 150 mM NaCl] were 
used for both inhibition and disaggregation studies [pH 6.6 for Cu(II) samples; pH 7.4 for 
metal-free and Zn(II) samples]. For the inhibition experiment, A (25 M) was first treated 
with or without a metal chloride salt (CuCl2 or ZnCl2, 25 M) for 2 min followed by addition 
of morin, quercetin, galangin, or luteolin (50 M, 1% v/v final DMSO concentration). The 
resulting samples were incubated at 37 °C for 24 h with constant agitation. For the 
disaggregation experiment, A in the absence or presence of a metal chloride salt (CuCl2 
or ZnCl2) was initially incubated at 37 °C for 24 h with steady agitation. The compound 
was added afterward, followed by an additional 24 h of incubation at 37 °C with constant 
agitation. 
 
2.4.3. Gel electrophoresis with Western blotting 
The A peptide experiments described above were analyzed by gel 
electrophoresis followed by Western blotting (gel/Western blot) using an anti-A antibody 
(6E10).16-27 Each sample (10 L, [A] = 25 M) was separated using a 10-20% gradient 
Tris-tricine gel (Invitrogen, Grand Island, NY, USA). The gel was transferred to a 
nitrocellulose membrane and blocked with a bovine serum albumin (BSA) solution (3% 
w/v; Sigma, St. Louis, MO, USA) in Tris-buffered saline (TBS; Fisher, Pittsburgh, PA, 
USA) containing 0.1% Tween-20 (TBS-T; Sigma-Aldrich) for 3 h at room temperature. 
The membrane was treated with the A monoclonal antibody (6E10; Covance, Princeton, 
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NJ, USA; 1:2,000; BSA, 2% w/v, in TBS-T) for overnight at 4 °C and then probed with a 
horseradish peroxidase conjugated goat anti-mouse secondary antibody (1:5,000; 
Cayman Chemical, Ann Arbor, MI, USA) in 2% BSA in TBS-T solution for 1 h at room 
temperature. A species were visualized using Thermo Scientific Supersignal West Pico 
Chemiluminescent (ECL) Substrate (Rockford, IL, USA) or self-made ECL solution (2.5 
mM luminol, 0.20 mM p-coumaric scid, 0.018% H2O2 in 100 mM Tris, pH 8.6). Note that 
the gel analysis presented herein is qualitative due to properties of resulting A species. 
 
2.4.4. Transmission electron microscopy (TEM) 
Samples for TEM were prepared following previously reported methods.16-27 Glow 
discharged grids (Formar/Carbon 300-mesh; Electron Microscopy Sciences, Hatfield, PA, 
USA) were treated with samples from either inhibition or disaggregation experiments (5 
L) for 2 min at room temperature. Excess sample was removed with filter paper and the 
grids were washed with ddH2O three times. Each grid was stained with uranyl acetate 
(1% w/v ddH2O, 5 L) for 1 min. Uranyl acetate was blotted off and grids were dried for 
20 min at room temperature. Images of samples were taken by a JEOL JEM-2100 
transmission electron microscope (200 kV, 25 000× magnification). 
 
2.4.5. Cu(II) binding studies 
The interaction of flavonoids with Cu(II) was determined by UV−Vis based on 
previously reported procedures.18-20,23 A solution of ligand (25 M in 20 mM HEPES, pH 
7.4, 150 mM NaCl) was prepared, treated with 0.5 and 1 equiv of CuCl2, and incubated 
at room temperature for 10 min. In order to verify if Cu(II) binding to ligand occurs in the 
presence of A40, optical studies were performed on samples of A40 (25 M) 
preincubated with 0 or 1 equiv of CuCl2 in the absence and presence of flavonoids (25 
M). The optical spectra of the resulting solutions were measured after 10 min incubation. 
 
2.4.6. 2D nuclear magnetic resonance (NMR) spectroscopy 
The interaction between ligands and 15N-labeled A40 was monitored by 2D band-
Selective Optimized Flip-Angle Short Transient Heteronuclear Multiple Quantum 
Coherence (SOFAST-HMQC) at 10 °C.47 Uniformly 15N-labeled A40 (rPeptide, Bogart, 
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GA, USA) was dissolved in 1% NH4OH, aliquoted, and lyophilized. The peptide (80 M 
peptide) was re-dissolved in 3 L of DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) 
and diluted into PBS (20 mM PO4, pH 7.4, 50 mM NaCl; 7% v/v D2O). Compounds were 
titrated into the peptide solution from a 50 mM stock solution in DMSO-d6 up to 10 equiv 
(800 M). Spectra were acquired using 64 complex t1 points and a 0.1 sec recycle delay 
on a Bruker Avance 600 MHz spectrometer equipped with a cryoprobe. 2D data were 
processed using TOPSPIN 2.1 (from Bruker) and assignment was performed using 
SPARKY 3.1134 using published assignments for A40 as a guide.48,58,59 Chemical shift 
perturbation (CSP) was calculated by the following equation (eq 1): 
∆𝛿𝑁𝐻 = √∆𝛿𝐻2 + (
∆𝛿𝑁
5
)
2
 (eq 1) 
 
2.4.7. Ion mobility-mass spectrometry (IM-MS) 
All Ion Mobility-Mass Spectrometry (IM-MS) experiments were carried out on a 
Synapt G2 (Waters, Milford, MA).60,61 Samples were ionized using a nano-electrospray 
source operated in positive ion mode. MS instrumentation was operated at a backing 
pressure of 2.7 mbar and sample cone voltage of 40 V. For peptide-derivative-metal 
ligation studies aliquots of A40 peptides (final concentration 20 M) were sonicated for 5 
sec prior to preincubation with or without a source of Cu(II) (Copper(II) acetate, 20 M) at 
37 °C for 10 min. After preincubation, samples were titrated with or without the flavonoid 
of interest (final concentrations: 20, 40, 80, and 120 M) and incubated at 37 °C for 30 
min prior to analysis. Solution conditions were 100 mM ammonium acetate (pH 7.5) with 
1% v/v DMSO. For control purposes, all data are compared against incubations of A40 
peptides with EGCG under the same conditions. Collision cross-section (CCS) 
measurements were externally calibrated using a database of known values in helium, 
using values for proteins that bracket the likely CCS and ion mobility values of the 
unknown ions.50,54 CCS values are the mean average of five replicates, with errors 
reported as the least square product. This least square analysis combines inherent 
calibrant error from drift tube measurements (3%),54 calibration curve error, and twice the 
replicate standard deviation error. Measurements (Kd) for A–flavonoid binding were 
calculated using the total ion count extracted from the peak of interest at its full width half 
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maximum using methods previously described.52,53 All other conditions are consistent 
with previously published methods.17 
 
2.4.8. Cytotoxicity studies 
The human neuroblastoma SH-SY5Y cell line was purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in media 
containing 1:1 Minimum Essential Media (MEM; GIBCO, Grand Island, NY, USA) and 
Ham’s F12K Kaighn’s Modification Media (F12K; GIBCO), 10% (v/v) fetal bovine serum 
(FBS; Sigma), and 1% (v/v) penicillin (GIBCO). The cells were grown and maintained at 
37 °C in a humidified atmosphere with 5% CO2. Cell viability with treatment of A and/or 
flavonoids was determined using the MTT assay (Sigma) as previously reported.18,20 SH-
SY5Y cells were seeded in a 96 well plate (15,000 cells in 100 L per well) and treated 
with A (10 M) and/or flavonoids (10 M; final 1% v/v DMSO). After 24 h incubation at 
37 °C, MTT (25 l of 5 mg/mL in phosphate buffered saline, PBS, pH 7.4; GIBCO) was 
added to each well and the plates were incubated for 4 h at 37 °C. Formazan produced 
by the cells was dissolved overnight at room temperature by the addition of a solubilization 
buffer (100 L) containing N,N-dimethylformamide (DMF; 50% v/v, aq, pH 4.5) and 
sodium dodecyl sulfate (SDS; 20% w/v). The absorbance (A600) was measured on a 
microplate reader. Cell viability was determined relative to cells containing an equivalent 
amount of DMSO (1% v/v). Error bars were calculated as standard errors (SEs) from four 
independent experiments. 
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Chapter 3: Identification of Structural Moieties Essential for Regulating  
Metal-free and Metal-associated Amyloid- and Free Radicals 
 
 
 
 
This chapter is based on work that will be submitted for publication. We thank Professor 
Ayyalusamy Ramamoorthy and Kyle J. Korshavn for NMR experiments; Professor Kwang 
S. Kim, Dr. Han M. Lee, Dr. Woo J. Cho, and Dr. Zahra A. Tehrani for calculation studies; 
Dr. Akiko Kochi for in vitro PAMPA assay; Younwoo Nam for synthesis of compounds, 
studies of metal binding, solution speciation, docking, ESI-MS, gel analysis for A 
aggregation and cell experiments. I was involved in copper binding, docking studies, gel 
and TEM analyses for A aggregation, determination of antioxidant properties, as well as 
manuscript writing with Younwoo Nam. 
 
 
3.1. Introduction  
Alzheimer’s disease (AD) is one of the most fatal neurodegenerative disorders 
featured by a progressive neuronal loss and cognitive impairment.1-6 The cause and 
mechanism of AD onset and progression remain unclear resulting in lack of fundamental 
cures for the disease.1-6 Neurotoxicity associated with amyloid- (A) peptide has been 
suggested as one of the hypotheses for AD pathogenesis since misfolded A aggregates 
are primary components of senile plaques in the AD-afflicted brain.1-9 A is produced 
upon the proteolytic cleavage of amyloid precursor protein (APP) [two major isoforms, 
A40 and A42 (ca. 90 % and 9 % in the brain, respectively), that are aggregation-prone 
to form aggregates from various oligomers to mature fibrils].1-9 Soluble A oligomers are 
observed to be toxic from recent studies; however, the relationship between specific A 
conformations and neurotoxicity is still unidentified.1-9  
In addition, the AD-affected brain exhibits highly concentrated metal ions within 
senile plaques [e.g., ca. 0.4 mM for Cu(I/II), 1 mM for Zn(II), 0.9 mM for Fe(II/III)].1-13 
Previous studies in vitro demonstrated that these metal ions, particularly Cu(I/II) and 
Zn(II), can interact with A peptides and promote the peptide aggregation.3-16 
Furthermore, complexes of A with redox-active metal ions, such as Cu(I/II) and Fe(II/III), 
are shown to generate reactive oxygen species (ROS) via Fenton-like chemistry leading 
to oxidative stress.1-16 Thus, it has been proposed that the inter-relation between metal 
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ions, A, metal-bound A (metal–A), and ROS is linked to AD pathogenesis. Given the 
limited efficacy of current anti-AD agents only targeting individual pathogenic factors (e.g., 
metal-free A, metal ions, ROS), as well as such the interconnection, the development of 
single molecules which are able to regulate multiple pathogenic features could be more 
effective for toward the discovery of AD treatment. 
Hence, some chemical tools have been designed to control metal-free A and metal–A 
aggregation and associated toxicity.17-32 Toward this effort, the derivatization of amyloid 
imaging agents, such as p-stilbene and thioflavin-T (ThT) has been utilized as a strategy 
for the design and synthesis of chemical reagents which can target and interact with metal 
ions, metal-free A, and metal–A.17-32 Although several compounds showed their 
inhibitory reactivity toward A aggregation17-30 structural motifs responsible for such 
reactivity are not understood clearly. Herein, we report the determination of structural 
groups essential for reactivities toward metal-free A, metal–A, and free radicals 
employing a new series of small molecules (Figure 3.1). Our newly generated molecules 
are derived from the systematic structural variation of N1,N1-dimethyl-N4-(pyridin-2-
ylmethyl)benzene-1,4-diamine (L2-b) and N1,N1-dimethylbenzene-1,4-diamine 
(DMPD).20-23 L2-b displayed that it could interact with metal–A species and modulate 
metal–A aggregation pathways to form less toxic species both in vitro and in vivo.21-23 In 
addition, a recent report presents that a small and simple monodentate ligand, DMPD 
(Figure 3.1), a moiety of L2-b, affords the desired anti-amyloidogenic activity.20 DMPD is 
also able to interact with both metal-free A and metal–A and redirect their aggregation 
into off-pathway and form less toxic species both in vitro and in vivo.20 Moreover, L2-b 
and DMPD are shown to be antioxidants.20,23 Thus, structural moieties of both DMPD and 
L2-b may be important for modulating amyloidogenesis and scavenging free radicals.20   
In our chemical library, the compounds which contain a DMPD motif (DMPD, L2-
b, and L2-b2; Figure 3.1) exhibit noticeable modulation of metal-free A and/or metal–
A aggregation along with antioxidant capacity. Similar to DMPD and L2-b, L2-b2 is 
observed to attenuate metal-free A and metal–A induced toxicity in living cells. 
Particularly, biophysical analyses on the interaction of L2-b21-23 and L2-b2 with both 
metal-free A and metal–A suggest as follows: (i) their activity with metal-free A or 
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Figure 3.1. Chemical structures of the compounds employed in this study. DMPD (N1,N1-dimethylbenzene-
1,4-diamine; orange), L2-b (N1,N1-dimethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-diamine), L2-b1 (N,N-
dimethyl-6-((phenylamino)methyl)pyridin-3-amine), L2-b2 (N1-((5-(dimethylamino)pyridin-2-yl)methyl)-
N4,N4-dimethylbenzene-1,4-diamine), DPA1 (bis(pyridin-2-ylmethyl)amine), DPA2 (6-((((5-(dimethyl-
amino)pyridin-2-yl)methyl)amino)methyl)-N,N-dimethylpyridin-3-amine), PMA1 (pyridin-2-ylmethan-
amine), and PMA2 (6-(aminomethyl)-N,N-dimethylpyridin-3-amine). Potential donor atoms for metal 
binding are highlighted in blue. 
metal–A could occur via the complex formation between the ligand and metal-free A or 
metal–A; (ii) potential chemical reaction and observed antioxidant capability of the 
ligands might be associated with the redox-active DMPD moiety. Overall, our studies 
present that DMPD-containing compounds can interact with metal-free A and/or metal–
A, control their aggregation pathways into forming less toxic aggregaets and noticeably 
scavenge free radicals. Therefore, our present work demonstrates that the DMPD 
functionality is essential for the interaction and regulation of multiple causative factors 
(i.e., metal-free A, metal–A, ROS) in AD, which proposes its promising utilization for 
the development of chemical tools and therapeutics for misfolded-protein-related 
diseases. 
 
3.2. Results and discussion 
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3.2.1. Rational design, selection and preparation of small molecules 
Some stilbene-based molecules were previously examined to modulate metal-
free A and/or metal–A aggregation in vitro as well as reduce peptide-associated toxicity 
in living cells.21-24 Mechanistic understanding of their structure-related anti-amyloidogenic 
activity, however, has not been established and thus, the development of molecular 
frameworks has been limited. A recent report indicates that DMPD (Figure 3.1), a small 
chemical tool, is capable of controlling both metal-free A and metal–A aggregation 
pathways.20 Identification of pivotal structures for the reactivity (i.e., redirection of A 
aggregation pathways, regulation of free radicals, attenuation of cytotoxicity induced by 
metal-free A and metal–A) is critical for invention of new, effective chemical reagents 
for such targets. In our present studies, a chemical series of the DMPD and L2-b 
derivatives (Figure 3.1) was rationally selected to determine essential structural moieties 
(e.g., DMPD, the dimethylamino functionality, the metal chelation site of L2-b) for their 
desired reactivity.  
Scheme 3.1. Synthetic routes to (a) L2-b1, L2-b2, and (b) DPA2. 
 
Based on the structures of DMPD and L2-b, L2-b1 and L2-b2 (Figure 3.1) were 
first chosen to investigate the influence of the dimethylamino functionality on the reactivity 
toward aggregation and toxicity of metal-free A, metal–A, and free radicals. Since the 
dimethylamino group was known to be important for the interaction with metal-free A 
and metal–A,23-28 the position of this moiety has been altered from L2-b. PMA1 and 
PMA2 (Figure 3.1), composed of the metal chelation sites of L2-b and L2-b2, 
respectively, were included for the structure-reactivity investigation in our chemical library.  
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Figure 3.2. Effects of DMPD, L2-b, L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 on the formation of 
metal-free A40 and metal–A40 aggregates. (a) Schemes of the inhibition (I) and disaggregation (II) 
experiments. (b) Visualization of molecular weight (MW) distributions of the resultant A40 species by gel 
electrophoresis followed by Western blotting (gel/Western blot) with an anti-A antibody (6E10). Conditions: 
[A40] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M; pH 6.6 (for Cu(II) experiments) or pH 7.4 
(for metal-free and Zn(II) experiments); 37 ˚C; constant agitation. Lanes: (C) A  [CuCl2 or ZnCl2]; (1) A 
 [CuCl2 or ZnCl2] + DMPD; (2) A  [CuCl2 or ZnCl2] + L2-b1; (3) A  [CuCl2 or ZnCl2] + L2-b2; (4) A  
[CuCl2 or ZnCl2] + DPA1; (5) A  [CuCl2 or ZnCl2] + DPA2; (6) A  [CuCl2 or ZnCl2] + PMA1; (7) A  
[CuCl2 or ZnCl2] + PMA2; (8) A  [CuCl2 or ZnCl2] + L2-b. (c) TEM images of the samples from (b). 
 
Through comparison between PMA1 and DMPD, the structural components 
responsible for the reactivity of L2-b can be determined. Moreover, DPA1 and DPA2 
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(Figure 3.1) were selected to elucidate whether increased denticity and flexibility of L2-b 
could tune the inhibitory effect of small molecules on metal-free A and metal–A 
aggregation as well as their antioxidant activity. The impact of the dimethylamino group 
on the overall structural frameworks (DPA1 versus DPA2, PMA1 versus PMA2) on the 
compounds’ reactivities with the targets can be further probed. Taken together, a 
structure-interaction-reactivity relationship determined within the selected compounds is 
able to address structural moieties needed for anti-amyloidogenic and antioxidant 
activities. For the preparation of new compounds, L2-b1, L2-b2, and DPA2 were 
synthesized based on previously reported methods with slight modifications (Scheme 
3.1).23,27  
 
3.2.2. Modulation of A aggregation pathways 
To evaluate the ability of compounds to modulate A aggregation pathways, two 
different experiments, inhibition and disaggregation experiments (Figures 3.2a and 3.3a), 
were carried out with A40 and A42, two major A isoforms found in the brain of AD.1-9 
The molecular weight (MW) distributions and morphological changes of the resultant A 
species were visualized and monitored by gel electrophoresis followed by Western blot 
(gel/Western blot) and transmission electron microscopy (TEM), respectively (Figures 3.2 
and 3.3).20-30 
From the inhibition experiment with A40, as shown in Figure 3.2b (left), metal-
free, various-sized A40 aggregates were indicated from the samples containing DMPD 
and L2-b2. In addition, noticeable changes in the size distribution of metal–A40 
aggregates were observed upon treatment with DMPD, L2-b2, or L2-b to different extents 
(Figure 3.2b, left; lane 2, 4, and 9). On the other hand, much less significant influence on 
metal-free A40 and metal–A40 aggregation was observed upon incubation with L2-b1, 
DPA1, DPA2, PMA1, or PMA2 (Figure 3.2b, left). Unlike compound-free samples (lane 
C), DPA1, PMA1, and PMA2 may stabilize higher MW Cu(II)–A40 aggregates (above 
150 kDa); DPA1 and DPA2 may be able to generate larger-sized Zn(II)–A40 aggregates 
(above 240 kDa). The DMPD-containing compounds (i.e., DMPD, L2-b, L2-b2) could 
effectively modulate metal-free A40 and/or metal–A40 aggregation. L2-b1, DPA1, 
DPA2, PMA1, and PMA2, lack of the DMPD moiety, presented no or very slight and  
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Figure 3.3. Influence of DMPD, L2-b, L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 on the metal-free 
A42 and metal–A42 aggregation pathways. (a) Schemes of the inhibition (I) and disaggregation (II) 
experiments. (b) Analysis of size distributions of the resultant A species by gel/Western blot with an anti-
A antibody (6E10). Conditions: [A42] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M; pH 6.6 
(for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); 37 ˚C; constant agitation. Lanes: 
(C) A  [CuCl2 or ZnCl2]; (1) A  [CuCl2 or ZnCl2] + DMPD; (2) A  [CuCl2 or ZnCl2] + L2-b1; (3) A  
[CuCl2 or ZnCl2] + L2-b2; (4) A  [CuCl2 or ZnCl2] + DPA1; (5) A  [CuCl2 or ZnCl2] + DPA2; (6) A  
[CuCl2 or ZnCl2] + PMA1; (7) A  [CuCl2 or ZnCl2] + PMA2; (8) A  [CuCl2 or ZnCl2] + L2-b. (c) TEM 
images of the samples from (b). 
different effect on metal–A40 aggregation. These results may indicate that the 
dimethylamino moiety itself may not be enough to redirect metal-free A40 and/or metal–
A40 aggregation pathways. From L2-b-, L2-b1- and L2-b2-treated samples, the position 
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of the dimethylamino functionality onto the whole structure of L2-b is shown to play a role 
in modulation of the peptide aggregation. In addition, based on the results obtained upon 
treatment of metal–A with L2-b, L2-b2, PMA2, and DPA2, the entire structure of 
molecules with the dimethylamino group(s) (not dimethylamino group itself) is observed 
to determine the reactivity toward metal-free A and metal–A. In the inhibition 
experiment with A42 (Figure 3.3b, left), similar to the results with A40, both metal-free 
A42 and metal–A42 aggregation pathways were altered by DMPD and L2-b2 (Figure 
3.3b, left; lanes 2 and 4). L2-b can only redirect metal–A42 aggregation as previously 
reported (Figure 3.3b, left; lane 9).21,23 The compounds without the DMPD motif did not 
present noticeable effect on A42 aggregation compared to compound-untreated 
samples.  
Furthermore, the morphologies of L2-b1- or L2-b2-treated metal-free A and 
metal–A aggregates were observed by TEM. The resultant A40 species incubated with 
L2-b2 are shown to be smaller and more amorphous than those from compound-free or 
L2-b1-treated samples (Figure 3.2c, left). Metal-free A42 and metal–A42 aggregates 
generated with L2-b2 have less structured or shorter fibrils than compound-free or L2-
b1-incubated A42 aggregates (Figure 3.3c, left). 
The results from the disaggregation experiments were similar to those from 
inhibition experiments except those from the samples of PMA2 with Cu(II)–A40 and 
DPA1- and DPA2-treated Zn(II)–A40 indicating similar MW distributions to the 
compound-free samples (Figures 3.2b, right). The compounds containing the DMPD 
motif, DMPD, L2-b and L2-b2, displayed noticeable various sized metal-free A40 and/or 
metal–A40 aggregates to different degrees (Figures 3.2b, right). Among the small 
molecules without the DMPD moiety, DPA1 and PMA1, may generate Cu(II)–A40 
aggregates with high MWs (Figure 3.2b, right) similar to the results from the inhibition 
experiments (Figure 3.2b, left). DPA2 and PMA2 could not influence preformed A 
aggregates under both metal-free and metal present environments (Figure 3.2b, right). 
Moreover, the compounds containing the DMPD group could also affect preformed metal-
free A42 and/or metal–A42 aggregates (Figure 3.3b, right). The compounds without the 
DMPD motif could not alter the aggregation process (Figure 3.3b, right). Besides, the 
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morphological changes upon addition of L2-b2 to both metal-free A40/A42 and metal–
A40/A42 aggregates were more significantly occurred than L2-b1-treated samples 
(Figures 3.2c and 3.3c). The A samples incubated with L2-b2 presented more  
 
Figure 3.4. Solution speciation studies of (a) L2-b1, (b, left) DPA1, (b, right) DPA2, (c, left) PMA1, and (c, 
right) PMA2. Left: Variable-pH spectrophotometric titration spectra in the range of pH 2–9. Right: Solution 
speciation diagrams in the range of pH 2–9 (FL = fraction of species at the given protonation). Bottom: 
Summary of the acidity constants (pKa) of L (L = L2-b1, DPA1, DPA2, PMA1, and PMA2). Charges are 
omitted for clarity. aError in the parentheses is shown in the last digit. Conditions: [compound] = 30 M; I 
= 0.10 M NaCl; room temperature. 
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amorphous or thinner fibrils than compound-free and L2-b1-contained samples (Figures 
3.2c and 3.3c). 
Taken together, our results and observations from the inhibition and 
disaggregation studies of A aggregation employing our chemical library suggest that the 
overall framework containing the DMPD moiety at proper structural positions, instead of 
the dimethylamino functionality itself, is essential for the ability of small molecules to 
control metal-free A and/or metal-induced A aggregation pathways. 
 
3.2.3. Solution speciation studies 
Acidity constants (pKa) for L2-b1, DPA1, DPA2, PMA1, and PMA2, were 
determined by variable-pH spectrophotometric t itrations following previous  
procedures.23,29 It is noted that the pKa values of DMPD and L2-b2 were not able to be 
experimentally obtained due to their instability (vide infra). As summarized in Figure 3.4, 
single pKa values were obtained for L2-b1 [pKa1 = 6.1(7)], PMA1 [pKa1 = 2.0(0)], and 
PMA2 [pKa1 = 3.7(2)]; two pKa values for DPA1 [pKa1 =2.2(9) and pKa2 = 7.4(8)]; three 
pKa values for DPA2 [pKa1 = 2.2(6), pKa2 = 4.0(3), and pKa3 = 8.2(2)] in the pH range 2–
9. These pKa values suggest the presence of monoprotonated (LH) and neutral (L) forms 
of L2-b1, PMA1, and PMA2; L, LH, and diprotonated (LH2) forms for DPA1; and L, LH, 
LH2, and triprotonated (LH3) forms for DPA2 in the pH range of 2–9 (Figure 3.4). Based 
on these pKa values, speciation diagrams were drawn to illustrate the fraction of ligand 
protonation states in the pH range from 2 to 9. The associated solution speciation 
diagrams indicate that the neutral form (L) of L2-b1 mainly presents at a physiological pH 
(i.e., pH 7.4) while the monoprotonated fom (LH) is the major species of DPA1, DPA2, 
PMA1, and PMA2 (Figure 3.4). 
 
3.2.4. Metal binding properties
Cu(II) or Zn(II) binding of L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 was 
monitored by UV–Visible (UV–Vis) and 1H nuclear magnetic resonance (NMR) 
spectroscopy. As depicted in Figure 3.5, the changes of UV–Vis spectra (e.g., change in 
absorbance intensity, new optical bands) were observed upon addition of CuCl2 to L2-
b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 in CH3CN or EtOH, indicative of Cu(II)  
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Figure 3.5. Cu(II) binding studies of L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2. UV–Vis spectra of (a) 
L2-b1 and L2-b2 with CuCl2 (1–5 equiv and 1–2 equiv, respectively) in CH3CN; (b) DPA1 and DPA2 with 
CuCl2 (1–5 equiv) in EtOH; (c) PMA1 and PMA2 with CuCl2 (1–5 equiv) in EtOH. Conditions: [L2-b1, DPA1, 
DPA2, PMA1, and PMA2] = 50 M or [L2-b2] = 25 M; room temperature; incubation for 30 min (for L2-b1 
and L2-b2) and 10 min (for DPA1, DPA2, PMA1, and PMA2). 
 
binding to the compounds (Figure 3.5). New optical bands at 400 nm and 483 nm from 
L2-b1 with Cu(II) and 392 nm and 496 nm from L2-b2 with Cu(II) were detected. In the 
case of DPA1 and PMA1, the intensity of absorption spectra was increased when Cu(II) 
was added. The optical spectral shifts from 323 nm to 337 nm and 334 nm were observed 
when DPA2 or PMA2 was treated with Cu(II), respectively. Furthermore, Zn(II) binding of 
L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 were investigated by UV–Vis and 1H NMR 
spectroscopy. The introduction of Zn(II) to the solution of L2-b2, DPA1, and DPA2 (in 
CH3CN or EtOH) resulted in changes of optical spectra. As shown in Figures 3.6a-c, a 
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new optical band at 472 nm for L2-b2, the enhanced intensity of spectra for DPA1, as 
well as the shifted optical spectrum from 323 nm to 336 nm for DPA2 were indicated. The 
addition of Zn(II) (1 equiv) to the CD3CN solutions of L2-b1, PMA1, and PMA2 caused 
the alteration of chemical shifts of the pyridyl protons (Figures 3.6d-f), suggesting the 
involvement of the N donor atoms from the pyridine ring in Zn(II) binding. Overall, our 
optical and NMR studies demonstrate that L2-b1, L2-b2, DPA1, DPA2, PMA1, and 
PMA2 can interact with Cu(II) and Zn(II). 
 
Figure 3.6. Zn(II) binding of L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2. UV–Vis spectra of (a) L2-b2 
with ZnCl2 (1–5 equiv) in CH3CN; (b) DPA1 and (c) DPA2 with ZnCl2 (1–5 equiv) in EtOH. Conditions: [L2-
b2, DPA1, and DPA2] = 50 M; room temperature; incubation for 30 min (for L2-b2) and 10 min (for DPA1 
and DPA2). 1H NMR spectra of (d) L2-b1 (black), (e) PMA1 (black), and (f) PMA2 (black) with ZnCl2 (1 
equiv, red) in CD3CN. Conditions: [L2-b1, PMA1, and PMA2] = 4 mM; room temperature; incubation for 5 
min. 
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3.2.5. NMR studies for the interaction of compounds with metal-free A and Zn(II)-
bound Amonomers and fibrils 
Direct interaction of L2-b, L2-b1, and L2-b2 with monomeric A40 was 
investigated by 2D band-selective optimized flip-angle short transient heteronuclear 
multiple quantum correlation (SOFAST-HMQC) NMR spectroscopy. As depicted in  
Figure 3.7, small but detectable chemical shifts were presented upon the titration of 10  
 
Figure 3.7. Interactions of L2-b, L2-b1 and L2-b2 with monomeric A40. (a) 2D 1H–15N SOFAST-HMQC 
NMR spectra of monomeric A40 upon addition of compound. Spectra were recorded as L2-b (left) L2-b1 
(middle) or L2-b2 (right) [0 (red spectra) and 10 (blue spectra) equiv] was titrated into a solution of 15N-
labeled A40. (b) Plots of the corresponding chemical shift perturbations (CSPs) of A40 residues upon the 
titration with L2-b, L2-b1, and L2-b2. The average chemical shifts (dashed line) plus standard deviation 
(dotted line) were presented. Conditions: [A40] = 80 M; [L2-b, L2-b1, or L2-b2] = 0-800 M; 20 mM PO4, 
pH 7.4, 50 mM NaCl; 7% D2O (v/v); 10 °C. 
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equiv of compounds to soluble A40 peptides. The chemical shift perturbation (CSP) was 
monitored to determine the potential binding site and modes of compounds to the peptide.  
 
Figure 3.8. Interactions of L2-b and L2-b2 with monomeric Zn(II)-bound A40 and metal-free A40 or Zn(II)-
associated A40 fibrils. 2D 1H–15N SOFAST-HMQC NMR spectra of (a and c) monomeric 15N-labeled with 
and without Zn(II); (b and d) 15N-labeled A40 pretreated with Zn(II) followed by addition of L2-b (left) or L2-
b2 (right). (e and f) Plots of the corresponding chemical shift perturbations (CSPs) of the spectra from 15N-
labeled A40 with Zn(II) (blue) and Zn(II)-treated-15N-labeled A40 with L2-b or L2-b2 (black). Conditions: 
[A40] = 80 M; [ZnCl2] = 80 M; [L2-b and L2-b2] = 80-800 M; 20 mM PO4, pH 7.4, 50 mM NaCl; 7% v/v 
D2O (g and h) Normalized STD intensities mapped to compound’s structure [(g) L2-b or (h) L2-b2] against 
metal-free A fibrils (left) or Zn(II)–A42 fibrils (right). Yellow, orange, and blue circles indicate the STD 
effects of  75%, 50-75%, and,  50%, respectively. Gray circles indicate the absence of the STD effect. 
All L2-b,22 L2-b1, and L2-b2 triggered moderate chemical shifts (lower than 0.02 
ppm) from the different regions of A40. These ligands could interact with the self-
recognition region of A40 peptides (residues from L17 to A21)2-5 and C-terminal regions 
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of A40 which are shown to be critical for the peptide aggregation.2-5 L2-b and L2-b1 were 
observed to interact with more than two residues from the self-recognition site (L17 and 
F20 for L2-b; V18, F19 and F20 for L2-b1) while L2-b2 was indicated to affect the 
chemical shift of only F19. In addition, all of these compounds induced the chemical shift 
of V40 at the C-terminus which may reflect the rearrangement of the disordered C- 
terminus to pack against the compounds instead of interaction or binding between the 
ligand and peptide.22 These NMR results are consistent to docking studies employing 
A40 monomer (PDB 2LFM33) which visualize the interaction between compounds and 
A40 peptide. L2-b, L2-b1, and L2-b2 are resided in the groove between the -helix and 
N-terminal random coil of A peptides (Figure 3.9a). L2-b, L2-b1, and L2-b2 showed 
weak interaction with A40 monomer and this interaction may not have noticeable effect 
on modulation of peptide aggregation pathways. There may be other mechanisms to 
redirect the peptide aggregation that require more than the interaction between 
compounds and A peptides (vide infra).  
In addition, the interaction between L2-b or L2-b2 and Zn(II)–15N-labeled A40 
monomer was further analyzed by 2D NMR. As shown in Figure 3.8, L2-b strongly 
interacted with R5 and H13 close to a metal binding site in A40.1-7 L2-b2 caused chemical 
shifts on the residues suggested to be associated with metal binding as well. These 
observations from NMR studies are also visualized by docking studies using Zn(II)-bound 
A16 (PDB 1ZE934). From our docking investigations, both L2-b and L2-b2 might have 
con tac ts  w i th  the  amino  ac id  res idues  c lose  to  meta l  b ind ing reg ion 
 (Figure 3.9b). Overall, our NMR and docking studies between the compounds and Zn(II)–
A suggest their direct interaction with Zn(II)–A (particularly with the metal binding site 
of A1-7), which could be related to their activity to modulate Zn(II)–A40 aggregation 
pathways, observed in Figure 3.2. 
Moving forward, the interactions between L2-b or L2-b2 and metal-free A42 or 
Zn(II)–A42 fibers were studied by STD. Signals in STD NMR are proportional to each 
atoms of ligand to its macromolecular binding partner, allowing atomic-level mapping of 
ligand binding to be made.35 Similar saturation patterns were monitored from both metal-
free A42 fibrils and Zn(II)–A42 fibrils with L2-b. On the pyridine ring of L2-b, relatively 
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strong saturation effects were detected indicating that the pyridine ring portion of L2-b 
could play an important role in the interactions with both metal-free A42 and Zn(II)–A42 
fibrils (Figure 3.8g). Different from L2-b, dimethylamino groups of L2-b2 presented 
stronger saturation effects than other moieties with both metal-free A42 and Zn(II)–A42 
fibrils. When Zn(II) was introduced to A42 fibrils, the saturation effects on the pyridine  
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Figure 3.9. Docking studies of DMPD, L2-b, L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 with (a) A40 
monomer or (b) Zn(II)-bound A16 monomer. The lowest energy conformation of DMPD (orange), L2-b 
(blue), L2-b1 (purple), L2-b2 (green), DPA1 (light blue), DPA2 (light purple), PMA1 (yellow), and PMA2 
(pink) with cartoon (left) and surface (right) depictions of (a) A40 (PDB 2LFM33) or (b) Zn(II)-bound A16 
(PDB 1ZE934) monomer by AutoDock Vina. The helical region and metal binding sites of metal-free A40 
and Zn(II)–A16 are illustrated in yellow and in light gray, respectively, in the surface representation. 
Potential hydrogen bonding is indicated with dashed lines (1.8-2.3 Å ). Bottom: Summaries of the calculated 
binding energies of DMPD, L2-b, L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 to metal-free A40 and 
Zn(II)-bound A16. 
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ring of L2-b2 were more noticeable. Additionally, since the STD intensities were relatively 
distributed through the whole molecule of L2-b2 against Zn(II)–A42 fibrils, its framework 
could be packed into the fibrillar conformation of Zn(II)–A42. Taken together, the 
dimethylamino group from the DMPD motif of L2-b2 is shown to be involved in the 
interactions between metal-free A fibrils, which could direct L2-b2 possibly to control the 
peptide aggregation. In addition, the pyridine ring of L2-b and L2-b2, associated with the 
metal chelation, is observed to be more related to the contact with Zn(II)–A42 fibrils than 
metal-free fibrils, indicating the compounds’ modulating ability toward the Zn(II)–A42 
aggregation. Overall, our STD NMR results help understand the results from the 
disaggregation experiments treating L2-b and L2-b2 to preformed metal-free 
Aaggregates and/or Zn(II)–A aggregates (vide supra, Figure 3.3b, right). 
 
3.2.6. Transformation of compounds 
Previous study suggests that the oxidative transformation of DMPD is linked to its 
inhibitory activity toward both metal-free A and metal–A.20 To elucidate the noticeable 
inhibitory reactivity of L2-b and L2-b2 with metal-free A and/or metal–A, their 
transfiguration was optically monitored following reported methods.20 Absorption spectra 
of L2-b or L2-b2 were obtained in a time-dependent manner upon incubation with or 
without A40 in the absence and presence of Cu(II) and Zn(II) (Figures 3.10). Under metal-
free and Zn(II) present conditions, characteristic optical changes of L2-b or L2-b2 (i.e., 
increase in the intensity, appearance of new bands) were indicated in both the absence 
and presence of A40 (Figure 3.10). Moreover, the optical variations of L2-b or L2-b2 in 
the presence of A are much slower than those of A40-free conditions affording fewer 
amounts of new species (Figure 3.10). The absorption bands at 510 nm (for L2-b) and 
496 nm (for L2-b2) upon transformation are possibly resulted from the oxidized forms of 
L2-b and L2-b2 in the both absence and presence of A40.36-38 These results are 
consistent with those measured by electrospray ionization mass spectrometry (ESI-MS) 
(vide infra; Figure 3.11). Unlike metal-free conditions, in the presence of Cu(II), different 
optical changes were observed for both L2-b and L2-b2. As discussed in the section of 
metal binding above, after the addition of Cu(II) to the A40-free ligand solutions distinct  
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Figure 3.10. Transfigurations of L2-b and L2-b2 in the absence and presence of metal ions and A40, 
monitored by UV–Vis spectroscopy. Time-dependent changes in UV–Vis spectra of (a) L2-b and (b) L2-b2 
were obtained. Blue, orange, red, black, and green lines correspond to the spectra recorded after incubation 
for 1, 10/30 min, 4, 12, and 24 h, respectively. Conditions: [A40] = 25 M; [CuCl2 or ZnCl2] = 25 M; [L2-b 
and L2-b2] = 50 M; pH 6.6 (for Cu(II) experiments) or pH 7.4 (for metal-free and Zn(II) experiments); room 
temperature; no agitation. Triangles, asterisks, and circles indicate optical bands for the expected 
transformation of the compound (oxidized L2-b, a cationic radical of DMPD, and oxidized L2-b2, 
respectively). 
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Figure 3.11. ESI-MS studies of the solutions containing L2-b or L2-b2 with and without a metal chloride 
salt (CuCl2 or ZnCl2, 25 M) at various incubation times. (a) ESI-MS spectra of L2-b or L2-b2 without metal 
ions. (b and c) ESI-MS spectra of L2-b or L2-b2 with CuCl2 or ZnCl2. Conditions: [L2-b or L2-b2] = 50 M; 
[CuCl2 or ZnCl2] = 25 M; room temperature; incubation for 0, 4, 12, or 24 h. 
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optical features for L2-b and L2-b2 were indicated (Figure 3.10) suggesting the formation 
of metal-ligand complexes. Over further incubation, the broad doublet peaks at ca. 550 
nm were typically shown for both L2-b and L2-b2 without A, maximized at 4 h incubation 
(Figure 3.10). These absorption bands are characteristic for the generation of a cationic 
radical of DMPD,20 which suggests that the Cu(II)-catalyzed hydrolytic cleavage of L2-b 
or L2-b2 possibly produce DMPD or other structural analogs. In the presence of both 
Cu(II) and A40, different optical variations occurred. Transformation of L2-b or L2-b2 was 
further monitored by ESI-MS in both the absence and presence of Cu(II) or Zn(II) at 
various incubation times (0, 4, 12, and 24 h).  
Under metal-free conditions, m/z signals (228/271, 227/270, 227/269, and 
224/269; Figure 3.11a) of L2-b or L2-b2 at different incubation times possibly correspond 
to the original ligand form (at 0 h), and an oxidized form (from 4, 12, and 24 h 
incubation).36-38 In the presence of Cu(II), different m/z values were indicated for both 
compounds, compared to those under metal-free and Zn(II)-added conditions (Figure 
3.11b). When L2-b was incubated with CuCl2 for 4 h, a reproducible signal at m/z 138, 
possibly corresponding to 4-dimethylaminophenol (calculated m/z (138) of [M + H]+) that 
might be generated by the hydrolytic cleavage of L2-b, was indicated while various m/z 
signals were randomly detected from the samples incubated longer. For L2-b2 treated 
with CuCl2, the signals of m/z 271 (the original form, at 0 h) and 267 (oxidized form, from 
4, 12, and 24 h incubation) were dominantly observed in a time-dependent manner 
(Figure 3.12b). The signal of m/z 137 for L2-b2 could correspond to DMPD (calculated 
m/z (137) of [M+H]+) as supported by optical analysis (Figure 3.10; vide supra). Both 
compounds, L2-b and L2-b2, can oxidize faster in the presence of Cu(II) than metal-free 
and Zn(II) present environments (Figure 3.11). These resultant oxidized forms of L2-b 
and L2-b2 may be related to the interaction and modulation of A peptide aggregation 
observed above.  
 
3.2.7. Computational studies 
The values of the first and second ionization potentials (IP1 and IP2) for DMPD, 
L2-b, L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 were calculated (Figure 3.12). The 
overall observations for these values indicate that the compounds containing the DMPD  
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Figure 3.12. Calculated ionization potentials (IP1 and IP2) of compounds. Isosurface plots of SOMOs of the 
compounds (blue, N; gray, C; white, H). Bottom: Summary of calculated values of IP1 and IP2 (kcal/mol). 
The IP1 and IP2 values of DMPD are previously reported.20 
 
functionality are shown to have lower IP values than those which do not have a DMPD 
group. As depicted in Figure 3.12, DMPD, L2-b, and L2-b2 (Figure 3.12; top row) display 
the singly occupied molecular orbitals (SOMOs) on the DMPD moiety, indicating that this 
structural portion can be easily oxidized, and thus could afford to the formation of a 
cationic radical of DMPD. Based on the IP1 and IP2 values of our chemical series, possible 
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oxidative transformation of compounds could be involved in their reactions with metal-
free A or metal-bound A. 
 
 
3.2.8. Blood-brain barrier (BBB) permeability prediction and free radical 
scavenging capability 
The potential BBB permeability of the compounds, predicted by Lipinski’s rules 
and calculated logBB values (Table 3.1), was evaluated by the in vitro parallel artificial 
membrane permeability assay adapted for BBB (PAMPA-BBB).23,28,39-41 As summarized 
in Table 3.1, these theoretical and empirical values indicate that all compounds in our 
chemical library are potentially BBB permeable. 
Table 3.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe)a for DMPD,20 L2-b1, L2-b2, DPA1, 
DPA2, PMA1, and PMA2. 
 
aMW, molecular weight; clogP, calculated logarithm of the octanol water partition coefficient; HBA, hydrogen 
bond acceptor atoms; HBD, hydrogen bond donor atoms; PSA, polar surface area; logBB = –0.0148  PSA 
 0.152  clogP + 0.139 (logBB > 0.3, readily crosses BBB; logBB < –1.0, poorly distributed to the brain); 
–logPe values were determined using the Parallel Artificial Membrane Permeability Assay adapted for BBB 
(PAMPA-BBB) were then calculated by the PAMPA 9 Explorer software v. 3.8. bPrediction of a compound’s 
ability to penetrate the central nervous system (CNS) on the basis of literature values. Compounds 
categorized as CNS+ have the possibility to penetrate the BBB and are available in the CNS. In the case 
of compounds assigned as CNS– have poor permeability through the BBB, therefore, their bioavailability 
into the CNS is considered to be minimal. 
The free radical scavenging capability of DMPD, L2-b1, L2-b2, DPA1, DPA2, 
PMA1, and PMA2 was measured by the Trolox (vitamin E analogue) equivalent 
antioxidant capacity (TEAC) assay, which can evaluate their ability to quench ABTS 
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cation radicals [ABTS•+; ABTS = 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)] in 
an organic solution42,43 and in a more biological environment (e.g., cell lysates).28 As 
depicted in Figure 3.13, DMPD,20 L2-b1, and L2-b2 are shown to scavenge free organic 
radicals more significantly than DPA1, DPA2, PMA1, and PMA2. In addition, L2-b2 
presents a two-fold greater ability to quench radicals than Trolox in an organic solution 
(Figure 3.13). The trend of compounds for their free radical scavenging ability is expected 
from their lower IP1 and IP2 values (vide supra, Figure 3.12). Moreover, DMPD, L2-b1, 
and L2-b2 indicate their free radical scavenging capacity within human neuroblastoma 
SK-N-BE(2)-M17 (M17) cell lysates (Figure 3.13, inset). Overall, DMPD, L2-b1, and L2-
b2 are shown to serve as free radical scavenging agents, possibly being BBB permeable. 
 
Figure 3.13. Free radical scavenging capability of DMPD,20 L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 
was identified by the TEAC assay in EtOH or employing SK-N-BE(2)-M17 (M17) cell lysates (inset). The 
TEAC values are relative to a vitamin E analogue, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid). 
 
3.2.9. Regulation of toxicity induced by metal-free A40 and metal–A40 in living 
cells 
More than 85% cell survival was exhibited when L2-b1, L2-b2, DPA1, DPA2, 
PMA1, and PMA2 were treated with M17 cells in the absence and presence of metal ions 
(Figure 3.14). The neuroprotective capability of L2-b2, with greater activities toward A, 
metal–A, and free radicals, was further examined against metal-free A40- or metal–
A40-induced toxicity in M17 cells.23 Cell viability [ca. 84% for metal-free A40; ca. 79% for 
A40 with Cu(II); ca. 80% for A40 with Zn(II)] was indicated (Figure 3.14a). Upon treatment 
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of L2-b2 to M17 cells preincubated with metal-free A40 or Zn(II)–A40, ca. 100% cell 
survival was observed (Figure 3.14a). Additionally, L2-b2 was observed to slightly 
recover the toxicity induced by Cu(II)–A40 (Figure 3.14a). Overall, these cell experiments 
indicate that the series of compounds in this study are relatively nontoxic. Moreover, L2-
b2 is able to attenuate metal-free A40- and metal–A40-induced cytotoxicity similar to 
DMPD20 and L2-b.23 
 
Figure 3.14. Viability of cells treated with L2-b1, L2-b2, DPA1, DPA2, PMA1, or PMA2 in the absence and 
presence of A40 with and without CuCl2 or ZnCl2. (a) Viability of M17 cells treated with metal-free A40 and 
metal-treated A40, followed by the addition of L2-b2. M17 cells were treated with (b) various concentrations 
of ligands (2.5-50 M), CuCl2/ligands ((c) 1:1 or (d) 1:2), or ZnCl2/ligands ((e) 1:1 or (f) 1:2; 1% v/v DMSO). 
Cell viability (%) was determined by the MTT assay compared to cells treated with DMSO only (0–1%,v/v). 
Error bars represent the standard error for three independent experiments. 
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3.3. Conclusion 
For the better understandings of AD pathogenesis, it is required to apply chemical 
tools which can target and interact with multiple pathological features involved in AD (i.e., 
metal ions, metal-free and -associated A, free radicals). Although several small 
molecules have been developed to modulate metal-free A and/or metal–A aggregation 
pathways, reduce free radical levels, and attenuate associated cytotoxicity, it has not 
been clearly studied which structural moieties are responsible for such activities. Thus, 
we have examined the interaction and reactivity of a rationally selected series of 
compounds toward metal-free A, metal–A, and free radicals. In our chemical library, 
DMPD, L2-b, and L2-b2 have the DMPD functionality in their structure and are shown to 
perform better abilities to alter metal-free A and/or metal–A aggregation pathways, 
scavenge free radicals, and present neuroprotective properties in living cells than other 
small molecules (L2-b1, DPA1, DPA2, PMA1, and PMA2) that have no DMPD motif. L2-
b and L2-b2 that contain a structural moiety of DMPD can interact with various A 
species, from the monomer to fibrils in the absence and/or presence of metal ions. 
Moreover, the DMPD moiety is indicated to be related to the oxidization of these 
compounds, which could be applied to antioxidant properties and possibly linked to the 
redirecting activity toward A aggregation pathways. In addition, a dimethylamino group, 
a structural portion of DMPD, is also observed to direct the reactivity of small molecules 
depending on its position at the overall structure. The dimethylamino functionality itself, 
however, may not be enough to present its reactivity toward the targets (particularly, 
metal-free A and metal-bound A). Taken together, our studies demonstrate that DMPD 
is a pivotal structural motif in the interaction with multiple pathological factors (e.g., metal-
free A and metal-bound A, metal ions, free radicals) found in AD. Thus, such a 
structural group can be utilized for the development of better chemical tools and 
therapeutics for protein-misfolding diseases. 
 
3.4. Experimental section 
 
3.4.1. Materials and methods 
All reagents and solvents were purchased from commercial suppliers and used as 
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received unless otherwise stated. Bis(pyridin-2-ylmethyl)amine (DPA1), pyridin-2-
ylmethanamine (PMA1), 6-(aminomethyl)-N,N-dimethylpyridin-3-amine (PMA2), and 
N1,N1-dimethylbenzene-1,4-diamine (DMPD) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). N1,N1-dimethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-diamine (L2-b) was 
synthesized as previously reported methods.23 N,N-dimethyl-6-
((phenylamino)methyl)pyridin-3-amine (L2-b1), N1-((5-(dimethylamino)pyridin-2-
yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine (L2-b2), and 6-((((5-(dimethyl-
amino)pyridin-2-yl)methyl)amino)methyl)-N,N-dimethylpyridin-3-amine (DPA2) were 
synthesized as previously reported procedures (vide infra).23,27 A40 and A42 were 
purchased from AnaSpec (Fremont, CA, USA) (A40 = DAEFRHDSGYEVHHQKLVFFA-
EDVGSNKGAIIGLMVGGVV; A42 = DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIG-
LMVGGVVIA). An Agilent 8453 UV–Visible (UV–Vis) spectrophotometer (Santa Clara, 
CA, USA) was used to measure the optical spectra. Transmission electron microscopic 
(TEM) images were taken using a Philips CM-100 transmission electron microscope 
(Microscopy and Image Analysis Laboratory, University of Michigan, Ann Arbor, MI, USA) 
or a JEOL JEM-2100 transmission electron microscope (UNIST Central Research 
Facilities, Ulsan, Republic of Korea). Absorbance values for biological assays, including 
cell viability assay, Parallel Artificial Membrane Permeability Assay adapted for Blood-
Brain Barrier (PAMPA-BBB), Trolox Equivalent Antioxidant Capacity (TEAC) assay were 
measured on a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, 
USA). Bruker HCT basic system mass spectrometer equipped with electrospray 
ionization (ESI) ion source was used to obtain time-dependent mass spectra of L2-b or 
L2-b2 with and without metal ions [Cu(II) or Zn(II)]. 
 
3.4.2. Preparation of N,N-dimethyl-6-((phenylamino)methyl)pyridin-3-amine (L2-
b1) 
L2-b1 was synthesized with slight modifications of the previously reported 
method.23 To a nitrogen purged flame dried flask, 150 mg (1.6 mmol) of aniline was added 
and dissolved in 15 mL of EtOH that was dried over molecular sieves. Then 285 mg (1.9 
mmol) of 5-dimethylamino-2-pyridinecarboxaldehyde was added and the solution was 
allowed to stir at 45 ºC for 10 min, and increased the temperature to 90 ºC for 1 h. The 
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solution was allowed to cool to room temperature and was concentrated until precipitates 
were formed. The resulting solid precipitate was then dissolved in dry MeOH and cooled 
to 0 ºC in a nitrogen-purged round-bottom flask. Then 307 mg (8.1 mmol) of sodium 
borohydride (NaBH4) was slowly added and the solution was allowed to stir at 0 ºC for 5 
min. After warming up the solution to room temperature, the resulting solution was stirred 
for 45 min. The reaction mixture was then quenched with water, extracted three times 
with dichloromethane (CH2Cl2), washed once with brine, and concentrated. The crude 
products were purified by column chromatography (SiO2; EtOAc:Et3N 100:0.1; Rf = 0.54) 
followed by recrystallization with Et2O and Hexanes (Hx) (260 mg, 1.1 mmol, 71%). 1H 
NMR (400 MHz, CD2Cl2) /  (ppm): 8.10 (2H, d, J = 3.0 Hz), 7.15 (3H, m), 7.00 (2H, dd, 
J = 8.6, 3.0 Hz), 6.66 (3H, m), 4.75 (1H, s(broad)), 4.30 (2H, d, J = 5.3 Hz), 2.95 (6H, s), 
13C NMR (100 MHz; CD2Cl2)/ (ppm): 149.0, 146.2, 146.0, 134.7, 129.6, 122.0, 120.0, 
117.5, 113.4, 49.0, 40.6, HRMS: Calcd for M+, 227.1422; Found, 227.1427. 
  
3.4.3. Preparation of N1-((5-(dimethylamino)pyridin-2-yl)methyl)-N4,N4-
dimethylbenzene-1,4-diamine (L2-b2) 
L2-b2 was synthesized with slight modifications of the previously reported 
method.23 50 mg (0.4 mmol) of DMPD was added into a flame-dried flask under nitrogen 
and then dissolved in 10 mL of ethanol that was treated with over molecular sieves. 70 
mg (0.5 mmol) of 5-dimethylamino-2-pyridinecarboxaldehyde was added and stirred for 
10 min at 45 ºC, followed by stirring at 90 ºC for 1 h. The resulting mixture was then 
allowed to cool to room temperature and the solvent was removed in vacuo. Dry methanol 
(MeOH) was then added to the flask under nitrogen and cooled down to 0 ºC. A portion 
of NaBH4 (70 mg, 1.9 mmol) was slowly introduced with stirring at 0 ºC for 5 min, followed 
by stirring for 45 min at room temperature. The reaction mixture was then quenched with 
water, extracted three times with CH2Cl2, washed once with brine, and concentrated. The 
crude products were purified by column chromatography (SiO2, 100:1 EtOAc:Et3N; Rf = 
0.29, 68 mg, 0.3 mmol, 70%). 1H NMR (400 MHz, CD2Cl2) / (ppm): 8.09 (1H, d, J = 3.0 
Hz), 7.15 (1H, d, J = 8.6 Hz), 6.99 (1H, dd, J = 8.6, 3.0 Hz), 6.69 (2H, d, J = 8.9 Hz), 6.62 
(2H, d, J = 8.9 Hz), 4.25 (1H, s (broad)), 2.95 (6H, s), 2.79 (6H, s). 13C NMR (100 MHz; 
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CD2Cl2) / (ppm): 147.0, 145.8, 14.6, 141.4, 134.8, 122.1, 120.0, 116.0 114.8, 50.1, 42.4, 
40.6, HRMS: Calcd for M+, 270.1845; Found, 270.1846. 
 
3.4.4. Preparation of 6-((((5-(dimethylamino)pyridin-2-yl)methyl)amino)methyl)-
N,N-dimethyl pyridin-3-amine (DPA2) 
DPA2 was synthesized with slight modifications of the previously reported 
method.27 A dried 100 mL round-bottom flask, equipped with a magnetic stir bar, was 
charged with 5-(dimethylamino)picolinonitrile (100 mg, 0.7 mmol) in dry MeOH (20 mL). 
To the resulting mixture was added Pd/C (10 wt %; 150 mg, 1.6 mmol) at room 
temperature. The solution was stirred under N2 for 10 min and then under H2 for 5 or 6 h 
at room temperature. The Pd/C was filtered through the Celite and washed with cold 
MeOH (2 x 15 mL). To the combined MeOH was slowly added 4 M HCl (0.4 mL), which 
became light yellow, with gentle vortexing. The mixture was concentrated in vacuo, 
generating light yellow products, and purified by recrystallization (MeOH/Et2O). The final 
product (yellow powder) was washed out with two solvents (CH2Cl2, and Et2O) via 
vacuum filtering (SiO2, MeOH:DCM = 1:10; Rf = 0.70; 66%). 1H NMR (400 MHz, CD3OD) 
/ (ppm): 8.25 (2H, d, J = 3.1 Hz), 8.07 (2H, d, J = 9.2 Hz), 7.83 (2H, dd, J = 4.6, 1.6 Hz), 
4.68 (4H, s), 3.18 (12H, s). 13C NMR (100 MHz; CD3OD) / (ppm): 149.7, 130.7, 130.4, 
127.4, 126.4, 47.8, 40.3, HRMS: Calcd for [M + H]+, 286.2026; Found, 286.2024. 
 
3.4.5. A aggregation experiments 
Experiments with A were conducted according to previously published 
methods.20-30 To prepare A peptides, either A40 or A42 was dissolved in ammonium 
hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized overnight, and stored at –80 °C. 
For the experiments, a stock solution of A was prepared by dissolving lyophilized peptide 
in 1% NH4OH (10 L) and diluting with ddH2O. The concentration of A peptides in the 
solution was determined by measuring the absorbance of the solution at 280 nm ( = 
1450 M–1cm–1 for A40;  = 1490 M–1cm–1 for A42). The peptide stock solution was diluted 
to a final concentration of 25 M in chelex-treated buffered solution containing HEPES 
[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 20 M, pH 6.6 for Cu(II) samples; 
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pH 7.4 for metal-free and Zn(II) samples] and 150 M NaCl. For the inhibition studies, 
DMPD, L2-b, L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 [50 M; 1% v/v dimethyl 
sulfoxide (DMSO)] was added to the sample of A (25 M) in the absence and presence 
of a metal chloride salt (CuCl2 or ZnCl2, 25 M) followed by incubation at 37 ˚C with 
constant agitation for 24 h. For the disaggregation studies, A with and without metal ions 
was incubated for 24 h at 37 °C with constant agitation. DMPD, L2-b, L2-b1, L2-b2, 
DPA1, DPA2, PMA1, and PMA2 were added afterward to the solution containing A 
aggregates, and incubated for additional 24 h at 37 °C. 
 
3.4.6. Gel electrophoresis and Western blot 
Molecular weight (MW) distribution of samples from the inhibition and 
disaggregation experiments were analyzed by gel electrophoresis and followed by 
Western blot (Gel/Western blot) using an anti-A antibody (6E10).20-30 Each sample (10 
L) was separated on a 10–20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA) and 
transferred onto nitrocellulose membrane which was blocked with bovine serum albumin 
(BSA) solution (3% w/v; Sigma Aldrich) in Tris-buffered saline containing 0.1% Tween-20 
(TBS-T) for 2 h at room temperature. Then, the membranes were incubated with a primary 
antibody (6E10, Covance, Princeton, NJ, USA; 1:2,000) in a solution of 2% w/v BSA (in 
TBS-T) overnight at 4 °C. After washing with TBS-T (3x, 10 min each), the horseradish 
peroxidase-conjugated goat anti-mouse secondary antibody (1:5,000; Cayman Chemical 
Company, Ann Arbor, MI, USA) in 2% BSA (in TBS-T) was added to the membrane and 
incubated for 1 h at room temperature. SuperSiganl West Pico Chemiluminescent 
Substrate (Thermo Scientific, Rockford, IL, USA) was used to visualize protein bands. 
 
3.4.7. Transmission electron microscopy (TEM) 
Samples for transmission electron microscopy (TEM) were prepared according to 
previously reported methods.20-30 Glow-discharged grids (Formar/Carbon 300-mesh, 
Electron Microscopy Sciences, Hatfield, PA, USA) were treated with samples from the 
inhibition and disaggregation experiments (5 L) for 2 min at room temperature. Excess 
sample was removed by blotting carefully with filter paper then washed twice with ddH2O. 
Each grid was treated with uranyl acetate (1% w/v ddH2O, 5 L) for 1 min. Excess stain 
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was blotted off and the grids were air dried for at least 20 min at room temperature. 
Images from each sample were taken on a Philips CM-100 (80 kV) or a JEOL JEM-2100 
TEM (200 kV) at 25,000x magnification. 
 
3.4.8. Determination of acidity constants for ligands 
The acidity constants (pKa) for L2-b1, DPA1, DPA2, PMA1, and PMA2 were 
determined by UV–Vis variable-pH titrations based on a previously published 
procedure.26-29 To obtain pKa values for a ligand, a solution (100 NaCl, 10 mM NaOH, pH 
12) of L2-b1, DPA1, DPA2, PMA1, and PMA2 (30 M) was titrated with small aliquots of 
HCl to acquire at least 30 spectra in the range from pH 2.0–9.0. The pKa values were 
calculated using the program HypSpec (Protonic Software, Leeds, UK).44 Speciation 
diagrams of ligands were modeled using the HySS2009 program (Protonic Software, 
Leeds, UK).45 
 
3.4.9. Metal binding studies 
The interaction of L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 with Cu(II) and 
Zn(II) was monitored by UV−Vis and 1H NMR, along with previously reported 
procedures.23,24,26,30 A solution of L2-b1 and L2-b2 [50 M and 25 M, respectively, in 
acetonitrile (CH3CN)], DPA1, DPA2, PMA1, and PMA2 (50 M in EtOH) was treated with 
1 to 5 (for L2-b1, DPA1, DPA2, PMA1, and PMA2) or 1 to 2 (for L2-b2) equiv of CuCl2 
or ZnCl2, and incubated at room temperature for 30 min (for L2-b1 and L2-b2) or 10 min 
(for DPA1, DPA2, PMA1, and PMA2). The optical spectra of the resulting solutions were 
measured by UV−Vis. In addition, the interaction of L2-b1, PMA1, or PMA2 with ZnCl2 
was observed by 1H NMR. ZnCl2 (1 equiv) was added to a solution of L2-b1, PMA1, or 
PMA2 (4 mM) in acetonitrile-d3 (CD3CN). 
 
3.4.10. Spectrophotometric studies 
All samples were prepared in Chelex-treated buffered solution [HEPES 20 M, pH 
6.6 for Cu(II) samples or pH 7.4 for metal-free and Zn(II) samples, 150 M NaCl]. For A-
free samples, L2-b, or L2-b2 (50 M) was treated with CuCl2 or ZnCl2 (25 M) for 2 min. 
For A-containing samples, A40 (25 M) was treated with CuCl2 or ZnCl2 (25 M) for 2 
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min, and then L2-b, or L2-b2 was added. The absorption spectra of the resulting solution 
was obtained at 1, 10/30 min, 4, 12, and 24 h incubation time points at room temperature 
without agitation. Metal-free samples with and without A40 were also monitored by 
UVVis in an anaerobic environment. All solvents required for the preparation of the 
anaerobic samples were degassed by freeze-pump-thaw cycling three times and stored 
in a N2-filled glove box. Anaerobic samples were prepared in a N2-filled glove box. UVVis 
spectra were recorded at 0, 4, 12, and 24 h incubation time points at room temperature 
without agitation. 
 
3.4.11. Docking studies of compounds with metal-free A40 and Zn(II)-bound A16 
monomers. 
Flexible ligand docking studies for DMPD, L2-b, L2-b1, L2-b2, DPA1, DPA2 
PMA1, or PMA2 against metal-free A40 and Zn(II)-bound A16 monomer were conducted 
using AutoDock Vina.46 The starting conformations of the monomer and fiber were 
obtained from NMR structures of A40 monomer (PDB 2LFM),33 and Zn(II)–A16 monomer 
(PDB 1ZE9).34 A model for compounds was first constructed and energy minimized using 
the MMFF94 energy minimization function in ChemBio3D Ultra 11.0 to optimize their 
structure for the docking studies. Individual structures of monomeric metal-free A40 or 
Zn(II)–A40 conformations and compounds were prepared in AutoDock Tools and 
imported into PyRx. The search space was constrained to the dimensions of the peptide. 
The exhaustiveness for the docking runs was set at 1024. Docked models of the 
compounds were visualized with A species using Pymol (The PyMOL Molecular 
Graphics System, Schrödinger, LLC). 
 
3.4.12. 2D NMR spectroscopy 
The interaction of A40 with L2-b, L2-b1, and L2-b2 was monitored by 2D 1H-15N 
SOFAST-HMQC NMR at 10 °C.47 Uniformly-15N-labeled A40 (rPeptide, Bogart, GA, 
USA) was first dissolved in 1% NH4OH and lyophilized. The peptide was re-dissolved in 
3 L of DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) and diluted with phosphate 
buffer, NaCl, D2O, and ddH2O to a final peptide concentration of 80 M (20 mM PO4, pH 
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7.4, 50 mM NaCl; 7% v/v D2O). Each spectrum was obtained using 64 complex t1 points 
and a 0.1 sec recycle delay on a Bruker Avance 600 MHz spectrometer. The 2D data was 
processed using TOPSPIN 2.1 (from Bruker). Resonance assignment was performed 
with SPARKY 3.1134 using published assignments for A40 as a guide.31,48 
 
3.4.13. Saturation transfer difference (STD) NMR spectroscopy 
For the STD NMR experiments, a 150 M solution of fibrillar A42 was prepared 
through incubation for 24 h at 37 °C with constant agitation in 10 mM deuterated Tris-DCl, 
95% D2O with or without ZnCl2 (80 M) at pD 7.4 (corrected for the isotope effect). The 
samples for STD experiments were prepared by diluting fibrils to 1 M (effective monomer 
concentration) into 10 mM deuterated Tris-DCl to which was added 100 M of ligand 
(0.5% DMSO-d6). STD experiments were acquired with a train of 50 dB Gaussian-shaped 
pulses of 0.049 sec with an interval of 0.001 sec at either –1.0 ppm (on resonance47,49,50) 
or 40 ppm (off resonance) with a total saturation time of 2 sec on a Bruker 600 MHz 
(metal-free samples) or 900 MHz spectrometer (Zn(II) samples).51 1024 scans were 
recorded for the reference spectrum at 25. An inter-scan delay of 1 sec was used for both 
the STD and the reference experiments. 
 
3.4.14. Mass spectrometric studies 
Samples containing L2-b or L2-b2 (50 M) and A40 (25 M) for experiments were 
prepared in 100 L of 1 mM NH4OAc (pH 7.4). The resulting solutions were incubated for 
0, 4, 12, and 24 h at 37 C with constant agitation. The samples were directly injected into 
the mass spectrometer at a flow rate of 240 L/h. ESI interface was operated in positive-
ion mode; spray voltage was set at 4.5 kV with capillary temperature at 300 °C and 
capillary exit voltage at 101 V. Mass spectra were taken in the range of m/z 50–500. 
 
3.4.15. Parallel artificial membrane permeability assay adapted for blood-brain 
barrier (PAMPA-BBB) 
PAMPA-BBB experiments of compounds were carried out using the PAMPA 
Explorer kit (pION, Inc. Billerica, MA, USA) with modifications to previously reported 
protocols.23,26,28,39-41 Each stock solution was diluted with Prisma HT buffer (pH 7.4, pION) 
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to a final concentration of 25 M (1% v/v final DMSO concentration). The resulting solution 
was added to the wells of the donor plate (200 L, number of replicates = 12). BBB-1 lipid 
formulation (5 L, pION) was used to coat the polyvinylidene fluoride (PVDF, 0.45 M) 
filter membrane on the acceptor plate. This acceptor plate was placed on top of the donor 
plate forming a sandwich. Brain sink buffer (BSB, 200 L, pION) was added to each well 
of the acceptor plate. The sandwich was incubated for 4 h at room temperature without 
stirring. UV−Vis spectra of the solutions in the reference, acceptor, and donor plates were 
measured using a microplate reader. The PAMPA Explorer software, v. 3.8 (pION), was 
used to calculate the value of –logPe for each compound. CNS± designations were 
assigned by comparison to compounds that were identified in previous reports.39-41 
 
3.4.16. Trolox equivalent antioxidant capacity (TEAC) assay 
The free radical scavenging capacity of DMPD, L2-b1, L2-b2, DPA1, DPA2, 
PMA1, and PMA2 were determined by the TEAC assay in EtOH or employing lysates of 
human neuroblastoma SK-N-BE(2)-M17 (M17) cells purchased from ATCC (Manassa, 
VA, USA). (a) The assay in solution was performed according to a previously reported 
method with slight modifications.28,42,43 To generate blue ABTS cation radicals [ABTS•+; 
ABTS = 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt; Sigma], 
ABTS (7.0 mM, Sigma, MO) with potassium persulfate (2.5 mM) was dissolved in 5 mL 
of water and incubated for 16 h in the dark at room temperature. The resulting solution of 
ABTS•+ was diluted with EtOH to absorbance of ca. 0.7 at 734 nm. The solution of ABTS•+ 
(200 L) was added to the wells of a clear 96 well plate and incubated at room 
temperature for 5 min in the plate reader. Various final concentrations (0, 1, 2.5, 5, 7.5, 
10, 15, and 20 M) of DMPD, L2-b1, L2-b2, DPA1, DPA2, PMA1, PMA2, or Trolox 
(Trolox = 6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; dissolved in EtOH) 
were treated and incubated with the ABTS•+ solution at room temperature for 10 min. The 
percent inhibition was calculated according to the measured absorbance at 734 nm [% 
inhibition = 100 × (A0 − A)/A0] and was plotted as a function of ligand concentration. The 
TEAC value of compounds for each time point was calculated as a ratio of the slope of 
the compound to that of Trolox. The measurements were carried out in triplicate. (b) The 
assay employing cell lysates was conducted following the protocol of the antioxidant 
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assay kit purchased from Cayman Chemical Company (Ann Arbor, MI, USA), with minor 
modifications.28 M17 cells were cultured in media containing 1:1 Minimum Essential 
Media (MEM, GIBCO, Grand Island, NY), Ham’s F12K Kaighn’s Modification Media 
(F12K, GIBCO), 10% (v/v) fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, 
GA, USA GIBCO), 100 U/mL penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). 
The cells were grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. 
For the antioxidant assay using cell lysates, cells were seeded in a 6 well plate and grown 
to approximately 80-90% confluence. Cell lysates were prepared following a previously 
reported method with modifications.48 M17 cells were washed once with cold PBS (pH 
7.4, GIBCO) and harvested by gently pipetting off adherent cells with cold PBS. The cell 
pellet was generated by centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was 
sonicated on ice (5 sec pulses, 3 times with 20 sec intervals between each pulse) in 2 mL 
of cold Assay Buffer (5 mM potassium phosphate, pH 7.4, containing 0.9% NaCl and 
0.1% glucose). The cell lysates were centrifuged at 5,000 x g for 10 min at 4 °C. The 
supernatant was removed and stored on ice until use. To standard and sample 96 wells, 
10 L of the supernatant of cell lysates was delivered followed by addition of compound, 
metmyoglobin, ABTS, and H2O2 in order. After 5 min incubation at room temperature on 
a shaker, absorbance values at 750 nm were recorded. The final concentrations (0.045, 
0.090, 0.135, 0.180, 0.225, and 0.330 mM) of compounds and Trolox were used. The 
antioxidant concentration was calculated according to the measured absorbance (% 
Inhibition = (A0 – A)/A0, where A0 is absorbance of the supernatant of cell lysates). The 
measurements were conducted in triplicate. 
 
3.4.17. Cell viability measurement 
M17 cells were seeded in a 96-well plate (15,000 cells in 100 L per well), 
according to previously reported methods.23,24,28,30 These cells were treated with various 
concentrations of L2-b1, L2-b2, DPA1, DPA2, PMA1, and PMA2 (0-10 M, 1% v/v 
DMSO) in the absence and presence of CuCl2 or ZnCl2 (1:1 or 1:2 metal/ligand ratio) with 
and without A40 (A : metal : ligand = 10 : 10 : 20 M). After 24 h incubation at 37 °C, 25 
L MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 5 mg/mL in 
phosphate buffered saline (PBS), pH7.4, GIBCO] was added to each well and the plates 
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were incubated for 4 h at 37 °C. Formazan produced by the cells was dissolved in a 
solution containing N,N-dimethylformamide (DMF, 50% v/v aq, pH 4.5) and sodium 
dodecyl sulfate (SDS, 20% w/v) overnight at room temperature. Subsequently, 
absorbance at 600 nm was measured on a microplate reader. 
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Chapter 4: Interaction and Reactivity of Human Serum Albumin with  
Metal-free and Metal-associated Amyloid- Peptides 
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Hugh I. Kim and Taesu Choi at Pohang University of Science and Technology  
(POSTECH) for ESI-MS, IM-MS, SAXS, and CID analysis for HSA–A interaction (results 
and discussion are not shown in the chapter due to incomplete studies); Dr. Yeon Ju 
Kwak for cell viability studies. I was involved in the experiments of the ThT assay, gel 
electrophoresis with Western blot, and TEM investigations for identifying A aggregation, 
as well as cell imaging studies for identifying cellular membrane permeability of A with 
HSA. 
 
 
 
4.1. Introduction 
The cause and mechanism of the onset and progression of Alzheimer’s disease 
(AD) have not been clearly understood.1-8 Among potential pathological features, the 
aggregation of misfolded proteins, such as amyloid- (A), have been suggested to be 
involved in AD etiology.1-8 Especially, soluble and structured oligomeric forms are 
considered as toxic species.1-8 In addition, previous studies demonstrate that highly 
concentrated metal ions [i.e., Cu(I/II), Zn(II)] are co-localized in senile plaques (ca. 0.4 
and 1.0 mM, respectively) in the AD affected brain.1-9 These metal ions can bind to A 
peptides and facilitate the peptide aggregation.1-10 Moreover, A peptides have been 
presented to bind to or interact with various other proteins. In particular, more than ca. 
90% of A peptides are bound to human serum albumin (HSA) in human blood plasma.11-
19  
 HSA is the most abundant protein of blood serum and is composed of three 
hydrophobic domains which can bind to hormones, metal ions, other proteins, or drugs 
endogenously or exogenously via electrostatic or hydrophobic interactions as well as is 
observed to transport them.11-16 In the pharmaceutical industry, HSA has been of interest 
due to their delivery ability.11-16 Since HSA is able to transport proteins, such as A, it is 
possibly able to decrease the risk of AD by regulating the equilibrium of A between the 
brain and blood plasma across the blood-brain barrier (BBB).11,15,18 HSA could bind to A 
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by hydrophobic interactions (with the hydrophobic region of A); upon binding of HSA 
with A, A aggregation is suggested to be inhibited or interfered.11,15,20 Additionally, HSA 
is presented to serve as a physiological transporter for the essential metal ions, such as 
Cu(II) and Zn(II), in the blood serum.14,19-22 Although A peptides with metal ions, HSA 
with A, and HSA with metal ions have been studied individually, the interrelationships 
among all three of A, metal ions, and HSA have been rarely interrogated.  
Herein, we report the direct interactions of HSA with metal-free A or metal-
associated A (metal–A) as well as its influences on the peptide aggregation. 
Furthermore, we present the ability of HSA to attenuate cytotoxicity induced by metal-free 
A or metal–A and penetrate through the cellular membrane with A peptides in both 
the absence and presence of metal ions. From our studies, HSA is observed to affect 
metal-free A aggregation as similar to previous studies,11-13 as well as metal–A 
aggregation. HSA is not shown to inhibit A aggregation but delay or redirect the 
aggregation pathways to produce possibly less toxic species. Taken together, our studies 
with HSA, A, and metal ions found in the brain of AD, suggest the potential 
communication between these three elements via direct interactions, indicating the 
possible link of protein–protein-small molecule (metals) networks to AD onset and 
progression. 
 
4.2. Results and discussion 
 
4.2.1. Investigations of the influence of HSA on A40 aggregation pathways by 
thioflavin-T (ThT) assay 
 The thioflavin-T (ThT) assay is generally used to observe the degree of A 
fibrillization by measuring the fluorescence intensity induced by binding of ThT to A 
fibrils.12,20,23,24 We applied the ThT assay to monitor the influence of HSA on the formation 
of metal-free A and Zn(II)–A fibrils. Samples were prepared for the inhibition and 
disaggregation experiments. For the inhibition experiments (Figure 4.1a), freshly 
dissolved A with or without Zn(II) was incubated with HSA. For disaggregation 
experiments (Figure 4.2a), A aggregates were preformed by incubating without HSA for 
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24 h, and then treated with HSA for additional 24 h incubation. The A fibrllization growth 
curve was obtained from the ThT assay (Figure 4.1b). Once A peptides were incubated 
with HSA, the kinetics of the A fibril production were modulated to be delayed in both 
the absence and presence of Zn(II). As depicted in Figure 4.1b (left), under metal-free 
conditions, HSA could slow down the generation of A fibrils at early stages and alter the 
aggregation pathway. Up to 12 h incubation, A samples with HSA showed the less  
 
Figure 4.1. Influence of HSA toward both metal-free A40 and metal–A40 aggregation pathways. (a) 
Scheme of the inhibition experiment. (b) Analysis of A40 fibril formation from the samples incubated with 
metal-free A40 (left) or Zn(II)–A40 (right) in the absence and presence of HSA, monitored by the ThT 
assay. (c) TEM images of the 24 h incubated samples. Conditions: [A40] = 20 M; [ZnCl2 or CuCl2] = 20 
M; HSA = 20 M; pH 6.6 (for Cu(II) experiment) or pH 7.4 (for metal-free and Zn(II) experimetns); 37 C; 
constant agitation. 
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Figure 4.2. Effect of HSA on metal-free A40 and metal–A40 aggregation pathways. (a) Scheme of the 
disaggregation experiment. (b) Analysis of the degree of metal-free A40 (left) or Zn(II)–A40 (right) 
fibrillization in the absence and presence of HSA from the disaggregation experiments, monitored by the 
ThT assay. (c) TEM images of the 24 h incubated samples. Conditions: [A40] = 20 M; [ZnCl2 or CuCl2] = 
20 M; HSA = 20 M; pH 6.6 (for Cu(II) experiment) or pH 7.4 (for metal-free and Zn(II) experimetns); 24 h 
incubation; 37 C; constant agitation. 
fluorescence intensity than the HSA-free samples, indicating that less A fibrils were 
formed. The ability of HSA to postpone the generation of metal-free A fibrils is consistent 
with previous studies.12,20,23 Since HSA and A are indicated to bind directly,12,15,17,23,25 
the HSA–Acomplex formation may be able to affect and alter A aggregation pathways. 
Furthermore, when Zn(II) was introduced to A, the fiber generation was slower than that 
observed from metal-free conditions, as previously reported;1-4,10,20 HSA could make the 
Zn(II)–A fibrillization process much slower. A recent report presents that high negative 
charges on the surface of HSA could stabilize the protonated form of H13 of A peptide, 
possibly resulting in weakened Zn(II) binding to A and redirection of the peptide 
aggregation pathways.20 The fibrillization pathway of Zn(II)–A without HSA reached the 
maximum of fluorescence after 36 h incubation, while Zn(II)–A with HSA presented only 
ca. 20% of the maximum fluorescence intensity after 36 h incubation; upon 72 h 
incubation of Zn(II)–A with HSA, the samples exhibited ca. 91% of the maximum 
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fluorescence intensity. Compared to the metal-free case, HSA is more noticeably 
observed to postpone the formation of Zn(II)–A fibrils. In contrast, no difference in 
fluorescence intensity from the samples of A with or without HSA was indicated in the 
disaggregation experiment in both the absence and presence of Zn(II) (Figure 4.2b). 
These results suggest that HSA may not interact with higher order of A aggregates (e.g., 
higher order oligomers, protofibrils, fibrils), and disassemble or alter further aggregation 
from the peptide aggregates. Taken together, the results from both inhibition and 
disaggregation experiments, observed by the ThT assay, imply that HSA may prefer to 
interact with monomeric or smaller-sized A species over high molecular weight (MW) 
species, and could affect the aggregation pathways of both metal-free A and Zn(II)–A. 
4.2.2. Morphologies of A40 upon treatment with HSA, monitored by transmission 
electron microscopy (TEM) 
The morphologies of metal-free A and metal–A aggregates incubated with or 
without HSA were monitored by TEM. From the inhibition experiments, after 24 h 
incubation, metal-free A and metal–A aggregates with HSA presented more 
amorphous and thinner fibers than the A samples without HSA (Figure 4.1c). In the 
disaggregation experiments, there was no significant difference between HSA-treated 
and -untreated preformed A aggregates (Figure 4.2c). As anticipated from the results of 
the ThT assay, gel electrophoresis (vide infra), and TEM, HSA may interact with A 
monomers or smaller-sized species over higher order aggregates, causing morphological 
differences depicted only in the inhibition studies.  
 
4.2.3. Visualization of HSA–A40 complexes by gel electrophoresis  
As the ThT assay displayed the delay of metal-free A and Zn(II)–A aggregation 
by HSA, the MW distribution of the resultant A species with or without the treatment of 
HSA was visualized by gel electrophoresis followed by staining with coomassie blue 
(Figure 4.3, left) and Western blotting with an anti-A antibody, 6E10 (gel/Western blot; 
Figure 4.3, right).26-32 Clear bands around 70 and 140 kDa were detected from both 
coomassie blue stained and Western blotted gels. These bands are possibly 
corresponding to the complexes of HSA and metal-free A or metal–A [HSA monomers  
 95 
 
 
Figure 4.3. Gel analysis of the formation of HSA–A40 complexes in both the absence and presence of 
metal ions. Resultant A40 species after (a) 4 , (b) 8, (c) 12, and (d) 24 h incubation with or without HSA 
were visualized by gel electrophoresis with coomassie blue staining (left) and Western blotting using an 
anti-A antibody (6E10; right). Lanes: (1) A40; (2) A40 + HSA; (3) A40 + ZnCl2; (4) A40 + ZnCl2 + HSA; 
(5) A40 + CuCl2; (6) A40 + CuCl2 + HSA. Conditions: [A40] = 20 M; [ZnCl2 or CuCl2] = 20 M; HSA = 20 
M; pH 6.6 (for Cu(II) experiment) or pH 7.4 (for metal-free and Zn(II) experimetns); 4, 8, 12, or 24 h 
incubation; 37 C; constant agitation. 
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or dimers with monomeric or small-sized A or metal–A based on the MWs of HSA and 
A (around 66.5 and 4.3 kDa, respectively). Such formation of these HSA–A complexes 
may delay and redirect A aggregation pathways indicated in Figure 4.1b. In addition, 
since HSA–A complexes are presented from 4 to 24 h incubated samples, HSA may 
interact with monomeric or small-sized metal-free A or metal–A species and be 
stabilized as complex forms.   
 
4.2.4. Regulation of metal-free A- and metal–A-induced toxicity by HSA in living 
cells 
The neuroprotective properties of HSA against metal-free A- and metal–A-  
induced toxicity were examined in SH-SY5Y (5Y) cells. Upon incubation of 5Y cells with 
metal-free A, ca. 80-85% of viability was shown after 4, 8, 12, and 24 h incubation. With 
the treatment of HSA to 5Y cells incubated with A, cell viability was recovered by more 
than ca. 15% (Figure 4.4a). In addition, HSA could attenuate cytotoxicity triggered by 
metal–A as well [ca. 15% and 11% for Zn(II)–A (Figure 4.4b) and Cu(II)–A (Figure 
4.4c)]. These results may be caused from the formation of HSA–A complexes which can 
redirect A aggregation, possibly generating less toxic species than HSA-free 
A species. Moreover, since HSA has the anti-oxidant activity,14,33,34 HSA might reduce 
oxidative stress in cells induced by metal–A species attenuating cytotoxicity. Overall, 
our cell studies suggest that HSA may have the neuroprotective property against metal-
free A and metal–A. 
 
4.2.5. Cellular membrane permeability of A by HSA 
A peptides are suggested to be able to be penetrated into 5Y cells.35,36 Since 
intracellular A species could be more critical and toxic than extracellular A species, it 
would be valuable to evaluate if HSA could transport A species through cellular 
membranes. In order to investigate the cellular membrane permeability of A peptides, 
Hylite Fluor 488 conjugated A40 (HF488A40) was introduced to two different cellular media 
(fetal bovine serum (FBS) containing and FBS-free media) which were treated to 5Y cells. 
HF488A40 peptides can be traced by monitoring green HF488 fluorescence by a  
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Figure 4.4. Effect of HSA on toxicity induced by metal-free A and metal–A species in human 
neuroblastoma SH-SY5Y (5Y) cells. The cell viability (%) of 5Y cells incubated with (a) metal-free A40 as 
well as (b) Zn(II)- and (c) Cu(II)-associated A40 with or without HSA for 4, 8, 12, and 24 h, monitored by 
the MTT assay. Cell viability was calculated in comparison to that treated with water only (1%, v/v). Error 
bars represent the standard error from four independent experiments. Samples: (M) [ZnCl2 or CuCl2]; (1) 
A40  [ZnCl2 or CuCl2]; (2) HSA  [ZnCl2 or CuCl2]; (3) A40  [ZnCl2 or CuCl2] + HSA. Conditions: [A40] = 
10 M; [ZnCl2 or CuCl2] = 10 M; HSA = 10 M. 
fluorescence microscope. When cells were grown with FBS, after 1 h incubation without 
HSA, A40 species were shown to be outside of cell membranes (Figure 4.5a), which 
displayed similar results with 4 h incubation. In contrast, more A40 species were 
observed inside the cells in the presence of HSA than HSA-untreated cells even after 1 
h incubation. These trends were also observed from the cells cultured without FBS 
(Figure 4.5b). Furthermore, monomeric A species are favorable to penetrate cellular 
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membranes.35,37 Once the peptides begin aggregation, it would be difficult to pass through 
the cellular membrane.37 Upon treatment with HSA, however, A can form complexes 
with HSA which can be permeable by endocytosis into the cells as HSA itself can be 
done,36 which could direct more A species inside of the cells.From our observations, 
bovine serum albumin (BSA) in the FBS may not significantly facilitate the cellular uptake 
of A40 due to its stronger binding with A40 than HSA.38 This tightly bound complex 
between BSA and A40 may interfere the cellular uptake of A40. In addition, although 
BSA and HSA share the 76% sequence identity, the endocytosis mechanisms of each 
protein are different,34 interpreting the different internalization of the complex form of 
BSA– or HSA–A40. 
 
Figure 4.5. Cellular membrane permeability of Hylite Fluor 488 conjugated A40 (HF488A40) by HSA with or 
without Zn(II). Differential interference contrast (DIC) (left), fluorescence (middle), and overlayed (right) 
images of 5Y cells treated with metal-free HF488A40 with or without HSA after 1 or 4 h incubation. 5Y cells 
were cultured under (a) FBS (10%)-containing or (b) FBS-free medium. Conditions: [HF488A40] = 250 nM; 
[ZnCl2] = 250 nM; HSA = 250 nM. Scale bar = 20 m. 
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4.3. Conclusion 
From the experimental results, monomeric or small-sized metal-free A and metal–
A species are observe to interact and form a complex with HSA more favorably than 
higher oligomeric or fibrillar A. The complex formation between HSA and A and 
potential disruption of metal binding of A20 could delay and modulate the peptide 
aggregation to generate possibly less toxic A forms than HSA-free A aggregates. In 
addition, HSA is indicated to be an A transporter passing through the cellular 
membranes. Overall, our studies provide information on whether HSA and A interact 
with each other in both the absence and presence of metal ions; how HSA and metal ions 
affect the peptide aggregation pathways. This could step forward establishing the 
foundation of understanding a protein–protein–small molecule (metals) interaction toward 
AD pathogenesis. 
 
4.4. Experimental section 
 
4.4.1. Materials and methods 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. Human serum albumin (HSA) was acquired from Sigma-Aldrich 
(St. Louis, MO, USA) and used without further purification. Trace metal contamination 
was removed from buffers and solutions used for amyloid- (A) experiments by treating 
with Chelex (Sigma-Aldrich). A40 (DAEFRHDSGYEVHHQKLV-
FFAEDVGSNKGAIIGLMVGGVV) were purchased from Anaspec (Fremont, CA, USA). 
All double distilled H2O (ddH2O) used during experiments was obtained from a Milli-Q 
Direct 16 system (Merck KGaA, Darmstadt, Germany). The concentrations of proteins 
were determined by an Agilent 8453 UV–Visible (UV–Vis) spectrophotometer (Santa 
Clara, CA, USA). Transmission electron microscopy (TEM) images were recorded on a 
JEOL JEM-2100 transmission electron microscope (UNIST Central Research Facilities, 
UNIST, Ulsan, Korea). Differential interference contrast (DIC) and fluorescence images 
were taken by a FV1000 confocal microscope (UNIST-Olympus Biomed Imaging Center, 
UNIST, Ulsan, Korea). A SpectraMax M5 microplate reader (Molecular Devices, 
Sunnyvale, CA, USA) was used to measure the fluorescence intensity for the ThT assay 
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and absorbance for the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. 
 
4.4.2. A aggregation experiments 
Experiments with A were performed according to previously published 
methods.26-32 A peptides were dissolved with ammonium hydroxide (NH4OH, 1% v/v, 
aq), aliquoted, lyophilized, and stored at −80 °C. A stock solution (ca. 200 M) was 
prepared by dissolving A with NH4OH (1% w/v, aq, 10 L) followed by dilution with 
ddH2O, as reported previously.26-32 The A40 concentration was determined by measuring 
the absorbance of the solution at 280 nm ( = 1450 M-1cm-1). Buffered solutions containing 
HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (20 mM)] [pH 7.4 for metal-
free and Zn(II) samples; pH 6.6 for Cu(II) samples] and 150 mM NaCl were used for both 
inhibition and disaggregation studies. For the inhibition experiment, freshly dissolved A 
(20 M) was treated with HSA (20 M), and incubated at 37 °C with constant agitation. 
For the disaggregation experiment, A peptides were initially incubated at 37 °C for 24 h 
with steady agitation; HSA was added afterward, followed by an additional 24 h of 
incubation at 37 °C with constant agitation. 
 
4.4.3. ThT assay 
The kinetics of A fibrillization were monitored as previously published 
methods.12,23,24 Each sample (40 L; [A] = 20 M with or without [HSA] = 20 M) was 
obtained after 0, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, and 48 h incubation for metal-free 
condition; 0, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48, 60, 72, 84, and 96 h incubation for 
Zn(II)-present environment at 37 °C with constant agitation and diluted with buffered 
solutions (20 mM HEPES, pH 7.4, 150 mM NaCl). The samples were incubated for 20 
min with ThT (20 M) and read fluorescence. Maximum fluorescence of ThT was 
measured with excitation wavelength of 440 nm and emission wavelength of 490 nm. The 
fluorescence intensity was measured on a microplate reader and normalized relative to 
that of metal-free A aggregates generated through 48 h incubation. 
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4.4.4. Gel electrophoresis  
The A peptide experiments described above were analyzed by gel 
electrophoresis with two different visualization methods; coomassie blue staining and 
Western blotting (gel/Western blot) using an anti-A antibody (6E10).26-32 Each sample 
from both inhibition and disaggregation experiments was separated using a 10−20% 
gradient Tris-tricine gel (Invitrogen, Grand Island, NY, USA). First, the gel was stained 
with coomassie blue for about 30 min and washed with water to destain the gels for 
overnight. Gel images were obtained by ChemiDoc MP system (Bio-rad, CA, USA). Then, 
the dye was completely destained from the gel, and the gel was transferred to a 
nitrocellulose membrane and blocked 3 h at room temperature with a skimmed milk 
solution (10% w/v) in Tris-buffered saline (TBS, Fisher, Pittsburgh, PA, USA) containing 
0.1% Tween-20 (Sigma-Aldrich; TBS-T). The membrane was treated with the A 
monoclonal antibody (6E10, Covance, Princeton, NJ, USA; 1:2,000; BSA, 2% w/v, in 
TBS-T) for overnight at 4 °C and then probed with a horseradish peroxidase conjugated 
goat anti-mouse secondary antibody (1:5,000; Cayman Chemical, Ann Arbor, MI, USA) 
in 2% BSA in TBS-T solution for 1 h at room temperature. The protein bands were 
visualized using Thermo Scientific Supersignal West Pico Chemiluminescent Substrate 
(Rockford, IL, USA). 
 
4.4.5. Transmission electron microscopy (TEM) 
Samples for TEM were prepared following a previously reported method.26-32 Glow 
discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, 
USA) were treated with samples from either inhibition or disaggregation experiments (5 
L) for 2 min at room temperature. Excess sample was removed with filter paper and the 
grids were washed with ddH2O three times. Each grid was stained with uranyl acetate 
(1% w/v ddH2O, 5 L) for 1 min. Uranyl acetate was blotted off and grids were dried for 
20 min at room temperature. Images of samples were taken by a JEOL JEM-2100 
transmission electron microscope (200 kV, 25,000× magnification). 
 
4.4.6. Cell viability measurements (MTT assay) 
The human neuroblastoma SH-SY5Y (5Y) cell line was purchased from the 
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American Type Culture Collection (ATCC, Manassas, VA, USA). The cell line was 
maintained in media containing 1:1 Minimum Essential Media (MEM, GIBCO, Grand 
Island, NY, USA) and Ham’s F12K Kaighn’s Modification Media (F12K, GIBCO), 10% 
(v/v) fetal bovine serum (FBS, Sigma-Aldrich), and 1% (v/v) penicillin (GIBCO). The cells 
were grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell 
viability upon treatment of A with or without metal ions and/or HSA was determined using 
the MTT assay. 5Y cells were seeded in a 96 well plate (15,000 cells in 100 L per well) 
and treated with A40 (10 M), ZnCl2 or CuCl2 (10 M), and/or HSA (10 M). After 4, 8, 
12, and 24 h incubation at 37 °C, MTT (25 L of 5 mg/mL in phosphate buffered saline, 
PBS, pH 7.4, GIBCO) was added to each well and the plates were incubated for 4 h at 
37 °C. Formazan produced by the cells was dissolved overnight at room temperature by 
addition of a solubilization buffer (100 L) containing N,N-dimethylformamide (DMF, 50% 
v/v, aq, pH 4.5) and sodium dodecyl sulfate (SDS, 20% w/v). The absorbance (A600) was 
measured on a microplate reader, cell viability (%) was determined relative to that of cells 
untreated by Aand HSA. 
 
4.4.7. Imaging studies of cellular uptake 
Cell uptake experiments were conducted with Hylite Fluor 488 conjugated A40 
(HF488A40) peptides using a FV1000 confocal microscope (Olympus, Tokyo, Japan).35-37 
HF488A40 (250 nM) was incubated with 5Y cells at 37 °C in a humidified atmosphere with 
5% CO2 for 1 or 4 h with or without HSA (250 nM). Cells were washed with PBS (GIBCO) 
twice, and images were recorded to avoid further uptake while observing the cells on the 
microscope. The samples were excited at 488 nm (em = 520 nm).  
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Chapter 5: Concluding Remarks and Perspectives 
 
The interrelationships between multiple features [i.e., amyloid- (A), metal ions, 
metal-associated A (metal–A), reactive oxygen species (ROS), other proteins] have 
been suggested to be involved in the onset and progression of Alzheimer’s disease 
(AD).1-7 To advance our understanding of such interconnections, natural products or 
synthetic compounds, as chemical tools, which can target multiple pathological factors 
and control their reactivities have been screened or designed.5-17 These small molecules 
have been applied to uncover the roles of metal ions, A, metal–A and ROS as well as 
probe their association with AD pathogenesis in vitro and/or in vivo.8-17 
The studies described in Chapters 2-4 in this thesis present the investigations of 
a structure-interaction-reactivity relationship between flavonoids (Chapter 2) or synthetic 
small molecules (Chapter 3) and metal-free A/metal–A as well as of the protein–protein 
interaction (Chapter 4) related to AD pathogenesis. In Chapter 2, Upon structural 
variations of the number and position of hydroxyl groups on myricetin which was reported 
to show its inhibitory abilities toward metal–A40 aggregation and recovery of cytotoxicity 
induced by metal-free A40 and metal–A40 species,13 four flavonoids morin, quercetin, 
galangin, and luteolin, were selected and presented their ability to interact with A 
species, redirect metal–A aggregation pathways, and alleviate metal-free A/metal–A 
associated toxicity to different extents. These results lead us to advance knowledge about 
the importance of hydroxyl groups on the B ring of flavonoid for their reactivity toward 
metal–A. In the future, flavonoids with other structural variations (i.e., the position and 
number of hydroxyl groups on the A ring) will be examined and further optimized for the 
desired reactivity. Furthermore, to improve the blood-brain barrier (BBB) permeability of 
flavonoids, some structural adjustments could be required, such as glycosylation.18 The 
glycosylated flavonoids have been reported to show better BBB permeability.18 Once 
structural modified flavonoids can pass through BBB, they can be applied to in vivo 
systems.  
From the previous studies, L2-b and DMPD demonstrated their ability to modulate 
metal-free A and/or metal–A aggregation pathways, in vitro and in vivo.9,15,16 
Unfortunately, the critical motif for such reactivity has not been clearly identified; thus, as 
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discussed in Chapter 3, a chemical library was established to investigate the responsible 
moiety of L2-b for its redirecting activity toward metal–A aggregation. The L2-b 
derivatives (L2-b1 and L2-b2) with the dimethylamino functionality located at different 
positions were examined. L2-b1 could not alter both metal-free A and metal–A 
aggregation pathways while L2-b2 could modulate the peptide aggregation pathways. 
Moreover, PMA1 and PMA2, structural moieties from the metal binding regions of L2-b 
and L2-b2, respectively, as well as DPA1 and DPA2, small molecules designed to 
increase the denticity and flexibility of L2-b and L2-b2, respectively, were also included 
in our chemical library in order to complete our investigations for identifying a structural 
group critical for interacting with metal-free A and metal–A, subsequently altering their 
aggregation. PMA1, PMA2, DPA1, and DPA2 are not able to redirect metal-free A and 
metal–A aggregation pathways and noticeably scavenge free radicals. From the 
comparison of experimental results from our chemical series, the structural component 
essential for the reactivity of L2-b and L2-b2 is the DMPD motif. Furthermore, the 
dimethylamino group itself may not be enough to present its inhibitory activity toward A 
aggregation unless it is located at the proper position of the entire structure of L2-b or 
DMPD. Therefore, the DMPD derivatives (i.e., the number and position of the 
dimethylamino group, different substituents) can be the next series of compounds to be 
investigated their reactivity toward metal-free A and metal–A species for obtaining a 
greater understanding of structure-interaction-reactivity relationships and further 
optimizing the reactivity of DMPD.  
In addition, in Chapter 4, human serum albumin (HSA), the most abundant protein 
in blood serum19 is observed to interact with small-sized metal-free A and metal–A 
species and form the complexes. Upon binding to A, HSA may delay the fibrillzation of 
both metal-free A and Zn(II)–A and possibly recover toxicity associated with A species 
in living cells. Although we have studied the influence of HSA on the fibril formation of A, 
the binding modes and sites of two proteins are not clearly revealed. By employing 
biophysical methods [e.g., mass spectrometry and nuclear magnetic resonance (NMR) 
spectroscopy], the complexes of HSA and A are indicated to be formed in the absence 
and presence of metal ions.  
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The works presented in this thesis focus on understanding the interaction between 
pathological features (i.e., metal ions, metal-free A, metal–A, A–interacting proteins) 
and the potential influence on AD. Moving forward, based on the findings from Chapters 
2 and 3, small molecules with the DMPD functionlaity (i.e., DMPD, L2-b, L2-b2) can be 
applied to examine whether these are able to affect the actions of different amyloidogenic 
proteins involved in other neurodegenerative diseases [i.e., -synuclein (-Syn) in 
Parkinson’s disease20,21]. The small molecules may be necessary to be modified for other 
targets; however, it can offer efficient and economical benefits once these compounds as 
chemical tools can help identify multiple pathological factors linked to the onset and 
progression of diverse amyloidogenic diseases. 
Overall, the investigations from this thesis can be the first step for understanding of 
protein–protein–small molecule (metals) interactions in AD. The knowledge obtained from 
our studies provides insight into fundamental pathogenesis of various diseases related to 
aggregate-prone proteins, more importantly with new directions for discovery of effective 
therapeutics for the devastating disease. 
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Appendix A: Influence of the Inflammatory Response Proteins,  
S100 Protein Families on the Amyloid- Aggregation 
 
The work presented herein was conducted in collaboration with Professor Elizabeth Nolan 
and Toshiki Nakashige at MIT. We thank Professor Ayyalusamy Ramamoorthy and Kyle 
J. Korshavn for NMR experiments. In this present work, I have contributed to the 
experiments of the ThT assay, gel electrophoresis with Western blot, and TEM analyses 
for A aggregation with Dr. Masha Savelieff. 
 
A.1. Introduction 
Alzheimer’s disease (AD) is the most prevalent form of dementia and accounts for 
ca. 60% of neurodegenerative diagnoses.1-10 This illness begins with mild cognitive 
impairment and progresses to severe dementia, and ultimately death.2-10 Senile plaques 
which are consist primarily of the amyloid- (A) aggregates are present in the AD-
affected brain.2-10 A is produced in the brain as a result of the proteolytic cleavage of 
amyloid precursor protein (APP) by - and -secretases.2-9 A spectrum of various sized 
A peptides is produced (from 38 to 43 amino acid residues), but the predominant 
peptides are A40 (ca. 90%) and A42 (ca. 10%).7-15 Both peptides have a tendency to 
aggregate into mature fibrils and generated soluble oligomeric species have been 
indicated as toxic species.6-15 In addition, chronic inflammation, elevated oxidative stress, 
and metal ion dyshomeostasis are also pervasive in the brain of AD.2,7-16 From previous 
studies, highly concentrated transition metal ions [i.e., Cu, Zn ions (ca. 0.4 and 1.0 mM, 
respectively)] are co-localized in senile plaques in the AD-afflicted brain.3-10 These metal 
ions can interact with A peptides, facilitate the peptide aggregation and form toxic 
oligomeric A species.3-10 Particularly, redox active metal ions, [i.e., Cu(I/II), Fe(II/III)] can 
generate reactive oxygen species (ROS) with or without A peptides which may damage 
the membranes and disrupt signaling.3-10 Although the efforts have focused principally on 
A and metal ions, the AD etiology is still uncertain thus, unidentified parameters along 
with A and metal ions, may be involved in AD pathogenesis.2-10 As a result, much effort 
has been expended to investigate the interaction of A with various proteins present in 
the brain that may participate in pathways associated with AD pathology.16-22 The S100 
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protein family, [particularly calprotectin (S100A8/A9; CP) and S100B] an inflammatory 
response protein whose expression level is upregulated in response to elevated 
inflammation, has been suggested to be linked to AD etiology.16,20-27 CP and S100B have 
been detected in senile plaques from the tissue of AD-affected brains16,20-27 and 
upregulated in AD mouse models.16,20-27 
CP is a calcium responsive protein that adopts a heterodimeric (composed of 
monomeric subunits; S100A8 and S100A9) or heterotetrameric structures.16,25,27 CP has 
two calcium binding EF hands (one canonical, one noncanonical); Ca(II) binding induces 
the formation of CP dimer and tetramer.25 In addition to Ca(II) binding sites, CP can bind 
to other transition metal ions, such as Mn(II) or Zn(II) with binding affinities in the range 
of M and nM, respectively, at other metal binding sites.16,25-27 Due to its Zn(II) binding 
property, CP can indirectly affect the elimination of A peptides by deactivating matrix 
metalloproteases (MMPs) which require Zn(II) to be activated.23,26 It, however, has been 
rarely studied the direct influence of CP on A aggregation.21,27 Another S100 protein 
family, S100B, is also detected to be overexpressed in aged and AD-afflicted brains 
suggesting its involvement in AD pathogenesis.22 
We report herein the interaction of CP and S100B with metal-free A and metal-
associated A (metal–A) at the molecular level. Additionally, we demonstrate the ability 
of CP and S100B to interact with certain conformations of A and modulate A 
aggregation pathways in both the absence and presence of metal ions [i.e., Cu(II), Zn(II)]. 
In order to avoid the generation of disulfide bonds during the purification of CP, mutated 
CPs [C42 of S100A8 and C3 of S100A9 to serine residue (CP-Ser)] were employed in 
this study. Furthermore, to investigate the alternation of metal binding properties of CP-
Ser and S100B on the interactions between S100 proteins and metal-free A/metal–A, 
and its effects on A aggregation pathways, the proteins with mutation of the histidine 
and glutamic acid residues at metal binding sites of CP-Ser and S100B to alanine were 
prepared; CP-Ser and S100B. From our investigations, CP-Ser and S100B could 
redirect or inhibit both metal-free A40 and metal–A40 fibrillization under Zn(II)-present 
conditions (2 and 1 equiv, respectively), respectively, while CP-Ser and S100B could 
only modulate metal-free A40 and metal–A40 fibril formation processes with less than 1 
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equiv of Zn(II). Moreover, all S100 proteins herein could not influence on A42 fibrillization. 
Not only for A aggregation, but also all the S100 proteins shown in this work present a 
greater radical scavenging capability than Trolox, a water-soluble vitamin analogue.28-30 
Overall, our studies employing CP-Ser, CP-Ser, S100B, and S100B, A, and metal 
ions can provide insights into some protein–protein-small molecule (metals) interactions 
which could be linked to AD etiology. 
 
A.2. Results and discussion 
 
A.2.1. Effects of S100 proteins on A aggregation pathways, observed by the 
thioflavin-T (ThT) assay. 
Fibrillization of metal-free A and metal–A in both the absence and presence of 
proteins, CP-Ser, CP-Ser, S100B and S100B, was monitored by the ThT assay. 
Freshly dissolved A with or without metal ions [Cu(II) or Zn(II)] was incubated with the 
proteins for 24 h at 37 C as depicted in Fiugre A.1a. Upon incubation of A peptides with 
CP-Ser, CP-Ser, S100B or S100B, less metal-free A40 fibrillization is shown to occur 
than that from protein-untreated A40 samples. The production of metal–A40 fibrils was 
also reduced. Moreover, based on the stoichiometry of metal ions to A and S100 proteins, 
the inhibitory ability of S100 proteins toward metal–A aggregation is observed to different 
extent.   
CP-Ser could inhibit the formation of Zn(II)–A40 fibrils up to 2 equiv of Zn(II) to 
A40. Interestingly, if excess of Zn(II) (5 or 10 equiv) was introduced, CP-Ser may not be 
able to affect A40 aggregation pathways (Figure A.1b). On the other hand, CP-Ser 
may not have significant effects on A40 aggregation with more than 1 equiv of Zn(II) 
(Figure A.1b). Similar results were observed in the presence of Cu(II) (Figure A.2a). Up 
to 1 equiv of Cu(II) to A, CP-Ser could redirect the fibril formation, while CP-Ser only 
affects A peptide aggregation in the presence of less than 1.0 equiv of Cu(II) to A. 
These results indicate that CP-Ser and CP-Ser may inhibit metal-unbound A40 
aggregation. CP-Ser capable of binding to metal ions (up to 2 equiv) could modulate A40 
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fibrillization by effectively rendering metal-unbound A40, due to their high metal binding 
affinities and influence on the A fibrillization;25 however, CP-Ser which cannot interact 
 
Figure A.1. Effects of the proteins on both metal-free A40/A42 and Zn(II)–A40/A42 aggregation pathways. (a) 
Scheme of the inhibition experiment. Analysis of (b and c) A40 and (d and e) A42 fibril formation from the samples 
after 24 h incubation with (b and d) CP-Ser and CP-Ser; (c and e) S100B and S100B by the ThT assay. Samples: 
(1) A (2) A  protein; (3) A  0.1 equiv of ZnCl2; (4) A  0.1 equiv of ZnCl2 + protein; (5) A  1.0 equiv of ZnCl2; 
(6) A  1.0 equiv of ZnCl2 + protein; (7) A  2.0 equiv of ZnCl2; (8) A  2.0 equiv of ZnCl2 + protein; (9) A  5.0 
equiv of ZnCl2; (10) A  5.0 equiv of ZnCl2 + protein; (11) A  10.0 equiv of ZnCl2; (12) A  10.0 equiv of ZnCl2 + 
protein. Conditions: [A] = 20 M; [ZnCl2] = 2, 20, 40, 100, or 200 M; [protein] = 20 M; pH 7.4; 24 h incubation; 37 
C; constant agitation. 
with metal ions could not alter the A40 fibrillization in the presence of metal ions. To prove 
this, it may require further studies about the protein–protein interaction between CP-
Ser/CP-Ser and A40 with or without metal ions. 
In contrast, inhibition experiments with A42 showed different results from those 
with A40. Both CP-Ser and CP-Ser may not be able to modulate the A42 fibrillization 
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in both the absence and presence of metal ions (Figures A.1d and A.2b). These 
observations suggest that differentiated conformations and aggregation pathways of A40 
and A42 can cause CP-Ser/CP-Ser to affect the peptide aggregation pathway to 
different extents. Moreover, these ThT assay results were consistent to those obtained 
by TEM (Figures A.2c,d, vide infra).  
 Another S100 family protein, S100B, and its mutant, S100B have been examined 
their anti-amyloidogenic ability toward both metal-free A40/A42 and Zn(II)–A40/A42. 
These proteins also showed similar results to the experiments with CP-Ser and CP-Ser. 
S100B could inhibit metal-free A40 and Zn(II)–A40 aggregation (Figure A.1c) up to 1 
equiv of Zn(II) present environment and S100B could not alter the A40 aggregation 
treated with same amount of Zn(II) (Figure A.1c). Moreover, both S100B and S100B 
could not affect the both metal-free A42 and Zn(II)–A42 fibrillization, significantly (Figure 
A.1e). From these results, S100B which possibly bind to metal ions could influence on 
metal–A40 fibrillization and S100B which cannot interact with metal ions may not be 
able to prohibit metal–A40 fibril formation, as similar to CP-Ser and CP-Ser. Overall, 
S100 protein family may prefer to interact with A40 over A42 and modulate the peptide 
aggregation, potentially, metal-unbound A species. 
 
A.2.2. Morphological changes of A40 upon treatment of proteins, monitored by 
transmission electron microscopy (TEM) 
The morphologies of both metal-free A and metal–A aggregates treated by 
proteins were monitored by transmission electron microscopy (TEM). After 24 h 
incubation, metal-free A40 and metal–A40 aggregated generated with CP-Ser were 
indicated to be more amorphous than the protein-untreated A40 samples (Figures 
A.2c,d), consistent with those monitored by the ThT assay. On the other hand, CP-Ser 
with 1 equiv metal ions could not present morphological changes of the resultant A 
species. Furthermore, as expected from the results indicated by the ThT assay, both CP-
Ser and CP-Ser could not inhibit A42 fibril formation. 
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Figure A.2. Influence of CP-Ser and CP-Ser on A40/A42 aggregation with or without 0.1 and 1 equiv of metal ions. 
Fibrillization of (a) A40 and (b) A42 with or without Cu(II) upon treatment of CP-Ser and CP-Ser, monitored by the 
ThT assay. Samples: (1) A (2) A  protein; (3) A  0.1 equiv of CuCl2; (4) A  0.1 equiv of CuCl2 + protein; (5) A 
 1.0 equiv of CuCl2; (6) A  1.0 equiv of CuCl2 + protein. (c and d) TEM images of 24 h incubated samples with 1 
equiv of ZnCl2 or CuCl2. Conditions: [A] = 20 M; [ZnCl2 or CuCl2] = 2 or 20 M; [CP-Ser or CP-Ser] = 20 M; pH 
pH 6.6 (for Cu(II) experiments) or 7.4 (for metal-free and Zn(II) experimetns); 24 h incubation; 37 C; constant agitation. 
Scale bar = 500 nm. 
 
A.2.3. Visualization of protein–A40 complexes by gel electrophoresis 
Since the ThT assay and TEM displayed the inhibition of metal-free A40 and 
metal–A40 fibrillization by S100 porteins, the molecular weight (MW) distribution of the 
resultant A40 species treated or untreated with the proteins was visualized by gel 
electrophoresis followed by Western blotting with an anti-A antibody (gel/Western blot; 
upper row) or anti-S100A9 antibody (lower row) for CP-Ser or CP-Ser treated samples 
(Figure A.3a,b); gel/Western blot with anti-A antibody (upper row) and coomassie blue 
staining (lower row) for the samples incubated with S100B or S100B (Figure A.3c,d). 
Bands of proteins (littler higher than 10 kDa) were detected from the samples of both 
metal-free A40 and metal–A40 incubated with CP-Ser or CP-Ser. As the MWs of the 
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S100A9 subunit in CP-Ser/CP-Ser and A40 are ca. 13.2 and 4.3 kDa, respectively, the 
clear bands on the gels may correspond to the complex formation between the
 
Figure A.3. Gel analysis of the formation of CP-Ser/CP-Ser– and S100B/S100B–A40 complexes in the 
absence and presence of metal ions. Resultant A40 species after 24 h incubation with or without (a) CP-
Ser or (b) CP-Ser were visualized by gel/Western blot using an anti-A antibody (upper row) and anti-
S100A9 antibody (lower row); A samples treated with or without (c) S100B or (d) S100B were also 
visualized by gel/Western blot using an anti-A antibody (upper row) and coomassie blue staining. Lanes: 
(1) A (2) A  protein; (3) A  0.1 equiv of [ZnCl2 or CuCl2]; (4) A  0.1 equiv of [ZnCl2 or CuCl2] + 
protein; (5) A  1.0 equiv of [ZnCl2 or CuCl2]; (6) A  1.0 equiv of [ZnCl2 or CuCl2] + protein. Conditions: 
[A40] = 20 M; [ZnCl2 or CuCl2] = 2 or 20 M; [protein] = 20 M; pH 6.6 (for Cu(II) experiment) or pH 7.4 
(for metal-free and Zn(II) experimetns); 24 h incubation; 37 C; constant agitation. 
S100A9 subunit of CP-Ser/CP-Ser and metal-free A40 or metal–A40. Moreover, based 
on the MW of heterodimers of CP (S100A8 and S100A9) is approximately 24 kDa, the 
bands (little less than 35 kDa) on the gels could correspond to CP-Ser/CP-Ser–A40 
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complexes (Figure A.3a,b). In addition, CP-Ser or CP-Ser-treated samples displayed 
different trends of smearing bands compared to CP-Ser- or CP-Ser-untreated A40 
samples. These results suggest that the CP proteins may affect A40 aggregation 
pathways (i.e., less fibril formation) by generating the protein complexes. Furthermore, as 
anti-S100A9-blotted gels presented, CP-Ser may have the potential to aggregate itself by 
hydrophobic interactions. Previous studies demonstrate that once Zn(II) is introduced to 
CP-Ser, this protein can aggregate faster,16 which is consistent with our observation. 
In addition, S100B/S100B-added A40 samples also indicated the protein bands 
having little higher than 10 kDa which are also possibly the complexes of S100B/S100B 
and metal-free A40 and metal–A40 (Figure A.3c,d), based on the MWs (approximately 
10 and 4.3 kDa) of the monomeric subunit of S100B/S100B and A40. Furthermore, 
S100B/S100B–A40 complexes were also visualized considering the MW of S100B 
dimer (ca. 21 kDa;Figure A.3c,c). Overall, such complex formation between S100 proteins 
and A could alter metal-free A40 and metal–A40 aggregation pathways. 
 
A.2.4. Interaction of CP-Ser with monomeric A40 
The direct interaction of CP-Ser with monomeric A40 was investigated by 2D 
band-selective optimized flip-angle short transient heteronuclear multiple quantum 
correlation (SOFAST-HMQC) NMR. Chemical shifts of 15N-labeled A40 residues upon 
titration of CP-Ser were detected and monitored to determine the potential binding site 
and modes of CP-Ser to A40 peptide (Figure A.4). Less than 0.02 ppm of chemical shifts 
were induced upon addition of CP-Ser to the solution containing 15N-labeled A40. Almost 
entire A40 residues were evenly involved in the relatively weak interaction with CP-Ser, 
along with noticeably perturbed residues; E11, F19, E22, and I32. As expected from gel 
electrophoresis, CP-Ser and A peptide may interact with each other forming complexes; 
however, it may not be strongly bound. 
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Figure A.4. Interaction of CP-Ser with monomeric A40. 2D 1H–15N SOFAST-HMQC NMR spectra of 
monomeric 15N-labeled A40 upon addition of CP-Ser. Spectra were recorded as CP-Ser was titrated into a 
solution of 15N-labeled A40, and the plot of the corresponding chemical shift perturbations (CSPs). The 
average chemical shifts (dashed line) plus standard deviation (dotted line) were presented. Conditions: 
[A40] = 80 M; [CP-Ser] = 80 M; 20 mM PO4, pH 7.4, 50 mM NaCl; 7% D2O (v/v); 10 °C. 
 
A.2.5. Free radical scavenging capability of proteins 
The free radical scavenging capability of CP-Ser, CP-Ser, S100B and S100B 
was determined by Trolox (vitamin E analogue) equivalent antioxidant capacity (TEAC) 
assay which can evaluate the ability to quench ABTS cation radicals ABTS•+; ABTS = 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) in SK-N-BE(2)-M17 (M17) cell 
lysates.28-30 All the proteins could scavenge free organic radicals better (more than ca. 
1.5 times) than Trolox (Figure A.5).28-30 
 
A.3. Conclusion and future directions 
Four different proteins from S100 protein family, CP-Ser, CP-Ser, S100B, and 
S100B, were investigated for their ability to redirect metal-free A and metal–A 
aggregation pathways (particularly, the formation of fibrils), along with their free radical 
scavenging capacity. From the experimental results presented herein, all four proteins 
could affect the A fibrillization with or without metal ions. Moreover, these proteins are 
shown to scavenge free radicals. In order to reveal the interaction between S100 protein 
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family and A species in detailed, several biophysical methods (e.g., mass spectrometry, 
NMR) should be applied and analyzed. Overall, our studies provide information on 
whether the overexpressed protein in AD-affected brains, S100 protein, and A interact 
with each other with or without metal ions and their effects on A aggregation pathways. 
This could lead better understandings of a protein–protein-small molecule (metals) 
interaction in AD etiology. 
 
Figure A.5.  The free radical scavenging capability of CP-Ser, CP-Ser, S100B, and S100B, determined 
by the TEAC assay in SK-N-BE(2)-M17 (M17) cell lysates. The TEAC values are relative to that of a vitamin 
E analogue, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
A.4. Experimental section 
 
A.4.1. Materials and methods 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. CP and S100B proteins were obtained from Professor Elizabeth 
Nolan. Trace metal contamination was removed from buffers and solutions used for 
amyloid- (A) experiments by treating with Chelex (Sigma-Aldrich). A40 (DA-
EFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and A42 (DAEFRHDSGYE-
VHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were purchased from Anaspec (Fremont, 
CA, USA). All double distilled H2O (ddH2O) used during experiments was obtained from 
a Milli-Q Direct 16 system (Merck KGaA, Darmstadt, Germany). The concentrations of 
proteins were determined by an Agilent 8453 UV–Visible (UV–Vis) spectrophotometer 
(Santa Clara, CA, USA). Transmission electron microscopy (TEM) images were recorded 
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on a Philips CM-100 transmission electron microscope (Microscopy and Image Analysis 
Laboratory, University of Michigan, Ann Arbor, MI, USA). A SpectraMax M5 microplate 
reader (Molecular Devices, Sunnyvale, CA, USA) was used to measure the fluorescence 
intensity for the ThT assay.  
 
A.4.2. Preparation and purification of proteins 
E. coli codon-optimized genes for each subunit of human CP-Ser and (S100A8 
and S100A9) were subcloned into pET41a plasmids (pET41a-S100A8 and pET41a-
S100A9), and then transformed into E. coli BL21(DE3) cells. The fully assembled protein 
CP-Ser heterodimer was expressed and purified according to previously established 
methods. Briefly, each subunit was overexpressed separately; transformed BL21(DE3) 
cells were grown to saturation overnight in LB supplemented with 50 g/mL kanamycin, 
used to inoculate (1:100) larger scale LB media (1 to 4 L), which were shaken at 150 rpm 
at 37 °C. Protein expression was induced with 500 M IPTG at ca. 0.6 OD600 over 3-4 
hours till ca.1.5 OD600. Bacteria were pelleted at 4200 rpm for 30 min at 4 °C, flash frozen 
and kept at −80 °C. The CP-Ser was prepared in an analogous manner.  
S100B and S100B were overexpressed in E. coli BL21(DE3) in the pET41a 
vector, and purified by 100% ammonium sulfate precipitation, anion exchange 
chromatography, and size-exclusion chromatography (SEC). The proteins were 
partitioned into 50 L aliquots in pre-sterilized microcentrifuge tubes. 
 
A.4.3. A aggregation experiments 
Experiments with A were performed according to previously published 
methods.28,31-36 A peptides were dissolved with ammonium hydroxide (NH4OH, 1% v/v, 
aq), aliquoted, lyophilized, and stored at −80 °C. A stock solution (ca. 200 M) was 
prepared by dissolving A with NH4OH (1% w/v, aq, 10 L) followed by dilution with 
ddH2O, as reported previously.28,31-36 The A40 concentration was determined by 
measuring the absorbance of the solution at 280 nm ( = 1450 M–1cm–1 for A40;  = 1490 
M–1cm–1 for A42). Buffered solutions containing HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (20 mM)] [pH 7.4 for metal-free and Zn(II) samples; pH 6.6 
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for Cu(II) samples] and 150 mM NaCl were used for inhibition studies. For the inhibition 
experiment, freshly dissolved A (20 M) was treated with S100 proteins (20 M), and 
incubated for 24 h at 37 °C with constant agitation. 
 
A.4.4. ThT assay 
The kinetics of A fibrillization were monitored as previously published 
methods.17,37,38 Each sample (40 L; [A] = 20 M with or without [S100 proteins] = 20 
M) was obtained after 24 h incubation for both metal-free and metal present environment 
at 37 °C with constant agitation and diluted with buffered solutions (20 mM HEPES, pH 
7.4 for metal-free and Zn(II) experiments, pH 6.6 for Cu(II) experiemtns, 150 mM NaCl). 
The samples were incubated for 20 min with ThT (20 M) and read fluorescence. 
Maximum fluorescence of ThT was measured with excitation wavelength of 440 nm and 
emission wavelength of 490 nm. The fluorescence intensity was measured on a 
microplate reader and normalized relative to that of metal-free A aggregates generated 
through 24 h incubation. 
 
A.4.5 Gel electrophoresis with Western blot  
The A peptide experiments described above were analyzed by gel 
electrophoresis with two different visualization methods; coomassie blue staining and 
Western blotting (gel/Western blot) using two different antibodies; an anti-A antibody 
(6E10) or anti-S100A9 antibody (Santa Cruz Biotechnology, Dallas, TX, USA).28,31-36 
Each sample from inhibition experiments was separated using a 10−20% gradient Tris-
tricine gel (Invitrogen, Grand Island, NY, USA). First, the gel run with CP samples was 
transferred to a nitrocellulose membrane and blocked 3 h at room temperature with a 
skimmed milk solution (10% w/v) in Tris-buffered saline (TBS, Fisher, Pittsburgh, PA, 
USA) containing 0.1% Tween-20 (Sigma-Aldrich; TBS-T). The membrane was treated 
with the A monoclonal antibody (6E10, Covance, Princeton, NJ, USA; 1:2,000; BSA, 2% 
w/v, in TBS-T) or anti-S100A9 antibody for overnight at 4 °C and then probed with a 
horseradish peroxidase conjugated goat anti-mouse secondary antibody (1:5,000; 
Cayman Chemical, Ann Arbor, MI, USA) or donkey anti-goat secondary antibody 
(1:5,000; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) in 2% BSA in 
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TBS-T solution for 1 h at room temperature. The protein bands were visualized using 
Thermo Scientific Supersignal West Pico Chemiluminescent Substrate (Rockford, IL, 
USA). 
The gel run with S100B samples was stained with coomassie blue for about 30 
min and washed with water to destain the gels for overnight. Gel images were obtained 
by ChemiDoc MP system (Bio-rad, CA, USA). Then, the dye was completely destained 
from the gel, and the gel was transferred to a nitrocellulose membrane for Western blot 
with 6E10 (1:2000; BSA, 2% w/v, in TBS-T) and a horseradish peroxidase conjugated 
goat anti-mouse secondary antibody (1:5,000) as same as the gel run with CP samples. 
 
A.4.6. Transmission electron microscopy (TEM) 
Samples for TEM were prepared following a previously reported method.28,31-36 
Glow discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, 
Hatfield, PA, USA) were treated with samples from inhibition experiments (5 L) for 2 min 
at room temperature. Excess sample was removed with filter paper and the grids were 
washed with ddH2O three times. Each grid was stained with uranyl acetate (1% w/v 
ddH2O, 5 L) for 1 min. Uranyl acetate was blotted off and grids were dried for 20 min at 
room temperature. Images of samples were taken by a Philips CM-100 transmission 
electron microscope (80 kV, 25,000× magnification). 
 
A.4.7. 2D NMR spectroscopy 
The interaction of A40 with CP-Ser was monitored by 2D 1H-15N SOFAST-HMQC 
NMR at 10 °C.39  Uniformly-15N-labeled A40 (rPeptide, Bogart, GA, USA) was first 
dissolved in 1% NH4OH and lyophilized. The peptide was re-dissolved in 3 L of DMSO-
d6 (Cambridge Isotope, Tewksbury, MA, USA) and diluted with phosphate buffer, NaCl, 
D2O, and ddH2O to a final peptide concentration of 80 M (20 mM PO4, pH 7.4, 50 mM 
NaCl; 7% v/v D2O). Each spectrum was obtained using 64 complex t1 points and a 0.1 
sec recycle delay on a Bruker Avance 600 MHz spectrometer. The 2D data was 
processed using TOPSPIN 2.1 (from Bruker). Resonance assignment was performed 
with SPARKY 3.1134 using published assignments for A40 as a guide.40,41  
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A.4.8. Trolox equivalent antioxidant capacity (TEAC) assay 
The free radical scavenging capacity of CP-Ser, CP-Ser, S100B, and S100B 
were determined by the TEAC assay employing lysates of human neuroblastoma SK-N-
BE(2)-M17 (M17) cells purchased from ATCC (Manassa, VA, USA).28-30 The assay 
employing cell lysates was conducted following the protocol of the antioxidant assay kit 
purchased from Cayman Chemical Company (Ann Arbor, MI, USA), with minor 
modifications.28 M17 cells were cultured in media containing 1:1 Minimum Essential 
Media (MEM, GIBCO, Grand Island, NY), Ham’s F12K Kaighn’s Modification Media 
(F12K, GIBCO), 10% (v/v) fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, 
GA, USA GIBCO), 100 U/mL penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). 
The cells were grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. 
For the antioxidant assay using cell lysates, cells were seeded in a 6 well plate and grown 
to approximately 80-90% confluence. Cell lysates were prepared following a previously 
reported method with modifications.41 M17 cells were washed once with cold PBS (pH 
7.4, GIBCO) and harvested by gently pipetting off adherent cells with cold PBS. The cell 
pellet was generated by centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was 
sonicated on ice (5 sec pulses, 3 times with 20 sec intervals between each pulse) in 2 mL 
of cold Assay Buffer (5 mM potassium phosphate, pH 7.4, containing 0.9% NaCl and 
0.1% glucose). The cell lysates were centrifuged at 5,000 x g for 10 min at 4 °C. The 
supernatant was removed and stored on ice until use. To standard and sample 96 wells, 
10 L of the supernatant of cell lysates was delivered followed by addition of proteins, 
metmyoglobin, ABTS, and H2O2 in order. After 5 min incubation at room temperature on 
a shaker, absorbance values at 750 nm were recorded. The final concentrations (0.045, 
0.090, 0.135, 0.180, 0.225, and 0.330 mM) of proteins (CP-Ser, CP-Ser, S100B and 
S100B) and Trolox were used. The antioxidant concentration was calculated according 
to the measured absorbance (% Inhibition = (A0 – A)/A0, where A0 is absorbance of the 
supernatant of cell lysates). The measurements were conducted in triplicate. 
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